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Background – The NADPH oxidases (Noxs) are a family of reactive oxygen species 
(ROS)-generating enzymes with crucial roles in the regulation of redox signalling 
pathways, which have been implicated in several physiological processes including 
cellular differentiation, proliferation, and survival. Since the heart has the highest oxygen 
consumption among body organs, redox-mediated signalling is central to both cardiac 
function as well as pathophysiology. Nox4 is expressed in cardiomyocytes and has been 
shown to mediate distinct adaptive phenotypes in the heart in response to chronic 
disease stress. We previously identified that a splice variant of Nox4, Nox4D, is nuclear-
localised, capable of ROS production, and is associated with increased proliferation of 
neonatal cardiac myocytes. The aim of this project was to investigate the effects of 
Nox4D in adult cardiomyocytes in vivo. 
Methods and Results – We generated mice with inducible cardiomyocyte-specific 
overexpression of Nox4D (Ind-csNox4D). After tamoxifen induction in adult mice, Ind-
csNox4D showed a 10-fold increase in Nox4D protein levels in the heart compared to 
controls, whilst echocardiography revealed similar cardiac structure and function. No 
changes were found in baseline cardiomyocyte cell cycling or redox signalling as 
assessed by EdU nucleotide analog incorporation and the expression of cell cycle genes 
and pathways. The impact of Ind-csNox4D on the response to myocardial infarction (MI) 
induced by permanent left anterior descending coronary artery (LAD) ligation was next 
determined. At 4 weeks post-MI, Ind-csNox4D mice demonstrated region-specific 
improvements in contractile function, but no differences were found in global left 
ventricular (LV) function and volumes compared to control mice. This was consistent with 
a partial protective response in Ind-csNox4D hearts during postinfarction remodelling, 
but there were no differences in the gene expression of markers of the cell cycle versus 
control hearts in either the infarct border zone or remote zone. However, using a model 
of cultured adult cardiomyocytes stimulated to induce dedifferentiation, we found that 
Nox4D overexpression is associated with increased cell cycle progression compared to 
control cells.  
Conclusions – In vitro overexpression of Nox4D increases proliferation of neonatal 
cardiomyocytes but this is unchanged in adult hearts. Induction of cardiomyocyte-
specific overexpression of Nox4D in adult mice is well tolerated, capable of mediating a 
regionalised reparative and functional response in the setting of post-MI remodelling but 
insufficient to fully rescue recovery. Further research is needed to understand whether 
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1.1 The impact of cardiomyocyte loss 
1.1.1 Heart development and growth 
The heart is essential for vertebrate life. As one of the first organs to function, the heart 
supports blood circulation through the maintenance of continuous and rhythmic 
contractility.1,2 Cardiac morphogenesis progresses along a highly conserved 
developmental pathway, involving formation as a single tube, which then loops and 
expands to form the chambers.3 All vertebrates possess a closed and multi-chambered 
heart comprising 2 to 4 chambers, and therefore show marked variations in final structure 
between species and classes.1,4 The adult mammalian heart is composed of 2 atria and 
2 ventricles,5 the key component of which, as shared with most hearts, is the thickened, 
vascularised and innervated muscular wall.1 This muscular wall – the myocardium – is 
responsible for pump function and is enveloped by a thin endothelial cell layer in contact 
with the blood flow – the endocardium – and an outer mesothelial cell layer – the 
epicardium.6 The basic contractile unit of the myocardium is the cardiomyocyte.7 Though 
not necessarily the most abundant cell type of the adult mammalian heart; 
cardiomyocytes occupy 70 – 85% of the volume whilst only constituting 30 – 40% of the 
cellular population.8,9 During early development, mammalian heart growth is primarily 
shaped by cardiomyocyte division, however shortly after birth this ability is mostly lost, 
and growth becomes determined by physiological hypertrophy. This extensive transition 
to “terminal” differentiation has generated great interest, as identification of the extrinsic 
and intrinsic mechanisms that may modulate this proliferative switch is strongly linked to 
regeneration.10–12 
1.1.2 Acute myocardial infarction 
Several forms of heart disease are characterised by the loss of functional cardiac 
tissue.13 Coronary heart disease (CHD) is the most common type of cardiovascular 
disease (CVD), and remains the leading cause of death worldwide.14 CHD usually 
develops over time with increasing age, and is fuelled by concurrent health conditions 
including diabetes, hypertension and obesity in addition to habitual stressors such as 
smoking.15 The major pathological manifestation of CHD is acute myocardial infarction 
(MI), which usually arises due to the thrombotic occlusion of a coronary artery secondary 
to rupture of a vulnerable atherosclerotic plaque.16,17 The human left ventricle has 2 – 4 
billion cardiomyocytes, and a single myocardial infarction event can result in the loss of 
1 billion of these within hours.18 This massive depletion of cardiomyocytes is irreversible, 
and so represents the primary obstacle to complete functional recovery. The most cited 
basis for this is the limited regenerative ability of the adult mammalian heart to replenish 
significant numbers of cardiomyocytes.10 As a consequence, the heart instead 
undergoes a series of progressive adverse remodelling processes characterised by the 
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formation of a non-contractile fibrotic scar and compensatory alterations of remote 
cardiac tissue, which ultimately culminate in the development of heart failure.11,19   
Despite major advancements in the acute management of MI with revascularisation by 
primary percutaneous coronary intervention, pharmacological therapies that aim to 
prevent or delay the progression of heart failure are limited.20,21 Current clinical guidelines 
recommend a number of drug treatments post-MI that target the mechanical 
characteristics of the cardiovascular system, including inhibitors of the renin-angiotensin 
system and the sympathetic nervous system.22,23 The implementation of these strategies 
over the last 30 years has contributed significantly to the improvements seen in early 
and long-term survival after MI.24,25 According to the British Heart Foundation, there are 
over 200,000 hospital admissions in the UK each year due to MI, and 70% of these cases 
are now survived.14 However, improved survival has led to the growth of an ageing 
population and increased incidence of postinfarction heart failure. Epidemiological 
studies have suggested that this increase has even paralleled the decrease in mortality 
after MI, meaning that heart failure has become a global health and economic 
burden.17,24,25  
As such, currently used therapies are intrinsically non-curative as they remain focussed 
on myocardial salvage rather than replacement, and therefore fail to address the 
underlying issue of cardiomyocyte loss. This clearly underscores the clinical need for 
novel and targeted treatments that stimulate regenerative repair following MI, a concept 
that represents a key goal for cardiovascular research.19,21,23  
1.2 Potential for mammalian cardiomyocyte 
proliferation as a basis for cardiac regeneration 
1.2.1 Sources of cardiomyocytes and strategies for repair 
The concept of myocardial regenerative therapy is based on the premise that the 
replacement of cardiomyocytes in the injured heart would address the fundamental issue 
of cardiomyocyte death through the concomitant restoration of cardiac structure and 
rescue of cardiac function.26 For the development of such an intervention, it is important 
to consider the potential sources from which new cardiomyocytes may be derived. 
Current myocytes replacement strategies fall into 4 general categories: (i) reactivation of 
proliferation by induction of cell cycle re-entry in pre-existing cardiomyocytes;27 (ii) 
mobilisation of an endogenous cardiomyogenic cardiac progenitor cell (CPC) pool;28 (iii) 
exogenous delivery of cardiomyogenic progenitor cells or their cardiomyocyte derivatives 
originating from pluripotent stem cells (embryonic stem cells [ESCs] or induced 
pluripotent stem cells [iPSCs]) or adult progenitor cells,29 which may be bioengineered 
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as a patch;30 and (iv) direct reprogramming, or transdifferentiation, of non-
cardiomyocytes (such as fibroblasts) to a cardiomyocyte fate.31 
Although lineage-tracing studies have found insufficient evidence to support a significant 
contributory role of resident stem cell populations in myocardial repair,32,33 the last 15 
years have seen considerable effort into the development of stem cell-based therapies 
for cardiac regeneration.18,34 Studies in animal models and clinical trials in humans have 
demonstrated that direct transplantation of differentiated myocytes or myogenic stem 
cells has been associated with, at most, modest improvement in cardiac function.35,36 
The progress of these transplanted stem cell populations as cell replacement therapies 
has been limited by concerns over transient survival and poor retention in the heart, cell 
maturation, arrhythmogenesis, immunogenicity, and the need for large-scale 
production.10 Furthermore, the mechanistic basis of any functional improvement 
following stem cell engraftment remains unclear, and may be attributable to paracrine 
effects.37 Direct reprogramming of non-myocytes offers a cell-free approach, but requires 
further development due to the low efficiency of reprogramming vectors.38 
Based on the limited success of stem cell approaches, the focus of regenerative 
strategies has shifted to the stimulation of endogenous cardiomyocyte proliferation. 
Induction of cardiac renewal through the promotion of cardiomyocyte cell cycle activity 
in the surviving myocardium after injury is a particularly interesting strategy, as this 
appears to be the major source of new cardiomyocytes in animal models of 
regeneration.39,40 This method does not require stimulation of cellular differentiation and 
maturation, is likely able to generate new cardiomyocytes with excellent 
electromechanical and vascular integration within the myocardium, and therefore 
constitutes an attractive and the most direct approach for regenerating the heart.41,42  
1.2.2 The mammalian cell cycle 
In order to understand how adult mammalian cardiomyocytes may be manipulated to 
enhance their proliferative capacity, it is necessary to consider the molecular signals that 
regulate cell cycle progression.  
The cell cycle in mammalian cells is a tightly regulated process that revolves around 2 
main alternating sequences, namely interphase, during which a cell typically spends 
most of its lifetime, and division, in which the genome is halved to yield 2 identical 
daughter cells. These sequences are driven by an ordered series of molecular events, 
which comprise 5 distinct phases: 3 Gap phases – G0, G1, and G2, and S-phase 
(synthesis), and M-phase (mitosis and cytokinesis). Interphase collectively refers to G0, 
G1, S, and G2, i.e. all phases between mitoses. Cells in G0 are considered to have 
ceased proliferation, either due to a lack of mitogenic or the presence of antimitogenic 
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signals, and are considered to be in a state of quiescence. Upon stimulation, cells enter 
the G1 phase of the cell cycle, increase in size, and undergo ribonucleic acid (RNA) 
synthesis and protein synthesis. During late G1, a checkpoint control mechanism 
(restriction point) serves to regulate commitment to the cycle and permits preparation for 
chromosomal replication by doubling of the deoxyribonucleic acid (DNA) content in S-
phase. The second gap period (G2) proceeds after S-phase, during which cells continue 
to grow and synthesise protein and RNA, and prepare for M-phase following the G2/M 
checkpoint.43,44  
The end of G2 marks the onset of mitosis, a complex and highly regulated process, which 
is further divided into several stages sequentially known as prophase, prometaphase, 
metaphase, anaphase, and telophase. These events describe the alignment of 
condensed chromosomes in the centre of the cell and separation of sister chromatids to 
opposite poles of the mitotic spindle to allow the equal division of DNA and cellular 
components.45 This is accompanied by fragmentation and reformation of the nuclear 
envelope, and is facilitated by another important checkpoint known as the spindle 
checkpoint.45,46 The checkpoints of the cell cycle are therefore essential control 
mechanisms that monitor the transition between various phases by assessment of the 










Figure 1.1. Regulation of the mammalian cell cycle. Each round of cell division requires 
passage through Gap 1 (G1), S-phase (synthesis), Gap 2 (G2), and M-phase (mitosis and 
cytokinesis). Quiescent cells remain in Gap 0 (G0). Integrity is assessed at the 3 main 
checkpoints: the restriction point (red), at the G1/S transition; the G2/M checkpoint (blue); and the 
spindle checkpoint (green), at the metaphase to anaphase transition. Cell cycle progression is 
controlled by positive regulators (cyclin:Cdk complexes), which are negatively regulated by INK4 
and CIP/KIP CDKI family members. E2F transcription factors function at the restriction point, 
leading to activation of genes required for DNA synthesis. Cdk, cyclin-dependent kinase; CDKI, 
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cyclin-dependent kinase inhibitor; CIP, Cdk-interacting protein; INK4, inhibitor of Cdk4; KIP, 
kinase inhibitor protein. Adapted from Bicknell et al, 2007.43 
Orderly progression through each sequential phase of the cell cycle is dependent on the 
controlled expression of various cell cycle molecules – the positive regulators (cyclins 
and cyclin-dependent kinases [Cdks]) and the negative regulators (Cdk inhibitors 
[CDKIs]), which are in turn regulated by phosphorylation and dephosphorylation events. 
Cyclins (regulatory subunits) specifically interact with Cdks (catalytic kinase subunits) to 
form distinct active complexes that phosphorylate a number of substrates to drive the 
cell cycle from one phase to the next.43,44 The cyclins can be functionally grouped into 
the G1 cyclins (cyclins D and E), the S phase cyclins (cyclins A and E), and the mitotic 
cyclins (cyclins A and B).47 Most cyclins therefore show dramatic fluctuation in their 
messenger RNA (mRNA) and protein expression levels throughout the cell cycle as a 
consequence of changes in their transcription and ubiquitin-mediated degradation. The 
Cdks are a family of serine-threonine protein kinases that, on their own, possess no 
detectable kinase activity but require the sequential activation by their specific cyclin 
partner(s), and therefore play an essential regulatory role once complexed through the 
integration of signals from extracellular mitogenic molecules such as growth factors.43,44 
Growth factors can stimulate a number of signalling pathways, of which the Ras-
dependent mitogen-activated protein kinase (MAPK) pathway plays a major role in 
induction of G1 entry. The D-type cyclins (cyclins D1, D2, and D3) accumulate in 
response to mitogenic stimulation and bind to Cdk4 or Cdk6 in early G1.43,48 Cyclin 
D:Cdk4/6 complexes then initiate progression through G1 by phosphorylation of 
members of the retinoblastoma (Rb) family of pocket proteins, allowing the release of 
E2F transcription factors, which promotes cell cycle progression through the G1/S-phase 
transition by transcriptional activation of cyclins A and E and target genes required for 
DNA synthesis. Cyclins E and A form complexes with Cdk2 and are important for 
transition through the restriction point and progression through S-phase, respectively. 
The cyclin A:cell division cycle 2 (Cdc2, also known as Cdk1) complex forms in and 
promotes progression through G2, then cyclin B1:CDC2 promotes G2/M transition and 
progression through M-phase, degradation of which is required to enable exit from 
mitosis and cytokinesis.43,44  
The expression of the Cdks remains relatively constant throughout the phases of the cell 
cycle, and so their activity is negatively modulated by association with various CDKIs.44 
The CDKIs are categorised into 2 structurally distinct families – the inhibitor of Cdk4 
(INK4) family and the broader specificity CIP/KIP (Cdk-interacting protein/kinase inhibitor 
protein) family.49 The INK4 CDKIs comprise p14, p15, p16, p18, and p19, which target 
cyclin D:Cdk4/6 complexes, and are therefore involved in G1-phase control, whilst the 
25 
 
CIP/KIP CDKIs include p21, p27, and p57, and can inhibit all Cdks.43,44 Members of the 
2 CDKI classes show differential mechanisms of Cdk inhibition; the INK4 members 
indirectly block cyclin binding and complex formation by causing allosteric changes in 
the Cdk binding site, whereas the CIP/KIP members bind to and inhibit the catalytic 
kinase activity of the entire cyclin:Cdk complex.44 Although the degradation of cyclins via 
the ubiquitin-proteasome pathway is an important regulatory mechanism for cyclin:Cdk 
activity, the CDKIs function as another form of control during checkpoint regulation and 
in the modulation of cell cycle progression throughout.47 Their expression is therefore 
increased in response to antiproliferative signals such as contact inhibition,50 
senescence,51 and extracellular antimitogenic factors such as transforming growth 
factor-β (TGF-β).52  
1.2.3 Endogenous heart regeneration in lower vertebrates and neonatal 
mice in response to injury 
Discoveries of animals that can naturally regenerate their hearts after injury have 
provided great insight into the innate regulation and extrinsic environmental stimuli of 
cardiomyocyte proliferation.21 It is now clear that, in contrast to the limited regenerative 
ability of adult mammalian hearts, certain teleost fish and urodele amphibians possess 
a robust capacity for cardiac regeneration throughout life.13 Although there is a long 
history of research into the regeneration of urodele amphibian hearts, the zebrafish has 
emerged as possibly the most developed model system for adult heart regeneration in 
light of its high amenability to genetic manipulation.10,18  
Zebrafish hearts can regenerate with limited or no scarring in a variety of severe injury 
models.10 This was first demonstrated in 2002 by surgical resection of approximately 
20% of the apical myocardium, after which the wound is initially sealed by a fibrin-rich 
clot, which is not replaced by collagen but rather the gradual restoration of vascularised 
cardiac muscle, resulting in complete regeneration of the ventricle within 60 days.53 This 
mode of recovery has also been reproduced in cryoinjury of approximately 20% of the 
ventricular wall,54 genetic ablation of up to 60% of the myocardial cardiomyocyte 
population through inducible expression of cardiomyocyte-specific diphtheria toxin A,55 
and hypoxia-reoxygenation injury.56  
Such robust models of zebrafish heart regeneration have provided the ideal basis to 
directly assess the cellular source(s) of renewed myocardium through the use of 
tamoxifen-inducible, Cre-based genetic fate-mapping tools that irreversibly label 
cardiomyocytes with a fluorescent reporter protein prior to injury. Once activated, the 
reporter protein is expressed in all cardiomyocytes and their progeny, and is thus 
indicative of the source of newly generated cardiomyocytes.57 Such lineage tracing 
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experiments have conclusively shown that almost all new cardiomyocytes post-injury are 
labelled, and are therefore derived from pre-existing cardiomyocytes that are capable of 
entering the cell cycle and dividing.39,58 The mechanisms underlying proliferation of the 
pre-existing cardiomyocyte pool are considered to involve the reactivation of 
endogenous mitogenic pathways that guide embryonic heart development, including 
neuregulin 1 (NRG1)59 and Notch signalling,60 with upregulation of cell cycle regulators 
such as Mps1 (monopolar spindle protein 1 – a mitotic checkpoint kinase).53  Studies 
have also shown that this response involves the redeployment of embryonic or juvenile 
developmental gene programs, since most regenerating myocytes show activation of 
regulatory sequences of the transcription factor GATA4, an important gene during heart 
development known to regulate cardiomyocyte differentiation and survival.58,61,62 This is 
consistent with increased transcript expression of other transcription factor genes 
synonymous with early development, including GATA5 and Hand2.63 Interestingly, these 
findings coincided with observations that regenerating zebrafish cardiomyocytes acquire 
a less organised, dissociated sarcomeric structure with transient uncoupling of electrical 
conductance before cell division, then undergo a maturation process and reintegrate into 
the myocardium.39,55,58 These features are consistent with a reversion of maturity, and 
collectively describe cardiomyocyte dedifferentiation. Thus, it is now accepted that pre-
existing, differentiated adult cardiomyocytes reduce their contractile state by 
dedifferentiating to a more embryonic phenotype in order to facilitate cell division in the 
regenerating heart.1,11  
Although previously considered exclusive to zebrafish, other teleost fish and some 
urodele amphibians, it was later learnt in 2011 that the 1-day-old neonatal mouse heart 
is also capable of regenerating after surgical resection of approximately 15% of the 
cardiac apex. This regenerative response was characterised by cardiomyocyte 
proliferation with minimal residual scarring and hypertrophy, and normalisation of cardiac 
systolic function within 2 months of surgery.40 This has also been demonstrated in other 
models of injury, including MI64, in which a robust angiogenic response was also 
reported, and cryoinjury (partial regeneration).65 Reminiscent to that in zebrafish, lineage 
tracing and histological analysis revealed that the dominant cellular source of 
regenerated cardiomyocytes in the neonatal mouse heart is global proliferation of the 
resident cardiomyocyte pool, accompanied by evidence of sarcomere 
disassembly,40,64,65 and has also been show to require GATA4.66    
However, in contrast to the zebrafish heart whose regenerative capacity is retained 
throughout adulthood, the ability of the neonatal murine heart to regenerate after injury 
is lost by postnatal day 7 (P7).40,67 This is considered to coincide with the stage at which 
rodent cardiomyocytes lose their proliferative potential,68 and so the transient 
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regenerative response is likely to harness the early developmental growth pathways.11 
Indeed, the neonatal regenerative ability has even been argued to decline sharply within 
48 hours of birth as a result of differentially expressed transcripts encoding for 
extracellular matrix (ECM) components and cytoskeletal constituents, thus highlighting 
the regenerative influence of the local microenvironment rather than autonomous cellular 
proliferative mechanisms.69 Nevertheless, the discovery of regeneration in the neonatal 
mouse heart suggests that this mode of repair is not evolutionarily lost by mammals, and 
so it is paramount that factors are identified that may extend this response into 
adulthood.21  
1.2.4 The regulation of postnatal cardiomyocyte cell cycle withdrawal 
Cardiomyocyte cell cycle arrest in postnatal life is accompanied by the uncoupling of 
DNA synthesis and mitosis from cytokinesis.12 This characteristic switch in 
cardiomyocyte growth potential from a proliferative to a hypertrophic phenotype occurs 
at different stages of development in different species.43 In rodents, most cardiomyocytes 
exit the cell cycle within the first week of birth and become multinucleated and polyploid,70 
whereas in humans this occurs in early adulthood, with most cardiomyocytes remaining 
mononucleated throughout life.9 The molecular basis for this transition is defined by the 
changing expressions of cell cycle regulatory components, where positive regulators of 
cell cycle progression – certain cyclins, Cdks, and the major E2F transcription factors – 
are significantly downregulated in adult cardiomyocytes,71 whereas key repressors of cell 
cycle progression such as p21Cip1 and p27Kip1 become highly expressed.72 These 
changes underpinning postnatal arrest may in turn be critically regulated by the 
transcription factor Meis1, deletion of which has been shown to extend the postnatal 
proliferative window in mouse cardiomyocytes.73 Microarray analysis has also revealed 
a regulatory role for microRNAs (miRNAs) in mitotic arrest through the identification of 
the miR-15 family, known to target a number of cell cycle genes, as a highly upregulated 
miRNA subset in the postnatal mouse heart.74 
It remains unclear whether the signals that modulate cardiomyocyte exit from the cell 
cycle are intrinsic or extracellular.12 Correlative evidence suggests that multinucleation 
and polyploidisation create barriers to cytokinesis and therefore myocardial 
regeneration.75,76 In support of this inverse correlation between myocardial ploidy and 
regenerative capacity, a recent study has shown that approximately 99% of 
cardiomyocytes in the highly regenerative adult zebrafish heart are mononuclear and 
diploid. In addition, experimental polyploidisation of zebrafish cardiomyocytes was 
indeed sufficient to impair their proliferative capacity and ability to recover after apical 
resection such that scar formation was consistently observed.77  
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Both the zebrafish and mammalian foetal heart reside in relatively hypoxic environments. 
In contrast, oxygen tension rapidly rises soon after birth and drastically changes the 
oxygenation state of cardiomyocytes. Consequently, this is considered to predispose to 
the generation of reactive oxygen species (ROS) through the embryonic-to-postnatal 
switch from glycolysis to utilisation of oxygen-dependent mitochondrial oxidative 
phosphorylation as a major energy source.78 Although this confers a significant energy 
advantage, the postnatal increase in ROS levels in cardiomyocytes has been linked to 
mitochondrial-dependent oxidative stress and cell cycle arrest via activation of the DNA 
damage response (DDR) pathway.79 Furthermore, in comparison with the low-pressure, 
2-chambered zebrafish heart, mammalian hearts are structurally more complex, possess 
a greater fibroblast constituency, and are subjected to greater mechanical stretch as a 
result of increased blood pressure. The highly organised architecture of mature 
sarcomere proteins may even physically hinder cytokinesis. As such, the large-scale, 
organ-wide cardiomyocyte dedifferentiation and concomitant electric uncoupling 
required for proliferation, as seen in the zebrafish heart, may not be compatible with 
mammalian heart function or survival.11,12  
These hallmark metabolic and mechanical features of adult mammalian cardiomyocytes 
likely share considerable overlap in the modulation of cell cycle withdrawal, since the 
increased metabolic efficiency required to cope with increased workload might 
collectively represent an evolutionary trade-off at the expense of the ability to 
proliferate.78     
1.2.5 Evidence for cardiomyocyte turnover in the adult heart 
The adult mammalian heart has traditionally been viewed as a postmitotic, terminally 
differentiated organ limited to a single mechanism of growth by cardiomyocyte 
enlargement.80 With the development of significant technological advancements, this 
classical paradigm has been actively challenged and modified to accept the emerging 
consensus that whilst hypertrophy remains the dominant mechanism of growth, the adult 
heart retains some capacity for cardiomyocyte renewal, although very limited.81,82  
Labelled thymidine and thymidine analogs are stably incorporated into the genome 
during S-phase and have been widely used to measure cell cycle events.81 Using tritiated 
thymidine labelling assays, studies in the late 1990s were able to map cardiomyocyte 
DNA synthesis and cell cycle dynamics after birth in mice and showed a very modest but 
detectable level in adulthood, although the outcome of these cells with regard to 
polyploidisation, karyokinesis, and cytokinesis remained unclear (Figure 1.2).68,83,84   














Figure 1.2. Cardiomyocyte cell cycling fate in the adult mammalian heart. In the adult 
mammalian heart, most cardiomyocytes remain quiescent and are not progressing through the 
cell cycle. Rare events of cardiomyocytes that do re-enter the cell cycle may be classified as those 
that complete the cell cycle phases by undergoing mitosis followed by karyokinesis and 
cytokinesis, or more commonly, those that are non-proliferative. The latter cell cycle events of 
endoreplication describe an increase in DNA content with or without karyokinesis to produce 
multinucleate and polyploid cells, respectively, and pose a challenge for investigation of 
proliferation. Only cardiomyocyte cell cycles that result in hyperplasia may contribute to 
regeneration. Adapted from Karra and Poss, 2017.85 
To resolve this issue, a more direct assessment of cardiomyocyte cell cycling in the adult 
mouse heart was undertaken using multi-isotope imaging mass spectrometry combined 
with genetic fate mapping for detection of the non-radioactive thymidine analog 15N-
thymidine.86 This was able to demonstrate that cardiomyocytes are renewed from pre-
existing cardiomyocytes in young adult mice at an annual rate of 0.76% under normal 
homeostatic conditions, and at declined rates in aged mice. Importantly, cardiomyocyte 
exchange was augmented after permanent myocardial infarction in the border zone 
region, suggesting activation of endogenous proliferative pathways secondary to injury.86  
Further evidence gained from the adult mouse heart identified the potential for a small 
subset of cardiomyocytes to possess greater propensity to proliferate. Lineage tracing 
by hypoxia fate mapping was able to selectively label hypoxic cardiomyocytes through 
fusion of the oxygen-dependent degradation domain of hypoxia-inducible factor 1 alpha 
(Hif1α) to a tamoxifen-inducible Cre recombinase.87 Identification of this rare population 
of myocytes and their progenies revealed the contribution, though not exclusive, of 
hypoxia signalling to new cardiomyocyte formation in the adult heart (projected at 
























greater retention of characteristics resembling neonatal cardiomyocytes such as smaller 
size and mononucleation (as discussed in the regulation of postnatal cardiomyocyte cell 
cycle withdrawal in 1.2.4). It remains unclear whether this model describes a persistent 
subpopulation of myocytes or an oscillating state between hypoxia and normoxia.87  
The dramatic increase in atmospheric 14C as a result of post-war nuclear weapon tests 
enabled the investigation of cardiomyocyte turnover in humans using the radiocarbon 
dating technique in conjunction with stereological and flow cytometric analysis. These 
techniques were able to assess the pulse labelling of cardiomyocyte DNA in order to 
establish the age of cardiac cells.9,88 The measurements from human cardiac tissue 
revealed a low but continuous cardiomyocyte renewal level that falls with age, 
corresponding to a replacement rate of approximately 1% per year at the age of 20, 
declining to lower than 0.5% in elderly individuals. In the approach to the adult renewal 
rate in the second decade of life, DNA content was found to increase per cardiomyocyte 
nucleus, indicating a switch to polyploidisation. These data support a continuous turnover 
of the cardiomyocyte population in which cell birth is counterbalanced by cell death, thus 
maintaining the cardiomyocyte number established after the perinatal period constant 
throughout life.9,88 
Overall, collective analysis of these major studies and others by a consensus statement 
has established that in the healthy, uninjured adult mouse and human heart, the total 
number of cardiomyocytes remains essentially stable, and annual rates of turnover are 
currently estimated at 0.5 – 2% in both species.82  
1.3 Mechanisms stimulating cardiomyocyte renewal  
Regardless of the absolute level of intrinsic proliferative capacity retained by the adult 
mammalian heart, it is clear that heart failure frequently persists after significant 
myocardial injury. This means that, in the absence of intervention, this degree of cell 
turnover is evidently insufficient to compensate for the loss of up to 1 billion 
cardiomyocytes following a major ischaemic event. Although the underlying mechanisms 
for cardiomyocyte regeneration remain highly debated, a number of therapeutic 
strategies have been investigated in an attempt to counteract the initial cardiomyocyte 
loss by augmentation of cell cycle re-entry in the surviving cardiomyocyte population.26,89 
1.3.1 Genetic manipulation of cell cycle regulators 
Multiple attempts have been made to stimulate cardiomyocyte proliferation by 
overexpression of various cell cycle components. Cyclin A2 was one of the first cell cycle 
targets to demonstrate enhanced progression through the cell cycle in mature 
cardiomyocytes.23 Transgenic overexpression of cyclin A2, which is important during S-
phase and G2 progression, has been reported to stimulate cardiomyocyte proliferation,90 
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and mediate functional benefit associated with increased DNA synthesis and mitotic 
indices after ischaemic injury in mice.91 Subsequent studies have also shown that 
adenoviral-mediated delivery of cyclin A2 in a porcine model of myocardial ischaemia 
was associated with improved recovery and induction of cytokinesis of pre-existing 
cardiomyocytes in addition to preservation of sarcomeric structure in newly generated 
cells.92 
Overexpression of the early G1 D-type cyclins in transgenic mice has been sufficient to 
stimulate DNA synthesis in adult myocardium under basal conditions, but was associated 
with differential effects on recovery following injury. Mice overexpressing cyclins D1 or 
D3 showed a reduction in the level of cardiomyocyte synthesis following injury, whilst 
overexpression of cyclin D2 showed sustained DNA synthesis, leading to regenerative 
growth and infarct regression.93,94 However, there have been concerns that the 
demonstration of DNA synthesis in these studies has been inadequately accompanied 
by evidence of cytokinesis, and therefore may not be reflective of true proliferation.12  
More recently, adenoviral-mediated overexpression of a combination of 4 cell cycle 
regulators (Cdk1, Cdk4, cyclin B1, and cyclin D1) was shown to efficiently induce 
cardiomyocyte cell cycle activation in the adult mouse heart with significant improvement 
in cardiac function after myocardial infarction.95 Importantly, this study was able to 
rigorously assess cell division events in vivo by utilisation of the Cre-recombinase-
dependent mosaic analysis with double markers (MADM) lineage tracing system in order 
to genetically label cardiomyocytes demonstrative of cytokinesis, and therefore able to 
attribute the improved functional response to cardiomyocyte regeneration.95  
1.3.2 MicroRNAs 
MiRNAs represent a class of small, non-coding RNAs that negatively modulate gene 
expression either through the repression of protein translation or the promotion of mRNA 
degradation. A single miRNA can target hundreds of different mRNAs, whilst a single 
mRNA may be interfered with by multiple miRNAs.12 Given their capacity to suppress 
large collections of mRNAs encoding for proteins involved in common signalling 
pathways, miRNAs are now recognised as central regulators of cardiac development 
and disease.96 
As some miRNAs have been implicated in the postnatal cardiomyocyte cell cycle exit (as 
discussed in 1.2.4), it was reasoned that others could stimulate the reverse. This was 
addressed by a high-throughput screening assay using a genome-wide, human miRNA 
library, resulting in the identification of 40 miRNAs with the capacity to stimulate cell cycle 
activity as evidenced by DNA replication and cytokinesis of cultured mouse and rat 
neonatal cardiomyocytes.97 The most effective hits of this initial selection, namely miR-
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199a and miR-590, were also able to demonstrate evidence of cell cycle re-entry and 
division in cultured adult cardiomyocytes. The downstream targets of miR-199a and miR-
590, including the calcium signalling regulator Homer1 and the homeodomain protein 
Hopx, were all identified as inhibitors of cardiomyocyte proliferation. When administered 
by exogenous delivery to the adult mouse myocardium, these miRNAs selectively 
stimulated cardiomyocyte proliferation and markedly improved recovery of cardiac 
functional parameters with reduced fibrotic scarring following infarctive injury.97,98 
Furthermore, this has very recently been strengthened by evidence in large mammals, 
in which adeno-associated viral delivery of miR-199a was able to demonstrate marked 
improvement in both global and regional contractility after MI in pigs, mediated by 
endogenous cardiomyocyte proliferation and dedifferentiation. However, persistent and 
uncontrolled expression of the miRNA resulted in sudden arrhythmic death and 
myocardial infiltration of the proliferating cells, demonstrating the clinical potential of this 
strategy but reinforcing the importance of tight dosage control.99 
Another group of miRNAs implicated in cardiomyocyte proliferation is the miR-17-92 
cluster. Originally identified as a human oncogene, the miR-17-92 cluster has 
demonstrated its importance in cardiomyocyte cell cycle re-entry through gain- and loss-
of-function studies in which cardiomyocyte-specific deletion of this cluster resulted in 
cardiac hypoplasia, whilst its transgenic overexpression induced cardiomyocyte 
proliferation in embryonic, postnatal, and adult hearts; that latter of which was sufficient 
to enhance cardiac function after myocardial infarction.100 Interestingly, these effects 
were shown to be mediated via regulation of the tumour suppressor phosphatase and 
tensin homolog (PTEN) – an important endogenous inhibitor of the phosphoinositide 3-
kinase (PI3K) signalling pathway.100   
1.3.3 Signal transduction pathways 
Since the adult heart is composed of a heterogeneous cellular population, multiple cell 
types, including fibroblasts, endothelial, and smooth muscle cells, are likely to contribute 
to the regulation of cardiomyocyte biology through the release of diffusible molecules.12 
The identification of potential ligands and their receptors that play a role in cardiomyocyte 
proliferative and regenerative signalling has been an important target for research.101 
The Notch signalling pathway activates a set of genes encoding transcriptional activators 
that regulate genes involved in heart growth and patterning, and is thus a key pathway 
in cardiac development. Notch signalling is mediated via cell transactivation, in which a 
ligand-expressing cell transactivates a neighbouring cell, which positively propagates 
further signalling by upregulation of ligand and receptor expression in signalling and 
receiving cells, respectively.102 As discussed in section 1.2.3, the importance of Notch 
signalling in cardiac regeneration has been demonstrated in the adult zebrafish heart, 
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which involves the re-engagement of a number of developmental signalling 
pathways.60,89 Notch pathway activation has also been shown to sustain cardiomyocyte 
proliferation at birth in the mammalian heart.103,104 Despite these findings, reactivation of 
this pathway in the adult mouse heart has proved ineffective in inducing cardiac 
regeneration after myocardial infarction, as a result of blunted efficacy due to the 
presence of permanent epigenetic repressive marks at Notch-responsive promoters.105  
Likewise, NRG1 signalling is also essential during cardiac development, acting as a key 
mitogen via the ERBB2 and ERBB4 receptor tyrosine kinases of the epidermal growth 
factor receptor family.106,107 NRG1 signalling is also required for zebrafish heart 
regeneration, and its overexpression induces cardiomyocyte proliferation even in the 
absence of injury.59 Multiple downstream effectors of NRG1/ERBB signalling in cardiac 
models have been identified, including Akt and MAPK/extracellular signal-regulated 
kinase 1/2 (ERK1/2).101 In adult differentiated rat cardiomyocytes, NRG1 has been 
shown to stimulate DNA synthesis and cytokinesis facilitated by sarcomeric disassembly 
through the activation of ERBB4 signalling.75 When administered in vivo, recombinant 
NRG1 is associated with enhanced cardiomyocyte proliferation and functional recovery 
after myocardial infarction in adult mice,75 although the regenerative effects of this 
pathway in the adult heart have been contested (Figure 1.3).108 Furthermore, the 
signalling molecule p38 MAPK is a negative cell cycle regulator and its activity is 
therefore inversely correlated with cardiac growth during development. As such, 
inhibition of p38 has been shown to initiate dedifferentiation and proliferation of adult 
cardiomyocytes in vitro,109 and, when coupled with FGF1, p38 inhibition in vivo has 
demonstrated the ability to promote cardiomyocyte proliferation and enhance functional 
parameters post-MI in adult rats.110 However, it is important to note that even though 
these mitogens are associated with some degree of adult cardiomyocyte proliferation, 
their efficiency to stimulate cell cycle re-entry is considered to be low, and appears to be 
restricted to the mononucleated subset of cardiomyocytes in rodent models.89 As with 
Notch signalling, cardiac regeneration in the adult mammalian heart may not necessarily 
recapitulate the events of development, meaning that adult cardiomyocytes may not be 
permissive to cell cycle re-entry in response to the same developmental signals.12,89  
The Hippo pathway is an evolutionarily conserved pathway that has emerged as a major 
regulator of cell proliferation, growth, and organ size.111 Its core signalling components 
in mammals include the mammalian STE20-like protein kinases 1 and 2 (Mst1 and Mst2), 
the scaffolding protein Salvador (Salv), the large tumour suppressor homolog 1 and 2 
(Lats1 and Lats2) protein kinases, the terminal effector Yes-associated protein (Yap) and 
transcriptional co-activator with PDZ-binding motif (Taz). Activation of this signalling 
cascade leads to phosphorylation of Yap and Taz, resulting in their exclusion from the 
34 
 
nucleus and consequent disrupts their association with DNA binding transcription factors 
that normally drive cellular growth. Hippo signalling therefore acts to control heart size 
during cardiac development by limiting cardiomyocyte proliferation.111 Consistent with 
this, the levels of phosphorylated Yap in the heart have been found to increase in mice 
after P7 compared to hearts at P2.112  
The key components of the Hippo pathway have been studied for their effects on 
proliferation in mature cardiomyocytes. Hearts with postnatal cardiomyocyte-specific 
knockout of the gene encoding Salv have shown evidence of regenerated myocardium 
with reduced scar size after apical resection at P8, indicative of prolongation of the 
postnatal proliferative window. In addition, induction of Hippo deficiency in 2 genetic 
models by cardiac-specific knockout of Salv and both Lats1 and Lats2 was sufficient to 
mediate cardiomyocyte cell cycle re-entry and cytokinesis in unstressed adult mice, and 
confer regenerative protection from infarctive injury with normalisation of cardiac function 
within 3 weeks.112 Deletion of cardiomyocyte Salv in the adult mouse heart has also been 
shown to induce a reparative genetic response with increased cardiomyocyte renewal, 
scar border vascularity, reduced fibrosis, and recovery of function even when deleted in 
established ischaemic heart failure 3 weeks after myocardial infarction.113 Furthermore, 
the transgenic and viral-mediated overexpression of the downstream component Yap in 
the adult heart has similarly been shown to promote cardiomyocyte proliferation and elicit 
therapeutic benefit in models of cardiac injury.114,115   
These results clearly support the regulatory role for the Hippo pathway in cardiomyocyte 
proliferation not only during development but also during postnatal and adult life. 
Previous evidence suggests that this pathway may also be subject to modulation by 
ligand-receptor binding (Figure 1.3).116 The induction of Yap-mediated proliferation has 
been shown to de-repress the genes activated by the Wnt/β-catenin pathway,117 
involving the activation of insulin-like growth factor 1 (IGF1) receptor signalling, 
phosphorylation of Akt and inactivation of glycogen synthase kinase-3β (GSK-3β), 
leading to the stabilisation of β-catenin.115,118 Interestingly, investigation of the link 
between the Hippo pathway and the PI3K-Akt pathway identified Pik3cb – an isoform 
encoding the PI3K catalytic subunit – as a crucial direct target and effector of Yap, and 
further demonstrated that overexpression of Pik3cb in adult mice after MI was able to 
promote cardiomyocyte cell cycle activity and survival.119  
Implicated as a central signal transduction cascade in proliferation, the PI3K-Akt pathway 
plays an important role in cardiac viability and growth.120 The downstream effector, Akt, 
is a serine-threonine kinase that has been implicated in the inhibition of CDKIs and 
opposition of cell cycle arrest.121 Studies in which mice were genetically modified to 
overexpress a nuclear-targeted, constitutively active Akt revealed superior 
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cardiomyocyte survival,122 and a greater number of cardiomyocytes in the adult heart in 
the absence of hypertrophy, but smaller in volume with enhanced contractility.123 This 
model has also been associated with prolongation of the postnatal proliferative window 
3 weeks after birth.124     
1.3.4 Redox control of proliferation 
The intracellular activity of ROS has emerged as a an additional potential regulator of 
cardiomyocyte proliferation.101 As discussed in section 1.2.4, there has been research to 
suggest that ROS contribute a negative regulatory role to the cardiomyocyte cell cycle, 
particularly emphasised during the postnatal hyperplastic-to-hypertrophic transition.79 In 
support of this, the impact of increased oxygenation state in adult mammals has recently 
been further demonstrated by gradual exposure of mice to severe systemic hypoxaemia. 
This was shown to decrease ROS production and oxidative DNA damage, and reactivate 
cardiomyocyte mitosis sufficiently to enable a robust regenerative response with 
decreased myocardial scarring and improvement in left ventricular systolic function 1 
week after infarctive injury.125 Moreover, the ROS that are produced during the postnatal 
transition have additionally been shown to activate the Hippo pathway through 
modulation of Mst1 and Mst2.126 Conversely, a study that aimed to investigate the 
downstream factors that promote renewal in a heart regeneration mouse model of Hippo 
deficiency identified the homeodomain transcription factor Pitx2 as being upregulated in 
the border zone of infarcted hearts. Genomic analyses revealed a primary role for Pitx2 
in promoting ROS scavengers to mediate protection from oxidative damage, which was 
also found to involve Nrf2 as a regulator of the antioxidant response.127   
Nevertheless, the influences of hypoxia and ROS generation on cardiomyocyte 
proliferation remain somewhat unclear. ROS scavenging in the context of postnatal 
cardiomyocyte cell cycle arrest was only found to postpone, not impede this transition,79 
strongly suggestive that other intrinsic or extrinsic mechanisms are involved. 
Interestingly, the reactive species hydrogen peroxide (H2O2) has actually been proposed 
as a positive factor in zebrafish heart regeneration, since scavenging of this molecule by 
transgenic catalase overexpression was shown to impair regenerative recovery.128 
Treatment with low-level H2O2 has also been shown to enhance the proliferation of 
murine neonatal cardiomyocytes and embryonic stem cell-derived cardiomyocytes in 
vitro, involving downregulation of p27Kip1 and nuclear translocation of cyclin D1.129 
Additionally, transgenic mice with excess myocardial H2O2 generation have been 
reported to demonstrate larger, hyperplastic hearts with a prolonged postnatal 
cardiomyocyte cycling period.130 It is therefore evident that the modulation of cellular 
effects by ROS are crucially determined by the level and context in which they are 
released, and could be dependent on the differentiation between the functions of ROS 
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within redox-mediated signalling pathways as opposed to the concept of oxidative 
stress.131 
As such, it has become increasingly recognised that the proliferation of cardiomyocytes 
and other cell types is under the control of redox-regulated signalling pathways. Redox 
sensing of cell cycle regulation has been shown to involve targets such as reactive 
cysteine thiols present in cell cycle regulator molecules.132 Intracellular-generated ROS 
has also been shown to target mitogenic signalling cascades such as MAPK/ERK1/2 
and Akt,130,132 which may in part be mediated by inactivation of protein tyrosine 
phosphatases (PTPs) (Figure 1.3).133 It is thus of significant interest to understand the 
mechanisms that link intracellular ROS to increased cardiomyocyte proliferation by 
elucidation of the precise source, site of generation, and redox targets of the reactive 











Figure 1.3. Pathways controlling cardiomyocyte proliferation. Pathways that initiate 
cardiomyocyte proliferation may be targeted for cardiac regeneration. (1) Several ligands have 
been identified that promote proliferation in models of regeneration, including neuregulin 1 
(NRG1), which activates multiple downstream effector pathways through ERBB signalling in adult 
mononuclear cardiomyocytes. (2) Inhibition of upstream inhibitory Hippo kinases promotes 
nuclear entry of unphosphorylated Yes-associated protein (Yap), leading to transcriptional 
activation of factors that drive cellular growth. (3) Increased oxygenation and mitochondrial 
reactive oxygen species (ROS) formation after birth contribute to cardiomyocyte cell cycle arrest, 
but localised ROS also promote proliferation via redox modification of sensor proteins that are 
centrally involved in cell cycle regulation. (4) Cardiomyocyte proliferation requires cellular 
dedifferentiation by sarcomeric disassembly, which may be inhibited by the dystrophin 












signal-regulated kinase; GSK-3β, glycogen synthase kinase-3β; TEAD, TEA domain family 
members. Adapted from Tzahor and Poss, 2017.134  
1.4 Cardiac redox signalling 
1.4.1 The signalling functions of reactive oxygen species  
ROS have traditionally been viewed as by-products of mitochondrial oxidative 
metabolism with a primary role in causing macromolecular damage. Mitochondrial ROS 
are known to cause cellular toxicity by promoting damage of lipids, protein, or DNA, 
resulting in cell cycle arrest, apoptosis, or cellular senescence.78 As such, it has been 
considered that a pathologically high level of oxidant species in cells may underlie the 
development of many cardiovascular diseases, including atherosclerosis, hypertension, 
and heart failure, through exposure to oxidative stress.131,135 However, antioxidant 
strategies have failed to show efficacy in ameliorating disease progression, and so this 
concept has neglected the paradoxical wider roles of ROS in the maintenance of redox 
balance. ROS therefore also serve important biological functions through modulation of 
a variety of physiological processes by redox signalling reactions.131 
As opposed to the broad and non-specific range of oxidations that might occur in 
stressed tissues, redox signalling refers to the specific, usually reversible, oxidative and 
reductive reactions that result in the targeted post-translational modification of 
biomolecules involved in cellular signalling pathways.131,136 Such molecular targets are 
protein sensors that respond to variations in local redox state by a change in 
conformation, interactions, stability, and activity, and therefore serve as signal 
transducers. These proteins include receptors, ion transporters, enzymes (notably 
kinases and phosphatases), transcription factors, and cytoskeletal filaments, the most 
susceptible targets of which are likely cysteine residue thiols.131 The major reactive 
species involved in redox signalling are the superoxide anion (O2 ●−), the product of a 
one-electron reduction of oxygen, and the more stable nonradical H2O2 to which it 
dismutates, either spontaneously or catalysed by superoxide dismutases (SOD). H2O2 is 
relatively stable in vivo, but may be decomposed by catalase or oxidising enzymes such 
as peroxidase. It is also lipid-soluble, and can diffuse freely across cellular 
membranes.131,137 
In the heart, redox signalling plays a key role in the regulation of physiological processes 
(e.g. cellular differentiation, proliferation, survival), adaptation to stress, and 
pathophysiological processes (e.g. adverse ventricular remodelling). The signalling 
outcomes of ROS are crucially influenced by factors including the precise species 
released and half-life, cellular localisation, local concentration, and subcellular 
antioxidant pools. In addition to the ROS-decomposing enzymes stated above, the local 
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antioxidant environment is also determined by the ROS scavengers glutathione, which 
can reduce a diverse range of oxidised proteins, and thioredoxin, which may have more 
specific reductive functions.131,138   
1.4.2 The main sources of ROS in cardiomyocytes 
The predominant ROS sources in the heart include the mitochondria, metabolic 
enzymes, uncoupled nitric oxide synthases (NOSs), and the specialised enzymes of 
ROS generation – the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, 
also known as Noxs.131,138  
Mitochondria can generate ROS at different stages during the reduction of O2 to H2O in 
the electron transport chain (ETC) due to electron leakage.138 The steady-state levels of 
ROS produced here depend on the rates of production at different sites in the ETC as 
well as the activity of antioxidants present in the matrix and cytosol. Mitochondrial ROS 
may be particularly detrimental in the setting of mitochondrial dysfunction secondary to 
ischaemia-reperfusion injury.139 Metabolic pathways also contribute to the production of 
ROS during several oxidase-mediated biosynthetic reactions; in many cases the ROS 
are consumed, but oxidases that utilise O2 as the terminal electron acceptor generate 
O2●− or H2O2.131 Among these, xanthine oxidase and monoamine oxidases have been 
implicated in the pathology of heart failure.140,141 In addition, cardiomyocytes 
constitutively express certain NOS enzymes, which switch from NO to O2●− when they 
become uncoupled due to cofactor depletion.142 This is triggered by excessive 
mitochondrial ROS and so acts as an amplifying mechanism. Lastly, in contrast to the 
above described sources of ROS, which unlikely contribute a substantial role to regulated 
redox signalling, the Nox family enzymes catalyse the generation of ROS as their primary 
function, and so represent crucial regulators of redox-mediated signal transduction 
pathways.131   
1.5 The NADPH oxidase family of enzymes 
1.5.1 Nox structure and function 
The Noxs have no known biosynthetic or catabolic function but specifically serve as a 
dedicated source of ROS, and have emerged as the major cellular contributors of 
signalling ROS involved in redox pathways.143 Noxs use NADPH as an electron donor 
for the reduction of O2 to O2●− and H2O2 via electron transfer to flavin and heme moieties 
(Figure 1.4).131,138 They are a family of multisubunit transmembrane enzymes comprising 
7 known isoforms: Nox1 – Nox5 and dual oxidases Duox1 and Duox2, each with a 
distinct catalytic subunit responsible for oxidase activity, and with varying properties 
according to requirements for additional accessory subunits, predominant oxidative 
species produced, and intracellular compartments in which they are found.143 The Noxs 
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are particularly suited for their role in redox signalling because their activity and 
expression may be modulated by diverse agonists and conditions of stress, which, in 
combination with their precise localisation, allows for the tightly regulated and spatially 










Figure 1.4. NADPH oxidase structure and molecular organisation. All Nox enzymes contain 
an amino-terminal hydrophobic domain that is predicted to form a catalytic core of 6 
transmembrane-spanning α-helices. This region contains conserved histidine residues, which 
provide binding sites for 2 haem (Fe) groups. The carboxy-terminal portion folds into an 
independent cytoplasmic domain that contains binding sites for the co-enzymes flavin adenine 
dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate (NADPH). Nox1, Nox3, and 
Nox4 are nearly identical in size and structure to Nox2, whilst Nox5 contains an additional amino-
terminal calcium-binding domain. Nox enzymes catalyse the NADPH-dependent reduction of 
oxygen (O2) via transfer of 2 electrons from NADPH to FAD, forming the reduced flavin FADH, 
which are transported across the membrane by the haem electron carriers to form superoxide 
(O2●−) and hydrogen peroxide (H2O2).136 Adapted from Barnes and Gorin, 2011.144 
The Nox complexes are differentially expressed between tissues. The first discovered 
member of the Nox family, Nox2, also known as gp91phox, is most highly expressed in 
phagocytes where it is responsible for phagocytic respiratory burst. The isoforms Nox1, 
Nox2, Nox4, and Nox5 are expressed in the cardiovascular system, and among these, 
Nox2 and Nox4 are expressed in cardiomyocytes.143 Both isoforms exist as a 
heterodimeric flavocytochrome bound to a smaller p22phox subunit, but otherwise display 
significant differences in activation, function, and localisation.131 Nox2 is localised at the 
sarcolemma (plasma membrane of cardiomyocytes) and t-tubules and is acutely 
activated by agonists such as angiotensin II, endothelin-1, cytokines, growth factors, and 
mechanical forces. These induce a complex process involving post-translational 
modifications in cytosolic regulatory subunits (p47phox, p67phox, p40phox, Rac1), which 
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promote their association with Nox2-p22phox to form the fully activated enzyme and initiate 
O2●− production. By contrast, Nox4 is found in the sarcoplasmic reticulum (endoplasmic 
reticulum of cardiomyocytes) and possibly mitochondria, and seems to predominantly 
generate H2O2. Nox4 does not require acute activation but is constitutively active with no 
obligatory requirement for additional subunits other than p22phox. It is thus primarily 
regulated by changes in abundance induced by stimuli including hypoxia, endoplasmic 
reticulum stress, and pressure overload.131,138  
Current evidence from experimental animal studies suggests that under normal 
physiological conditions, the Nox proteins and their redox products contribute to the 
maintenance of cardiovascular homeostasis by participation in processes such as 
calcium regulation and vascular tone. Nox-regulated redox signalling may also potentiate 
diverse pathways involved in tissue repair including proliferation.145 Conversely, it is also 
established that their dysregulation may promote certain pathological conditions.143 Nox2 
has been closely linked to inflammation as its activation has been shown to mediate the 
release of pro-inflammatory cytokines,146 as well as trigger monocyte adhesion, which is 
critically implicated in atherosclerotic lesion formation.147 In the heart, Nox2 has also 
been shown to detrimentally participate in adverse cardiac remodelling and contractile 
dysfunction after injury, as Nox2-null mice demonstrate reduced hypertrophy and fibrosis 
and improved ventricular function 4 weeks post-MI.148 However, Nox-dependent ROS 
generation is also vital for signalling pathways that protect against myocardial injury. 
Cardiomyocyte Nox4 has been shown confer protection against pressure overload-
induced hypertrophy and remodelling via distinct pro-angiogenic effects on myocardial 
capillarisation.149,150 The cardioprotective effects of Nox4 have been additionally 
demonstrated in the context of acute cardiac injury through enhancement of the 
integrated stress response,151 and in haemodynamic overload via direct upregulation of 
Nrf2.152 
The magnitude of difference in the response of these cardiac Nox isoforms to injury 
highlights the selectivity that would be necessary for therapeutic targeting.143 
Furthermore, it is intriguing that alternative isoforms of Nox4 have additionally been 
discovered, with potential for variations in subcellular localisation and therefore key 
functional differences in redox-regulated cell signalling.153  
1.5.2 Identification of novel Nox4 splice variants  
The existence of 4 splice variants of Nox4 – termed Nox4B, C, D and E – was originally 
reported in both the human lung A549 cell line and lung tissues by Goyal et al in 2005 
during analysis of Nox4 expression.153 Western blot analysis of a specific antibody 
targeted to Nox4 demonstrated the presence of several bands between the 20-70 kDa 
range; results which were mirrored in parallel with the presence of several smaller bands 
41 
 
at the mRNA expression level, sequencing of which revealed the isolation of Nox4 splice 
variant products.153 
The differential splicing and structural organisation of the isoforms were characterised 
according to the exon structures and alignment of the corresponding amino acid 
sequences, which showed key differences in the expression of the Nox4 structural and 
functional domains. Similar to Nox4, the isoforms Nox4B and C were predicted to 
associate with the endoplasmic reticulum, but were found to possess dominant negative 
characteristics for ROS generation, which was structurally consistent with the critical 
deletion of the first NADPH binding site, and all FADH and NADPH binding sites, 
respectively. In contrast, the other variants Nox4D and E were found to lack the 
hydrophobic transmembrane domains, suggesting these as non-membrane-associated 
isoforms. Interestingly, whilst Nox4E, which additionally lacks the first NADPH binding 
domain, exhibited no change in ROS concentration, Nox4D generated ROS at a 
comparable rate to full-length Nox4.153  
In comparison to the full-length structure of Nox4, Nox4D skips exons 3 – 11 to generate 
a truncated protein (Figure 1.5). However, NADPH oxidase activity is preserved due to 
retained possession of the FADH and NADPH binding domains necessary for ROS 
production.153 The capacity of Nox4D to maintain such enzymatic activity in spite of its 
critical structural deletion proved particularly interesting in light of the conserved histidine 
residues of the classical Nox transmembrane domain that are considered essential to 
facilitate electron transfer through haem binding (Figure 1.4).136 This finding therefore 
questioned the necessity of these residues, although it was not addressed whether the 
function of Nox4D is dependent on additional partner subunits such as p22phox.153  
 
Figure 1.5. Exon structure of Nox4D splice variant. Nox4D is a truncated protein generated 
by splicing of exons 3 – 11 of Nox4. Nox4D lacks the characteristic Nox transmembrane domain 
but retains the binding sites for the co-enzymes flavin adenine dinucleotide (FADH) and 
nicotinamide adenine dinucleotide phosphate (NADPH), suggesting it is a non-membrane-




1.5.3 Nox4D is a nuclear-localised, redox-active splice variant of Nox4 
Further work on the characterisation of Nox4D was carried out in vitro by the Shah 
laboratory.154 This work uncovered a prominent localisation of Nox4D to the nucleus of 
multiple cardiovascular cell types, including neonatal cardiomyocytes, fibroblasts, and 
vascular smooth muscle cells (VSMCs), with a granular distribution within the nuclear 
matrix and focal staining corresponding to the nucleolus. This pattern of distribution was 
consistent with Western blotting of the membrane- and nuclear-fractionated VSMCs, the 
latter of which contained the more dominant band and major isoform found in this 
fraction, and was confirmed as 28 kDa Nox4D.154  
Consistent with the initial characterisation in lung cells,153 Nox4D was further 
demonstrated to be functionally active in terms of ROS generation. Catalase-inhibitable, 
NADPH-dependent H2O2 production by Nox4D was proven comparable to Nox4 using 
models of overexpression.154 Importantly, Nox4D was also demonstrated to exhibit 
electron transfer activity, which is supported by previous evidence that the Nox4 carboxy-
terminal dehydrogenase domain, which is preserved in Nox4D, is capable of constitutive 
electron transfer activity.  This represents an important discriminating feature since the 
equivalent regions of Nox1, Nox2, and Nox5 are associated with negligible constitutive 
electron transfer activity.155 Since the amino-terminal transmembrane portion of the full-
length Nox complexes functions to facilitate electron transfer across the membrane to 
generate ROS on the opposite side of the membrane, the constitutive activity of Nox4D 
together with its lack of transmembrane domain collectively suggest that this splice 
variant may specifically serve to generate intracellular ROS in cytosolic compartments. 
Although the transcriptional mechanisms that regulate Nox4 splicing are unknown, the 
nuclear localisation of ROS release may have several important implications for the post-
translational modification of site-specific protein sensors by manipulation of downstream 
effectors within the nucleus.154 Indeed, Nox4D-generated ROS was also shown to 
mediate nuclear-localised redox signalling through increased activation of ERK1/2, 
previously reported as a redox target of the Nox family enzymes,143 and downstream 
transcription factor Elk-1. Such effects could be mediated directly or indirectly via 
oxidative inactivation of nuclear phosphatases.154 
In summary, Nox4D represents a functionally active, nuclear-localised splice variant of 
Nox4, with the capacity to constitutively generate NADPH-dependent ROS and modulate 
redox signalling pathways. These initial data highlighted the potential for Nox4D to play 
important roles in the transduction of nuclear-localised signalling pathways.154 
Subsequent work by the Shah laboratory provided preliminary data to support the 
specific involvement of this Nox4 isoform in cardiomyocyte proliferation. This was 
realised after Nox4D-overexpressing neonatal cardiomyocytes showed characteristic 
43 
 
changes in cell size and number, accompanied by increased expression of proliferation 
markers and redox activation of signal transduction pathways involved in cell cycle 
modulation (discussed in more detail in 3.1.2). Given the extensive implication of redox-
mediated signal transduction pathways in the regulation of cardiomyocyte proliferation, 
it is essential to establish the sources of ROS that are crucially involved so that these 
may be therapeutically targeted. As such, it was of great interest to determine the effects 




1.6 Hypothesis  
An increase in cardiomyocyte Nox4D expression levels in the adult heart can increase 
cardiomyocyte cell number by enhancing the capacity for cell cycle re-entry and improve 
cardiac functional recovery following myocardial infarctive injury.   
1.7 Objectives 
(i) Investigate the effects of Nox4D in the adult mammalian heart in vivo by 
generation of a transgenic model of inducible cardiac-specific Nox4D 
overexpression and characterisation of baseline phenotype; 
(ii) Investigate the effects of inducible Nox4D overexpression in the pathological 
setting of myocardial infarction; 
(iii) Investigate the role of Nox4D in proliferation ex vivo using a cell culture model 









Nox4D STOP-flox transgenic (Nox4D Tg) mice were generated by Taconic Biosciences. 
α-myosin heavy chain-MerCreMer (αMHC-MCM) and ventricular myosin light chain 2-
Cre (Mlc2v-Cre) mice were originally obtained from The Jackson Laboratory. All mice 
were bred on a C57BL/6J genetic background and maintained in the institutional animal 
house, with free access to food and water and exposure to 12 hourly cycles of light per 
day. C57BL/6J strains are weakly regenerative.156  
All experimental procedures involving animals were conducted in healthy age- and 
gender-matched mice. Animals were cared for and used in accordance with 
governmental guidance as directed by the Animals (Scientific Procedures) Act 1986 
(Home Office, UK). Experiments were locally approved by the institutional Animal 
Welfare and Ethical Review Body at King’s College London.  
2.2 Generation of genetically-modified mice 
2.2.1 Nox4D transgenesis strategy and breeding 
The Nox4D Tg mouse line was originally generated by targeted cloning of the mouse 
Nox4D splice variant transgene to the Rosa26 locus, driven by the CAGGS promoter, 
which is composed of sequences from the chicken β-actin and human cytomegalovirus 
immediate early promoters, and can be expressed ubiquitously.157 This was designed in 
conjunction with a STOP-flox strategy, so that expression of the Nox4D transgene is 
silenced with a STOP sequence – a bacterial chloramphenicol acetyltransferase gene 
(CAT)158 – before the initial codon of Nox4D. Expression of the transgene is then 
dependent on the tissue-specific, Cre-mediated excision of the LoxP sequences that 








Figure 2.1. Generation of the Nox4D transgenic mouse line. The Nox4D transgene is targeted 
to the Rosa26 locus, driven by a human cytomegalovirus immediate early enhancer/chicken β-
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actin (CAGGS) promoter, and silenced by a STOP sequence. Nox4D transgene silencing is 
relieved by Cre-Lox recombination. From Taconic Biosciences.  
The Nox4D colony was maintained by crossing heterozygous Nox4D Tg females with 
C57BL/6J or heterozygous Nox4D Tg males to generate both heterozygous and 
homozygous offspring. The inducible cardiomyocyte-specific Nox4D (Ind-csNox4DInd-
csNox4D) Tg mouse model was then generated by crossing heterozygous or 
homozygous Nox4D females with heterozygous αMHC-MCM males, in which the ligand-
binding domain of a mutated murine oestrogen receptor (Mer) is fused to each end of 
Cre recombinase and expressed under the cardiac muscle-specific αMHC promoter.159 
Upon binding to tamoxifen, the MCM double fusion protein translocates from the 
cytoplasm to the nucleus and mediates recombination of the LoxP sites, thus allowing 
temporal regulation of targeted gene expression (Figure 2.2).157 The constitutive 
cardiomyocyte-specific Nox4D (csNox4D) Tg mouse model was generated by crossing 
heterozygous or homozygous Nox4D females with heterozygous Mlc2v-Cre males, in 
which Cre recombinase expression is directed in cardiac ventricular muscle, starting at 
approximately embryonic day 8 (E8).160 Littermates from the respective Ind-csNox4D 
and csNox4D breeding pairs with positive Nox4D transgene expression but negative Cre 
expression were designated wild type (WT) controls. The offspring from all breeding pairs 
were obtained at the expected Mendelian ratios, and no significant morbidity or mortality 
was observed. Assistance with the maintenance of all colonies was kindly provided by 
Mr Richard Thompson. 
Figure 2.2. Breeding strategy for generation of inducible cardiomyocyte-specific Nox4D 
transgenic mice. Animals with inducible cardiomyocyte-specific Nox4D (Ind-csNox4D) 
overexpression were generating by crossbreeding Nox4D transgenic female mice with α-myosin 
heavy chain-MerCreMer (αMHC-MCM) male mice to enable tamoxifen-inducible excision of the 
LoxP-flanked STOP cassette. Offspring with the STOP-floxed Nox4D allele only were used as 
wild type (WT) animals.  
2.2.2 Determination of genotype 
Nox4D, αMHC-MCM, Mlc2v-Cre, Ind-csNox4D, and csNox4D mice were lightly 
anaesthetised in a chamber with 2.5% isoflurane in 97.5% oxygen at 1 L/minute, then 












Samples were incubated with 300 μL sodium hydroxide (NaOH) 50 mM at 95ºC for 30 
minutes, then neutralised with 50 μL Tris hydrochloride (Tris-HCl, pH 8.0) 1 M for a 
further 30 minutes to extract the DNA. Reaction mastermixes were prepared containing 
12.5μL REDTaq® ReadyMix™ PCR reaction mix (Sigma), 2 μL forward and reverse 
primer mix 10 μM, 2 μL DNA, and 8.5 μL nuclease-free water. Nox4D, Rosa, Cre, and 
control primers were designed by the respective animal suppliers (Table 1).  
Table 1. Primers required per reaction for determination of genotype. Ctrl, control. 




Nox4D F - CTGTACCTCAGTCAAACAGATGG 
Nox4D R - CTTAAGCTAGCTCAGCTAACG 263 bp 
Ctrl F - GAGACTCTGGCTACTCATCC 
Ctrl R - CCTTCAGCAAGAGCTGGGGAC ~500 bp 
2 
Rosa F - CATGTCTTTAATCTACCTCGATGG 
Rosa R - CTCTTCCCTCGTGATCTGCAACTCC 299 bp 
Ctrl F - GAGACTCTGGCTACTCATCC 




Cre F - TGCCAGGATCAGGGTTAAAG 
Cre R - CCCGGCAAAACAGGTAGTTA 264 bp 
Ctrl F - GAGACTCTGGCTACTCATCC 





Nox4D F - CTGTACCTCAGTCAAACAGATGG 
Nox4D R - CTTAAGCTAGCTCAGCTAACG 263 bp 
Ctrl F - GAGACTCTGGCTACTCATCC 
Ctrl R - CCTTCAGCAAGAGCTGGGGAC ~500 bp 
2 
Cre F - TGCCAGGATCAGGGTTAAAG 
Cre R - CCCGGCAAAACAGGTAGTTA 264 bp 
Ctrl F - GAGACTCTGGCTACTCATCC 
Ctrl R - CCTTCAGCAAGAGCTGGGGAC ~500 bp 
 
Genomic DNA was amplified by polymerase chain reaction (PCR) in a thermal cycler 
(AB Applied Biosystems) under the following cycling parameters: initial denaturation at 
95ºC for 5 minutes, then 35 cycles of a separate denaturation step at 95ºC for 30 
seconds, an annealing step at 60ºC for 30 seconds, and an extension step at 72ºC for 1 
minute, followed by a final extension at 72ºC for 10 minutes. PCR products were 
electrophoresed on a 1.5% agarose gel (in Tris-acetate buffer containing Tris-acetate 40 
mM, ethylenediaminetetraacetic acid [EDTA] 1 mM, pH 8.3) containing Nancy-520 
(Sigma) 0.05 μL/mL as a nucleic acid stain in Tris-acetate as running buffer at 120V for 
20 – 30 minutes, then imaged under ultraviolet light. Genotypes were determined 




Figure 2.3. Analysis of genotype. Nox4D positivity (left) indicates that at least one allele 
possesses the sequence. Heterozygous Nox4D transgenic animals are indicated by the presence 
of a Nox4D band plus a Rosa band (middle), meaning the Rosa band is still present, whereas 
Nox4D positivity in the absence of Rosa is representative of a homozygous animal. Rosa positivity 
in the absence of Nox4D is equal to a wild type (WT) animal. αMHC-MerCreMer or Mlc2v-Cre 
positivity (right) in conjunction with Nox4D positivity is indicative of an Ind-csNox4D or csNox4D 
transgenic animal, respectively. Ctrl, control.  
2.3 Induction of Nox4D overexpression 
As performed previously in the Shah laboratory,150 to induce the nuclear translocation of 
MerCreMer and overexpression of Nox4D in cardiomyocytes of adult Ind-csNox4D mice, 
mice were injected intraperitoneally at 8 weeks of age with tamoxifen (Sigma) at 20 
mg/kg body weight once per day for 5 consecutive days. Littermate WT control mice 
received the same dosage in parallel. Tamoxifen injection was prepared by initial 
reconstitution at 1 in 10 parts of ethanol whilst heating at 37ºC for 30 minutes, then final 
dilution in peanut oil (Sigma) to approximately 5 mg/mL (containing <5% ethanol).  
The use of this induction protocol was initially validated in male and female WT and Ind-
csNox4D mice as part of the baseline characterisation studies by serial functional 
monitoring and analysis of Nox4D protein expression 3 weeks after tamoxifen 
administration (Figure 2.4). For the tamoxifen dose response experiment, male and 
female adult Ind-csNox4D mice were injected as above but randomised to receive 5 
mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg body weight, then harvested after 2 weeks.  
 
Figure 2.4. Experimental protocol for initial validation of tamoxifen induction. Adult WT and 
Ind-csNox4D mice received daily intraperitoneal tamoxifen injections for 5 days, and were 
monitored by echocardiography before and after until cardiac tissues were harvested for analysis 
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2.4 Surgical induction of myocardial infarction 
2.4.1 Permanent coronary artery ligation 
MI was induced in female adult mice at 10 – 12 weeks of age by permanent ligation of 
the left anterior descending coronary artery (LAD). Female mice were used exclusively 
as standard procedure in the laboratory group due to previous experience of frequent 
myocardial rupture and poorer survival rates when performed in male mice. After 
tamoxifen induction, cohorts of Ind-csNox4D and WT mice were randomly assigned to 
receive MI or sham surgeries, which were performed in parallel (Figure 2.5).  
Mice were anaesthetised by intraperitoneal injection of ketamine (75 mg/kg body weight) 
and medetomidine (1 mg/kg body weight) and warmed until asleep. Mice were then 
administered analgesia with 0.3 μg buprenorphine by intramuscular injection and 50 μg 
flunixin by subcutaneous injection. Fur was removed from the surgical area using an 
electric razor and lubricant gel was applied to both eyes. The trachea was intubated and 
100% oxygen at 1-1.5 L/minute was provided via mechanical ventilation. Mice were then 
secured in the supine position on a heating pad at 37ºC, and the chest area was 
disinfected with iodine followed by chlorhexidine. The correct depth of anaesthesia was 
confirmed by no response from the interdigital pedal reflex. An oblique transversal skin 
incision was made over the left thorax, and the muscle layers were separated by blunt 
dissection and retracted.  
A thoracotomy was then performed through the 4th intercostal space, the muscle layer 
was penetrated and retracted to expose the heart. The pericardium was gently pulled 
apart to visualise the anterior wall and an 8-0 nylon suture was passed underneath the 
LAD coronary artery, 1 – 2 mm below the edge of the left atrium. The LAD was then 
ligated, and successful induction of ischaemia was confirmed by blanching of the 
myocardium below the ligation. The chest cavity was closed with a 5-0 suture, the muscle 
layers and skin were sutured, and the anaesthesia was reversed by intraperitoneal 
injection of atipamezole. Mice were extubated upon signs of recovery, transferred to a 
new cage and kept warm in an incubator for 4 hours. Sham-operated animals were 
subjected to the same surgical procedures except the 8-0 nylon suture was passed 
underneath the LAD but was not tied. Tracheal intubation and LAD ligation and sham 
surgical procedures were kindly performed by experienced microsurgeons in the 






Figure 2.5. 4-Week myocardial infarction study protocol. Female WT and Ind-csNox4D 
transgenic mice were injected at 8 weeks of age with tamoxifen at 20 mg/kg body weight once a 
day for 5 days, then subjected to myocardial infarction (MI) or sham surgery at 10 – 12 weeks of 
age and harvested after 4 weeks. Plasma cardiac troponin I (cTnI) was measured 24 hours post-
surgery for quantification of cardiac injury, and cardiac function was measured before and after 
surgery by echocardiography.  
2.4.2 Cardiac troponin I sampling 24 hours post-surgery 
At 24 hours post-surgery, mice were bled via the jugular vein for sampling of plasma 
cardiac troponin I (cTnI) as a quantitative biomarker for myocardial injury. Mice were 
anaesthetised in a chamber with 4% isoflurane in 100% oxygen at 1 L/minute, fur was 
removed from the surgical area using an electric razor and lubricant gel was applied to 
both eyes. Mice were then transferred to a heating pad at 37ºC, secured in the supine 
position and maintained using a nose cone at 2% isoflurane. Analgesia was administered 
with 50 μg flunixin by subcutaneous injection and the surgical area was disinfected with 
iodine followed by chlorhexidine. The jugular vein was accessed by right-sided neck 
dissection. A heparinised, 29-gauge insulin needle (BD Micro-Fine™ Plus) was slightly 
curved and inserted through the overlying pectoral muscle to avoid bleeding on 
withdrawal. The vein was punctured and approximately 100 μL blood was withdrawn. 
This surgical procedure for plasma sampling was kindly performed by Dr Helena Zhang 
and Dr Greta Sawyer.  
Whole blood samples were transferred to microcentrifuge tubes and stored at 4ºC. The 
plasma was separated by centrifugation at 1,500 g at 4ºC, and the resulting supernatant 
was immediately transferred to a clean microcentrifuge tube with a Pasteur pipette, then 
stored at -80ºC until quantification.   
2.5 Echocardiography 
Echocardiography was performed at baseline, and prior to and after surgery. Mice were 
anaesthetised in a chamber with 4% isoflurane in 97.5% oxygen at 1 L/minute, then 
transferred to the imaging stage, secured in the supine position and maintained using a 
nose cone at 1.25 – 1.5% isoflurane. Fur was removed from the chest using a topical 
depilatory cream and thoroughly cleaned with water. Heart rate, respiration rate, and 
electrocardiograms were continuously monitored by attachment of limbs to the gel-
















36ºC and 37ºC, using a heating lamp if required. Heart rate was maintained above 400 
beats per minute (bpm) by control of body temperature and adjustment of isoflurane 
anaesthesia. Each mouse was permitted to acclimatise for a minimum of 5 minutes prior 
to collection of data.   
After stabilisation of parameters, ultrasound transmission gel was applied to the chest 
and mice were imaged within a heart rate range of 400 – 500 bpm with a handheld 40-
MHz linear probe, using either a Vevo® 2100 or a Vevo® 3100 Imaging System 
(Visualsonics). The probe was positioned to obtain parasternal long axis (PLAX) and 
parasternal short axis (PSAX) views in motion-mode (M-mode) and brightness-mode (B-
mode) for measurement of systolic function and left ventricular (LV) dimensions. All echo 
images were kindly acquired by experienced cardiac sonographer in the laboratory 
group; Mr Norman Catibog.  
Echo images were analysed using Vevo® LAB ultrasound analysis software 
(Visualsonics). For the baseline characterisation of LV structure and function before and 
after tamoxifen induction, basic LV parameters were measured by LV trace of end-
diastole and end-systole over 2 cardiac cycles in B-mode images in PLAX view. 
Interventricular diastolic septum thickness was measured over 2 cardiac cycles in PLAX 
M-mode. For animals subjected to MI or sham surgery, the Vevo® Strain package was 
used for advanced assessment of traditional LV parameters as well as global and 
regional myocardial dysfunction by deformation analysis. Images were analysed in B-
mode PLAX by careful LV tracing of the endocardial and epicardial borders over 2 
cardiac cycles, starting in end-diastole, for determination of volume-dependent 
parameters and global longitudinal strain (GLS) (Figure 4.3). This mode of analysis relies 
on speckle tracking algorithms that harness the high spatial and temporal resolution of 
high frequency ultrasound.161 Further strain analysis was carried out using the 
quantitative Segmental Synchronicity Page within Vevo® Strain, which divides the 
anterior and posterior regions of the LV into 3 different segments each (Figure 4.6). This 
was used to detect regional differences in myocardial contractile function by analysis of 
longitudinal and radial strain rate in each LV segment. All echo data were analysed in a 
blinded manner by identification of each animal by unique number only.  
2.6 EdU labelling 
5-ethynyl-2’-deoxyuridine (EdU), a thymidine nucleoside analog, was used to label 
cycling cells in vivo by incorporation in DNA. EdU (Thermo Scientific) was administered 
by intraperitoneal injection at 50 mg/kg body weight. EdU injection was prepared by 
reconstitution in PBS to 10 mg/mL, and heated at 37ºC for 30 minutes. Adult WT and 
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Ind-csNox4D mice were administered 2 doses of EdU during basal characterisation, 




Figure 2.6. Experimental protocol for assessment of EdU incorporation in the absence of 
injury. Male and female WT and Ind-csNox4D transgenic mice were injected at 8 weeks of age 
with tamoxifen on days 1 – 5, then EdU on days 5 and 8 followed by cardiac harvest on day 10. 
Adult WT and Ind-csNox4D mice were also injected with EdU post-MI or -sham, 
commencing 24 hours after surgery and repeated every 4 days thereafter until tissues 




Figure 2.7. 2-Week myocardial infarction study protocol for assessment of EdU 
incorporation. Female WT and Ind-csNox4D transgenic mice were injected with tamoxifen for 5 
days at 8 weeks of age, then subjected to myocardial infarction (MI) or sham surgery at 10 – 12 
weeks of age and harvested after 2 weeks. EdU was injected 24 hours post-surgery and every 4 
days thereafter.  
2.7 Cardiac tissue harvest 
Animals were weighed, then anaesthetised in a chamber with 4% isoflurane in 97.5% 
oxygen at 1 L/minute and transferred to the supine position and maintained using a nose 
cone at 3% isoflurane. A lateral incision was made below the diaphragm, the chest cavity 
was opened, and the ribs were retracted to expose the heart. The LV was injected with 
200 μL 5% potassium chloride (KCl) in phosphate buffered saline (PBS) to induce 
diastolic arrest. The heart was excised and washed twice in 0.9% saline solution to 
remove blood, then dried. Excess tissue was removed, heart weight was recorded, and 
the heart was dissected using a 22 surgical scalpel blade according to experiment.   
For the baseline characterisation studies, hearts were transversely sectioned into the 
base, mid, and apex regions for RNA extraction, frozen tissue sections, and protein 
extraction, respectively. The base and apex samples were snap frozen in liquid nitrogen 
and stored in liquid nitrogen. The mid segment was mounted on cork embedded in 
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optimal cutting temperature (OCT) medium and stored at -80ºC. Hearts subjected to MI 
and sham surgeries were allocated to harvest for RNA extraction or frozen tissue 
sections. For RNA, the heart was transversely cut just above the ligature and at the apex. 
Samples were then cut according to MI region: infarct zone, border zone (defined as a 2 
mm area encircling the dense fibrotic scar area of pathologic infarction162), and the non-
infarcted remote zone, and snap frozen as described above. The mid segment, 
containing all 3 MI regions, was cut above the ligature and embedded in OCT as 
described above. Similar anatomic regions were dissected from sham-operated hearts. 
For the tamoxifen dose response studies, the mid region was cut for frozen tissue 
sections as above, and the apex was cut for high performance liquid chromatography 
(HPLC), snap frozen and stored at -80ºC. 
2.8  Adult cardiomyocyte isolations 
Adult cardiomyocytes were isolated by a Langendorff-free method as recently 
described.163 Adult WT and csNox4D mice at 10 – 12 weeks of age were used for 
cardiomyocyte culture experiments. As discussed in section 2.2.1, cardiomyocyte-
targeted Nox4D is constitutively expressed in the csNox4D Tg mouse model, 
commencing during embryonic development. This model was used here in preference 
to the Ind-csNox4D model to avoid the additional step of tamoxifen induction. The level 
of Nox4D overexpressed in csNox4D mice is demonstrated in Figure 2.8. For 
optimisation of assessment of Nox4D localisation in the Ind-csNox4D Tg model, adult 
cardiomyocytes were isolated from WT and Ind-csNox4D mice 2 weeks after tamoxifen 
induction.   
Figure 2.8. Nox4D overexpression in csNox4D hearts. Representative immunoblot (left) and 
relative quantification (right) of Nox4D protein expression in hearts of adult WT and csNox4D 
transgenic mice. csNox4D hearts show a 2-fold increase in Nox4D protein level compared to 
control mice. n = 5 per group. Data represent mean ± SEM. *P<0.05 by unpaired two-tailed t-test. 













































2.8.1 Surgical procedure 
Animals anaesthetised in a chamber with 4% isoflurane in 97.5% oxygen at 1 L/minute 
and transferred to the supine position and maintained using a nose cone at 3% 
isoflurane. Full anaesthesia was confirmed by reduced respiration rate and no response 
from the interdigital pedal reflex. The mouse chest was disinfected with 70% ethanol. A 
lateral incision was made below the diaphragm, the chest cavity was opened, and the 
ribs were retracted to expose the heart. The descending aorta and inferior vena cava 
were cut, and 7 mL EDTA buffer (Table 2) was injected into the base of the right ventricle 
(RV) over 1 minute to cease contractions and clear the heart of blood. The ascending 
aorta was then clamped, and the heart was removed and transferred to the first petri dish 
containing 10 mL EDTA buffer.  
2.8.2 Heart dissociation 
The heart was digested ex vivo by sequential perfusion with several buffers by injection 
through the LV wall, 2 or 3 mm above the apical point. Application of the aortic clamp 
ensures myocardial perfusion by forcing passage of the buffers through the coronary 
circulation. All buffers were manually perfused via sterile 27-gauge needles (a list of 
buffers is shown in Table 2). The heart was submerged in the first dish, and injected with 
10 mL EDTA over 6 minutes. The heart was then transferred to the second dish 
containing perfusion buffer, and 3 mL perfusion buffer was injected over 2 minutes via 
the same entry site created by the first injection. The heart was transferred to the third 
dish containing collagenase buffer (collagenase, Worthington Biochemicals; protease 
XIV, Sigma), and the LV was further injected through the same point with 40 mL 
collagenase buffer over approximately 20 minutes. Enzymatic digestion steps were 
performed at 37ºC by prewarming collagenase buffer. Digestion was confirmed by a pale 
appearance and loss of shape and rigidity, the clamp was then removed and the heart 
was transferred to the last dish containing fresh collagenase buffer. The tissue was 
dissociated by gentle separation and trituration, then enzymatic activity was inhibited by 
addition of 5 mL stop buffer to the cell-tissue suspension. The suspension was further 
triturated, and cellular yield was estimated by brightfield microscopy.  
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NaCl 130 mM, KCl 5mM, NaH2PO4 0.5 mM, HEPES 10 mM, 
glucose 10 mM, BDM 10 mM, taurine 10mM, EDTA 5 mM 
In ultrapure H2O, pH 7.8, sterile filtered 
  
Perfusion 
NaCl 130 mM, KCl 5mM, NaH2PO4 0.5 mM, HEPES 10 mM, 
glucose 10 mM, BDM 10 mM, taurine 10mM, MgCl2 1 mM 
In ultrapure H2O, pH 7.8, sterile filtered 
  
Collagenase 
Collagenase type 2 0.5 mg/mL, collagenase type 4 0.5 mg/mL, 
protease XIV 0.05 mg/mL 
In perfusion buffer, pH 7.8, sterile filtered 
  
Stop FBS 5% In perfusion buffer 
 
2.8.3 Cardiomyocyte purification and culture 
The cell suspension was passed through a 100 μm filter and washed with a further 5mL 
stop buffer. Rod-shaped, viable cardiomyocytes were purified by 4 sequential rounds of 
gravity settling – an initial 20-minute settling period followed by 3 incremental calcium 
reintroduction buffers (Table 3) for 10 minutes each to gradually restore calcium 
concentration to physiological levels. The supernatant, containing non-viable myocytes, 
non-myocytes, and debris, was removed from each round to produce a cell pellet highly 
enriched for cardiomyocytes.  
Pre-coated glass tissue culture surfaces (Nunc™ Lab-Tek™ Chamber Slide system, 8-
well, Thermo Scientific) with laminin (Sigma) at 25 μg/mL in PBS were aspirated and 
washed once with PBS. The total cardiomyocyte yield per heart was resuspended in 2 
mL prewarmed culture medium and 2 mL plating medium (Table 3), then seeded over 
16 wells, evenly distributed and supplemented with a further 150 μL plating medium per 
well. Cells were placed in a humidified culture incubator at 37ºC/5% carbon dioxide/95% 
air and allowed to adhere for 1 hour. After 1 hour, wells were carefully washed 
individually, and re-incubated in 300 μL culture medium containing 2% heat-inactivated 
foetal bovine serum (FBS). Medium was replaced every 48 hours thereafter. 
Cardiomyocytes isolated from WT and Ind-csNox4D mice were fixed (as described in 
2.8.5) after plating for Nox4D immunostaining.  
57 
 






For total volume of 20 mL per buffer: 
Buffer 1: perfusion buffer 15 mL, culture medium 5 mL 
Buffer 2: perfusion buffer 10 mL, culture medium 10 mL 




FBS 5%, BDM 10 mM, 1x L-glutamine-penicillin-
streptomycin solution (Sigma) 




FBS 2%, BSA 0.1%, insulin-transferrin-selenium 1x 
(Sigma), BDM 10 mM, chemically defined lipid 
concentrate 1x (Thermo Scientific), 1x L-glutamine-
penicillin-streptomycin solution  
In Medium 199 (M2154), sterile filtered 
(BDM removed after first 48 hours of culture) 
 
2.8.4 Cardiomyocyte viability assays  
Following isolation, cell viability was assessed after 72 hours in culture by dye exclusion 
tests with trypan blue and 7-aminoactinomycin D (7-AAD). Trypan blue (Sigma) was 
added directly to the media and stained for 5 minutes at room temperature at a final 
concentration of 0.04%. To reduce background, trypan blue was further diluted with PBS 
to 0.01% and cells were imaged by brightfield microscopy.  
In parallel, half the culture media was removed and 20 μL 7-AAD solution was added per 
well (containing 0.5 μL 7-AAD and 0.4 μL Hoechst [Thermo Scientific] in PBS), then 
incubated at room temperature in the dark for 15 minutes. Confocal stitched images were 
obtained with a 20x objective using an inverted spinning disc microscope (Nikon Eclipse 
Ti-E). 
2.8.5 Adult cardiomyocyte dedifferentiation 
Isolated adult cardiomyocytes were allowed to recover in culture medium for the first 48 
hours, after which 2,3-butanedione monoxime (BDM) was removed from the medium. 
The concentration of mouse oncostatin M (OSM [Sigma]) to be used for the induction of 
cardiomyocyte dedifferentiation was first optimised by exposure to OSM at 20, 50, and 
100 ng/mL for 8 days. The lowest effective concentration of OSM (50 ng/mL) was 
selected as the optimum concentration for further experiments. For assessment of 
proliferation events by EdU incorporation, the concentration of EdU to be used was 
optimised and the detection was validated in the H9c2 rat cardiomyoblast cell line. 
Cultured H9c2 cells were incubated with EdU overnight at 5, 10, and 20 μM, then 
detected using the Click-iT™ EdU imaging kit (Invitrogen), as described in 2.11.3. This 
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identified 10 μM as the optimum concentration of EdU and was selected for use in 
cardiomyocyte cultures (Figure 2.9).  
Figure 2.9. Optimisation of EdU labelling and validation of detection in vitro. Representative 
images of fluorescence staining for 5-ethynyl-2’-deoxyuridine (EdU) (green) incorporation, 
labelling cells that have synthesised DNA, with Hoechst (blue) as a nuclear marker in H9c2 cells 
after overnight culture with EdU at 5, 10, and 20 μM. Scale bars: 50 μm. n = 1. 
Cardiomyocytes were then incubated with OSM 50 ng/mL for 6 days followed by 
treatment with mouse fibroblast growth factor 2 (FGF2 [Cell Signaling Technology]) 100 
ng/mL for the final 2 days. Cardiomyocytes were also treated with OSM only for 8 days, 
and without OSM but with FGF2 from day 6 to 8. Untreated cardiomyocytes were 
maintained in culture medium throughout the protocol. All experimental conditions were 
cultured with EdU 10 μM from day 6 to day 8. Cells were fixed on day 8 by removal of 
the media and incubation with 200 μL 4% paraformaldehyde (PFA [Thermo Scientific) in 




Figure 2.10. Experimental protocol for induction of dedifferentiation in cultured adult 
cardiomyocytes and assessment of proliferation. Adult cardiomyocytes were isolated from 
WT and csNox4D mice and recovered for 2 days in culture. Oncostatin M (OSM) 50 ng/mL was 
commenced on day 0 and medium (containing 2% foetal bovine serum) was replaced every 48 
hours. FGF2 100 ng/mL treatments and EdU 10 μM were added on day 6 for the final incubation 
period, and cells were fixed on day 8.  
2.9 qPCR analysis of gene expression 
2.9.1 RNA extraction 
H9c2 cells were lysed in 350 μL lysis buffer RLT (containing β-mercaptoethanol) and 
centrifuged through a QIAshredder™ spin column (Qiagen) for 2 minutes at 13,000 g. 
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RNA was extracted using the RNeasy® Mini Kit according to the manufacturer’s 
instructions (Qiagen) and eluted in nuclease-free water. Cardiac tissue samples (10 – 20 
mg) were lysed in 500 μL lysis buffer LBA (containing 1-thioglycerol) (Promega) and 
homogenised using FastPrep® lysing matrix D beads (MP Biomedicals) in a Precellys® 
24 tissue homogeniser (Bertin Instruments) at 2 x 20 seconds at 6000 rpm. RNA was 
extracted using the ReliaPrep™ RNA Tissue Miniprep System according to the 
manufacturer’s instructions (Promega) and eluted in nuclease-free water. The 
concentration and purity of all RNA samples were quantified using a NanoDrop® ND-
1000 spectrophotometer (Labtech International). RNA extracts were stored at -80ºC. 
2.9.2 Reverse transcription 
Complementary DNA (cDNA) was synthesised by reverse transcription of the single-
stranded RNA template. Samples were prepared by dilution of 1 μg RNA to 13 μL with 
nuclease-free water, to which 1 μL oligo-dT18 primers 1 μg/μL and 1 μL dNTPs 10 mM 
(Promega) were then added. Samples were initially heated at 70ºC for 3 minutes to 
disrupt any secondary structures, then cooled to 4ºC. This was followed by addition of 4 
μL 5x reverse transcriptase buffer (Promega), 0.5 μL RNase inhibitor (Promega), and 
0.5 μL reverse transcriptase enzyme (Moloney murine leukaemia virus [Promega]) to 20 
μL final reaction volume. Equivalent samples were prepared as negative controls, 
containing all reaction components except reverse transcriptase, to enable identification 
of genomic DNA contamination. All samples were then heated in a thermal cycler (AB 
Applied Biosystems) at 42ºC for 90 minutes, then 70ºC for 10 minutes. The resulting 
cDNA was diluted to 10 ng/μL with nuclease-free water and stored at -20ºC. 
2.9.3 Quantitative PCR 
Quantitative PCR (qPCR) was used to determine the relative mRNA expression of genes 
of interest through fluorescence detection. This methodology was employed using a non-
specific fluorescent dye (SYBR® Green), which intercalates with double-stranded DNA to 
emits a fluorescent signal that increases proportionally to the amount of double-stranded 
DNA that is amplified within each PCR cycle.   
Each qPCR reaction was prepared with 2 μL cDNA template, 2 μL primer mix 3 μM, 10 
μL 2x qPCRBIO SyGreen Mix Hi-ROX (PCR Biosystems), and 6 μL nuclease-free water 
to 20 μL final reaction volume. qPCR was performed by a StepOnePlus™ Real-Time 
PCR machine (Applied Biosystems). Samples were initially denatured at 95ºC for 10 
minutes, then amplified for 40 cycles of: denaturation (95ºC for 15 seconds) and 
annealing and extension (60ºC for 30 seconds). Samples were then heated at 95ºC for 
15 seconds, 60ºC for 1 minute, then re-heated to 95ºC in 0.3ºC increments for 15 
seconds for melt curve analysis of primer specificity.   
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For the Nox4D knockdown experiments in H9c2 cells, qPCR reaction conditions were 
optimised for the detection of Nox4D. The 2 primer sets with greatest specificity were 
selected from the original series and trialled at reduced concentration in conjunction with 
increased cDNA template volume. This identified 2 μM and 4 μL as the optimum primer 
concentration and template volume, respectively, for the detection of Nox4D knockdown. 
mRNA expression was calculated relative to housekeeper control gene (GAPDH or β-
actin) using the cycle threshold (Ct) value as determined by the amplification plot for each 
gene. The Ct value represents the cycle number at which the emitted fluorescence 
reaches the fixed signal threshold and is thus indicative of the relative abundance of the 
target sequence between samples. Relative mRNA expression was determined using 
the ΔΔCt method.164 Normalised expression was further normalised as a fold-change 
relative to the respective control group within each experiment. 
2.9.4 qPCR primer design  
Gene-specific primers were designed using the NCBI primer design tool against set 
criteria, including target amplicon size of 70 – 200 base pairs, spanning of exon-exon 
boundaries, and an optimal melting temperature of 60ºC (Table 4). For the Nox4D 
knockdown optimisation studies in H9c2 cells, a series of 5 primers sets were designed 
for the forward sequence to target exon 1 or 2, and the reverse sequence to target the 
exon 2/12 junction specific to Nox4D (Table 5). Primer specificity was evaluated by the 
ability to demonstrate a single melting peak and further assessed by detection of a single 
PCR product after gel electrophoresis (as described in 2.2.2).   
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Table 4. Mouse qPCR primer sequences. 
Gene Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
 
Angpt2 AGTCAGGACTCACCACCAGT TCCATGTCACAGTAGGCCTTG 
ANP CGTCTTGGCCTTTTGGCTTC GGTGGTCTAGCAGGTTCTTGAAA 
Aurkb CGGGAGAAGAAGAGCCGTTT ATGTTGGGATGTTTCAGGTGC 
β-actin CGTGAAAAGATGACCCAGATCA TGGTACGACCAGAGGCATA 
BNP CTTCGGTCTCAAGGCAGCA TACAACAACTTCAGTGCGTTACA 
Cdk2 CACTCATGAGGTGGTGACCC GGTGCTGGGTACACACTAGG 
Cdk4 GGCCCTCAAGAGTGTGAGAG AGACATCCATCAGCCGTACA 
ckit CGTTCCTCGCCTCCAAGAAT AATCTTTGTGATCCGCCCGT 
Cyclin A2 TGGCTTTTAATGCAGCTGTCTCTT AGACATATCCATAGCATGTGGTGA 
Cyclin D1 GCCATCCATGCGGAAAATCG GGAAGACCTCCTCGCAC 
Cyclin E1 GGCGAGGATGAGAGCAGTTC AGTCCTGTGCCAAGTAGAACG 
Dab2 CAGCCTTGAGGCTTCGGG GGGCAGGTCTCAAAAGGACA 
GAPDH GGGTTCCTATAAATACGGACTGC CCATTTTGTCTACGGGACGA 
GATA4 AAACGGAAGCCCAAGAACCT TGGCATTGCTGGAGTTACCG 
Gclc GTTATGGCTTTGAGTGCTGCAT ATCACTCCCCAGCGACAATC 
Gsta2 GCTTGATGCCAGCCTTCTG GGCTGCTGATTCTGCTCTTGA 
Myh6 AACCTGTCCAAGTTCCGCA ATTCCTCGTCGTGCATCTTCTTG 
Myh7 CCTTACTTGCTACCCTCAGGTGG GTAAGCCCAGGCCTGTAGAAG 
Nox4 CCGGACAGTCCTGGCTTATC TGCTTTTATCCAACAATCTTCT 
Nox4D ACAACCAAGGGCCAGAATAC TCGTTCTGTCCAGTCTCCTAC 
p21Cip1 CAGCAGAATAAAAGGTGCCACA GACAACGGCACACTTTGCTC 
p27Kip1 GTTTCAGACGGTTCCCCGAA CTTAATTCGGAGCTGTTTACGTC 
Runx1 ACGATGGCTTCAGACAGCATT CTCATCTTGCCGGGGCTC 
ssTNI AGCTCCACGAGGACTAAACT CCTCTCAACTTCCGGCATGG 
Vegfa GCAGCGACAAGGCAGACTAT AACCTCCTCAAACCGTTGGC 
 
Table 5. Primer sequences used for Nox4D knockdown in vitro. 
Gene Set Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
 
Nox4D 
1 CACCTCTGTCTGCTTGTTTGG TTGCTTTGGTTTCAGTAGGACAGC 
2 GCTGTCCCTAAATGTCCTGC TGCTTTGGTTTCAGTAGGACA 
3 ACCTTCCTGCTGTACAACCA TGCTTTGGTTTCAGTAGGACAG 
4 ACCTTCCTGCTGTACAACCA TTGGTTTCAGTAGGACAGCC 
5 ACCTTCCTGCTGTACAACCA GGTTTCAGTAGGACAGCCCAAC 
β-actin CGTGAAAAGATGACCCAGATCA TGGTACGACCAGAGGCATA 




2.10 Western blotting 
2.10.1 Protein extraction 
H9c2 cells were lysed in triplicates per 6-well culture plate in a total of 250 μL lysis buffer 
(Table 6). If necessary, lysates were sonicated briefly for 5 seconds to further disrupt 
cellular membranes, then centrifuged for 5 minutes at 13,000 g at 4 ºC. The supernatant 
was collected into a clean microcentrifuge tube and stored at -80ºC. Cardiac tissue 
samples (10 – 20 mg) were lysed in lysis buffer (Table 6) at 25 μL/mg tissue, and 
homogenised as described in 2.9.1. Tissue lysates were transferred to clean 
microcentrifuge tubes and stored at -80ºC. 
Table 6. Lysis buffers used for protein extraction in cells and tissue. 
Lysis buffer Constituents 
  
Cells 
NaCl 150 mM, Tris base 50mM, SDS 0.1%, Nonidet P-40 1% 
In ultrapure H2O, pH 8.0 
Protease inhibitor mixture (Sigma) added at 1:200 before use  
  
Tissue 
NaCl 150 mM, Tris base 25 mM, EDTA 5 mM, EGTA 2 mM, 
Nonidet P-40 0.5% 
In ultrapure H2O, pH 7.4 
Protease and phosphatase inhibitor mixtures (Sigma) added at 
1:100 before use 
 
2.10.2 Protein content determination 
The bicinchoninic acid (BCA) assay (Pierce™ BCA Protein Assay Kit [Thermo Scientific]) 
was used for the colorimetric detection and quantification of total protein. This assay 
relies on the reduction of copper ions by protein and chelation of reduced copper ions 
with BCA to form a purple-coloured complex. Protein content was determined against 
the reference protein bovine serum albumin (BSA) according to the manufacturer’s 
instructions. Briefly, a BSA standard curve was prepared by serial dilution of the 2 mg/mL 
stock solution with the same lysis buffer used to prepare the samples, to produce a 
working range of 0 – 1000 μg/mL. Samples were first diluted at 1:5 (cells) or 1:10 (tissue) 
with respective lysis buffer, then pipetted along with the standards in 25 μL duplicates 
into a 96-well plate (Thermo Scientific). 200 μL BCA working reagent (containing 50 parts 
reagent A to 1 part reagent B) was then added to each well and mixed thoroughly. The 
plate was incubated for 30 minutes at 37ºC, and the absorbance was read at 562 nm on 
a plate reader (GENios pro, Tecan).  
Protein concentrations were quantified against the BSA standard curve, then samples 
were prepared at 1 μg/μL by dilution in 5x sample buffer (containing 0.5 M DTT, 0.02% 
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bromophenol blue, 30% glycerol, 10% SDS in 250 mM Tris base, pH 6.8), then 1x sample 
buffer to final volume, sonicated for 5 seconds and stored at -80ºC. 
2.10.3 Immunoblotting 
Proteins were separated according to their molecular weight by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using a Bio-Rad system. 10% 
separating gels were cast (containing 3.3 mL 30% acrylamide/bis-acrylamide, 2.5 mL 
Tris HCl 1.5 M pH 8.8, 4 mL distilled water, 100 μL 10% SDS, 85 μL 10% ammonium 
persulphate, 20 μL TEMED) and layered with stacking gel (containing 650 μL 30% 
acrylamide/bis-acrylamide, Tris HCl 0.5 M pH 6.8, 3.05 mL distilled water, 50 μL 10% 
SDS, 25 μL 10% ammonium persulphate, 10 μL TEMED). Protein samples were loaded 
at 20 μg per well and electrophoresed at 120V for 80 minutes in running buffer 
(containing Tris base 25 mM, glycine 192 mM, 0.5% SDS). Proteins were transferred 
onto nitrocellulose membranes at 65V for 60 minutes in transfer buffer (containing Tris 
base 25 mM, glycine 192 mM, 20% methanol). 
Membranes were stained with Ponceau S solution (Sigma) to confirm efficient protein 
transfer, then blocked with 5% non-fat milk (in tris buffered saline containing 0.1% 
Tween-20; TBS-T) for 60 minutes, then probed overnight with primary antibody (Table 
7) at 4ºC under agitation. Membranes were washed 3 times for 15 minutes in TBS-T then 
incubated with secondary antibody (Table 7) for 1 hour at room temperature under 
agitation. Membranes were washed again 3 times for 15 minutes in TBS-T then once for 
10 minutes in TBS, and developed by direct near-infrared fluorescence using an 
Odyssey® CLx imaging system (LI-COR® Biosciences). Membranes were then re-
exposed to loading control primary antibody (GAPDH, α-tubulin, or total protein of 
phosphorylated target).  
Relative protein levels were determined by quantification of blots using Image Studio™ 
software. The signal of the target protein was normalised to the signal of the respective 
loading control, then further normalised as a fold-change relative to the respective control 




Table 7. Primary and secondary antibodies used for immunoblotting.  













1:1,000 Cell Signalling Technology p27 Kip1 
Akt (pan) 
GAPDH 1:4,000 Sigma 
α-tubulin 1:10,000 Sigma 
Secondary  
Donkey anti-rabbit, conjugated 
to IRDye®800CW or 
IRDye®680RD 1:10,000 Milk 5% (in TBS-T) 
LI-COR® 
Biosciences Donkey anti-mouse, conjugated 






2.11 Cell and tissue staining 
2.11.1 Cryosections 
Frozen tissue sections were prepared using a cryostat (CryoStar™ NX70 [Thermo 
Scientific]). Transverse sections were cut at 10 μm thickness and 3 sections were 
mounted per glass microscope slide (Superfrost Plus™ [Thermo Scientific]). Slides were 
air-dried for 30 minutes then stored at -80ºC. Prior to tissue staining, cryosections were 
thawed at room temperature for 30 minutes then fixed with 4% PFA in PBS for 15 
minutes. 
2.11.2 Immunostaining 
Fixed cryosections and fixed cultured adult cardiomyocytes were washed twice with 3% 
BSA in PBS, permeabilised with 0.5% Triton™ X-100 in PBS (Sigma) for 20 minutes, 
then washed twice with 3% BSA. Slides were incubated with blocking buffer (containing 
3% BSA and 1% goat serum [Sigma] in PBS) for 20 minutes, then incubated with primary 
antibody diluted in blocking buffer for 60 minutes in a humidified chamber at room 
temperature (a list of antibodies and dilutions is provided in Table 8). Slides were washed 
3 times with 3% BSA then incubated with the corresponding rabbit or mouse fluorescent-
conjugated secondary antibody (Invitrogen) diluted at 1:200 in blocking buffer for 60 
minutes at room temperature. Slides were washed again 3 times with 3% BSA, then 
nuclei were stained with Hoechst diluted 1:2000 in PBS for 30 minutes. Slides were 
washed twice with PBS, then mounted with Mowiol® mounting medium or DAPI mounting 
medium (Vectashield® [Vector Laboratories]), if nuclei not stained with Hoechst, and 
covered with glass coverslips. Negative controls were incubated with secondary antibody 
only to detect background fluorescence.  
For the optimisation of immunostaining for Nox4D localisation, initial attempts were made 
in tissue staining by prolongation of permeabilisation time to 60 minutes, and extension 
of Nox4 primary antibody incubation time to overnight at a range of concentrations. This 
was further optimised in isolated adult WT and Ind-csNox4D cardiomyocytes, in which 
an additional step was taken after permeabilisation to quench autofluorescence by 
incubation with freshly prepared sodium borohydride (Sigma) 1 mg/mL in PBS for 10 
minutes. Finally, Nox4 immunostaining in isolated cardiomyocytes was optimised by 
enhancement of antibody concentration and binding. The blocking buffer was modified 
(3% BSA, 1% goat serum, plus 0.1% Triton™ X-100 in PBS), the blocking period was 
extended to 40 minutes, Nox4 antibody dilution was increased to 1:100, and the 




Table 8. Primary and secondary antibodies used for immunostaining.  
Antibody Dilution Diluent Manufacturer 
 
Primary  
Ki67 Cells 1:200 Tissue 1:100 
Blocking buffer 
(BSA 3%, goat 
serum 1% in PBS) 
Novus Biologicals 
Phospho-histone H3 






Sarcomeric α-actinin Sigma-Aldrich 
γ-H2AX (serine 139) Cell Signalling Technology 
Nox4 1:100 
Blocking buffer 
(BSA 3%, goat 
serum 1%, Triton™ 




Alexa Fluor 488 
1:200 
Blocking buffer 
(BSA 3%, goat 
serum 1% in PBS) 
Invitrogen Goat anti-mouse Alexa Fluor 546 
Goat anti-mouse 
Alexa Fluor 488  
 
2.11.3 EdU detection 
EdU staining was performed using the Click-iT™ Alexa Fluor 488 EdU imaging kit 
according to the manufacturer’s instructions. Detection of EdU incorporation is based on 
a click reaction, which is a copper-catalysed covalent reaction between an azide (Alexa 
Fluor dye) and an alkyne (EdU). Fixed cryosections and fixed cultured adult 
cardiomyocytes subjected to dedifferentiation were washed twice with 3% BSA in PBS, 
permeabilised with 0.5% Triton™ X-100 in PBS for 20 minutes, then washed twice with 
3% BSA. Optimisation of EdU staining in conjunction with sarcomeric α-actinin staining 
revealed that primary antibody binding was only visualised when performed before EdU 
(Figure 2.11). Therefore, primary and secondary antibody incubations were done after 
permeabilisation. Slides were then incubated with the Click-iT™ reaction cocktail 
(containing Click-iT™ reaction buffer, copper sulphate, Alexa Fluor 488 azide, and 
reaction buffer additive) for 30 minutes at room temperature, protected from light. The 
reaction cocktail was then removed, slides were washed once with 3% BSA in PBS, 









Figure 2.11. Optimisation of EdU detection and immunostaining. Representative images of 
immunofluorescence staining of EdU (green) incorporation, labelling cells that have synthesised 
DNA, with α-actinin (red) as a cardiomyocyte marker and Hoechst (blue) as a nuclear marker on 
cardiac cryosections. Optimisation of experimental conditions was carried out to resolve poor 
sarcomeric α-actinin staining: (1) 30-minute fixation and permeabilisation then EdU detection 
before immunostaining; (2) immunostaining before EdU detection; (3) Immunostaining only. 
Method (2) was compatible with visualisation of α-actinin staining. Scale bars: 50 μm. 
2.11.4 Wheat germ agglutinin and isolectin B4  
Wheat germ agglutinin (WGA) is a lectin that preferentially binds to residues of N-
acetylglucosamine and sialic acid, which are common structures to many membrane 
glycoproteins. Isolectin B4 (IB4) is also a lectin, the B subunit of which is selective for 
terminal α-galactosyl residues and is a useful marker for endothelial cells.165 
Fixed cryosections were washed 3 times with Hanks’ Balanced Salt Solution (HBSS, 
14175 [Gibco™]), then blocked with 3% BSA, 1% goat serum in PBS for 15 minutes. 
Tissues were washed 3 times with HBSS and incubated with biotinylated IB4 (Vector 
Laboratories) 1:50 in HBSS in a humidified chamber for 60 minutes at room temperature. 
Sections were washed 3 times with HBSS then incubated with fluorescein Avidin D 1:200 
and rhodamine-labelled WGA 1:250 (Vector Laboratories) in HBSS for 60 minutes as 
above. Sections were washed again 3 times with HBSS then permeabilised with 0.1% 
Triton™ X-100 in PBS for 10 minutes. Slides were washed 3 times with PBS and nuclei 
were stained with Hoechst 1:2000 in PBS for 10 minutes. Washing was repeated with 
PBS and slides were mounted with Mowiol® mounting medium. 
2.11.5 TUNEL staining 
Apoptotic DNA fragmentation was detected enzymatically in situ by terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL).166 This was performed 
using the ApopTag® In Situ Apoptosis Detection Kit (Merck), which is based on the 
TUNEL assay, according to the manufacturer’s instructions. Fixed tissue sections were 
washed 3 times with PBS, permeabilised with 0.5% Triton™ X-100 in PBS for 20 




10 minutes, then incubated with working strength TdT enzyme (containing 70% reaction 
buffer and 30% TdT enzyme) in a humidified chamber for 60 minutes. The reaction was 
stopped by washing 3 times with working strength stop/wash buffer, then washed 3 times 
with PBS. Sections were incubated with working strength anti-digoxigenin-rhodamine 
conjugate (containing 53% blocking solution and 47% anti-digoxigenin conjugate 
antibody) in a humidified chamber for 30 minutes, protected from light. Sections were 
washed 4 times in PBS, then blocked and co-stained with α-actinin as described in 
2.11.2. Positive controls were incubated with DNase I (Promega) 1:100 in DTT 0.1 mM 
for 10 minutes, washed 5 times with distilled water and followed with equilibration buffer.  
2.11.6 Picrosirius red 
Picrosirius red is a strong histological stain which associates along collagen fibres 
through acidic sulfonic groups that strongly interact with basic groups in collagen 
molecules, and is therefore used for the assessment of fibrillar collagen networks.167  
Slides were immersed in xylene for 5 minutes, then rehydrated through a decreasing 
ethanol gradient at 100%, 70%, 50%, 25% then distilled water (dH2O) for 1 minute each. 
Slides were washed in PBS for 5 minutes then fixed with 4% PFA in PBS for 5 minutes, 
and washed 3 times with dH2O. Sections were then incubated with 0.2% 
phosphomolybdic acid in dH2O (Sigma) for 30 seconds, and washed twice with dH2O. 
Slides were transferred to incubation with 0.1% picrosirius red solution (containing 0.1% 
Sirius red [Fluka] in 1.3% saturated picric acid [Fluka]) for 1 hour. Slides were washed in 
3 changes of acidified water (10% acetic acid in dH2O) for 10 seconds each, then 
incubated in saturated picric acid for 15 minutes. Tissues were rinsed 3 times with dH2O, 
then dehydrated through the same ethanol series as above but in reverse, for 1 minute 
each. Tissues were cleared in xylene for 5 minutes, and slides were mounted with DPX 
mountant (Sigma) and covered with coverslips.  
2.11.7 Microscopy 
Fluorescent images were captured with a Leica laser scanning confocal microscope 
(TCS-SP5) (Ind-csNox4D baseline studies) or an inverted spinning disc confocal 
microscope (Nikon Eclipse Ti-E) (Ind-csNox4D MI studies and isolated cardiomyocytes). 
All quantifications of control and experimental groups were analysed in parallel in a 
blinded manner with identical settings. 
For each genotype, 3 sections were imaged per heart, in which the whole LV was 
analysed in sham-operated and basal mice, and the infarct border and remote zones 
were analysed in MI mice. Using 40x or 60x oil immersion objectives, cardiomyocytes 
were carefully identified by positive sarcomeric α-actinin staining and Z-stack imaging to 
show overlap with positive nuclear staining. Positive cardiomyocytes were quantified by 
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positive Ki67, pHH3, EdU, γ-H2AX, and TUNEL staining in α-actinin-positive cells using 
NIS-Elements software. Z-stacks were imaged over a 15-μm range at a 0.3-μm step size, 
and deconvolved using NIS-Elements software. Sections stained with WGA and IB4 
were imaged using a 20x objective, and the cross-sectional area of cardiomyocytes with 
centrally located nuclei (minimum 200 per heart) and capillary density per area were 
analysed using the General Analysis module in NIS-Elements. Large images of isolated 
cardiomyocytes subjected to dedifferentiation were obtained by stitching, with the same 
fixed field dimensions and position per well. Positive cardiomyocytes were quantified 
manually relative to total cardiomyocyte number, and cell area was determined using 
ImageJ software.  
Picrosirius red slides were imaged by brightfield and polarised light using a Leica 
DM2000 LED microscope, and fibrosis was quantified relative to the area of the whole 
cross-section according to colour threshold using ImageJ software.  
2.12 Cardiac troponin I ELISA 
The concentration of cTnI in mouse plasma was quantified using the High Sensitivity 
Mouse Cardiac Troponin-I ELISA Kit (Life Diagnostics). This kit utilises an enzyme-linked 
immunosorbent assay (ELISA), which uses 2 different affinity purified antibodies that 
recognise an epitope on mouse cTnI. The first is immobilised in the solid phase and the 
second is conjugated to horseradish peroxidase (HRP), so that cTnI becomes 
sandwiched between both antibodies, the concentration of which may be detected by 
colorimetry upon addition of an HRP substrate.  
A standard curve was prepared by serial dilution of the reconstituted cTnI stock solution 
with standard diluent to produce a working range of 0 – 10 ng/mL. Plasma samples were 
prepared by 4-fold dilution of 30 μL with plasma diluent and further dilution to 200 μL with 
standard diluent. All standards and samples were pipetted in 100 μL duplicates into a 
microtiter plate, then mixed and incubated on an orbital shaker at 150 rpm at room 
temperature for 60 minutes. The microtiter wells were emptied and washed 6 times using 
the 1x wash solution at 400 μL per well. Residual droplets were removed, 100 μL HRP 
substrate (TMB Reagent) was added to each well and incubated on an orbital shaker as 
above for 20 minutes. The enzyme reaction and colour development were stopped by 
adding 100 μL Stop Solution to each well. The plate was mixed and the absorbance was 
read at 450 nm on a plate reader (Elx800, BioTek).  
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The corresponding cTnI plasma concentrations were quantified against the cTnI 








Figure 2.12. Representative cTnI standard curve. Plasma cardiac troponin I (cTnI) was 
quantified against the standard curve, in which the concentration of cTnI is proportional to the 
absorbance at 450 nm. Plasma concentration was quantified using a single-site, total and non-
specific binding model.  
2.13 ROS detection by HPLC 
ROS detection in Ind-csNox4D hearts treated with a tamoxifen dose response was 
carried out using dihydroethidium-HPLC (DHE-HPLC), kindly performed by Dr Celio XC 
Santos. Briefly, cardiac tissues were incubated with 500 μL DHE 100 μM (Molecular 
Probes) (in PBS, containing 100 μM DTPA [Sigma]) at 37ºC for 30 minutes, protected 
from light. Buffer was removed and tissues were washed with PBS. Organic extraction 
was performed by addition of 500 μL HPLC grade acetonitrile. Samples were sonicated 
briefly and centrifuged at 13,000 g for 10 minutes at 4ºC. The supernatants were 
collected and dried using a speed vacuum (Savant SpeedVac [Thermo Scientific]). The 
resulting solid powders were dissolved in 100 μL PBS-DTPA then analysed by HPLC 
and quantified as previously described.168,169 HPLC peak values were normalised to 
tissue weight.  
2.14 H9c2 cell culture 
H9c2 cells were cultured in a humidified incubator at 37ºC/5% carbon dioxide/95% air in 
Dulbecco’s modified Eagle’s medium (DMEM, D5671 [Sigma]), supplemented with 10% 
heat-inactivated FBS and 1x L-glutamine-penicillin-streptomycin solution. Cells were 
passaged and medium was changed every 4 days at a 1:5 ratio. Cells were 
cryopreserved in DMEM containing 40% FBS and 10% dimethyl sulfoxide at -20ºC 
overnight, then transferred to liquid nitrogen for long-term storage.  
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2.15 siRNA-mediated Nox4D knockdown in H9c2 cells 
Due to the difficulties associated with splice variant-specific targeting, the development 
of efficient small interfering (siRNA)-mediated knockdown of Nox4D required a series of 
optimisation steps to enhance both selectivity and detection (discussed in more detail in 
section 5.3.1). To enable discrimination from full-length Nox4, the choice for design of 
siRNA and primer sequences is limited to the short sequence spanning the exon 2/12 
junction that is created by splicing of exons 3 – 11.  
Custom-designed siRNA directed against rat and mouse Nox4D (sequence 5’ – 3’: 
ATGTTGGGC/TGTCCTACTGAA, where / denotes the exon 2/12 junction), and a control 
sequence (5’ – 3’: AATTCTCCGAACGTGTCACGT) were designed using the 
GeneAssist™ Custom siRNA Builder (Thermo Scientific). Commercially available, pre-
validated siRNA targeted to exon 3 of Nox4 (Ambion) was used as a positive control for 
the transfection protocol. Transfections were performed using the transfection reagent 
Lipofectamine™ RNAiMAX (Thermo Scientific), according to the manufacturer’s 
instructions. Briefly, H9c2 cells were seeded in 6-well culture plates to establish 60 – 
80% confluency at the time of transfection. Transfection reagent and siRNA were diluted 
separately in Opti-MEM™ Reduced Serum Medium (Gibco™), then mixed at a 1:1 ratio 
and incubated for 5 minutes. The medium was replaced with 750 μL serum-free DMEM, 
and 250 μL siRNA-lipid complex (containing 5 μL transfection reagent) was added per 
well. Additional control cells were incubated with Opti-MEM™ only (untreated) or Opti-
MEM™ plus transfection reagent. After 4 hours, the medium was supplemented with 5% 
FBS and cells were incubated for a further 72 hours, then harvested for mRNA and 
protein analysis for assessment of knockdown efficiency. All siControl and siNox4 were 
transfected at 10nM. siNox4D was initially transfected at 10 nM, which was later 
confirmed as the most optimal concentration after transfection of 2.5 nM – 20 nM.   
2.16 Recombinant adeno-associated virus production 
2.16.1 shRNA and plasmid production 
The corresponding short hairpin RNA (shRNA) sequence to the siNox4D sequence was 
designed and synthesised, and the shRNA oligo was cloned into an AAV construct 
containing the U6 promoter and GFP sequence, flanked by AAV2 inverted terminal 
repeats (pAAV-GFP-U6-shNox4D). A control plasmid was also made with a pre-
validated scrambled shRNA sequence (pAAV-GFP-U6-shScramble). The shRNA 
synthesis and plasmid cloning techniques were performed externally by Vector Biolabs. 
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2.16.2 AAV9 vector production 
Adenovirus-free recombinant adeno-associated virus serotype 9 (rAAV9) was produced 
by transient transfection in 293T cells. 293T cells were triple transfected at 70 – 80% 
confluency with the AAV2 ITR-containing plasmid carrying the shNox4D or shScramble 
expression cassette (AAV cis-plasmids), a separate construct expressing in trans the 
AAV2 Rep and AAV9 Cap genes, and a third plasmid providing the adenovirus helper 
factors (HGTI) in a 1:1:3 plasmid ratio using 1 mg/mL polyethyleneimine MAX 
(Polysciences, Inc).  
Cells were harvested 72 hours post transfection and centrifuged at 2,500 g for 10 
minutes at 4ºC. The cell pellets were resuspended in 10mL lysis buffer each (containing 
Tris HCl 50 mM, NaCl 150 mM, MgCl2 2 mM, pH 8.0) and lysed by 3 freeze-thaw cycles 
(-80ºC/37ºC), vortexing for 30 seconds between each cycle. Lysates were treated with 
benzonase 50 U/mL (Sigma) and incubated for 30 minutes at 37ºC, then cleared by 
centrifugation at 2,500 g for 30 minutes at 4ºC to remove cell debris. The supernatants 
obtained post-harvest were mixed with 31.3g ammonium salts per 100 mL collected 
media, incubated on ice for 30 minutes, then centrifuged at 8,300 g for 30 minutes. The 
pellets were resuspended with the cleared lysates and purified by an iodixanol gradient. 
The gradient was built in ultracentrifuge tubes (Beckman Instruments) by layering the 
lysate over iodixanol (OptiPrep™ Density Gradient Medium [Sigma]) in increasing order 
(15%, 25%, 40%, and 60%). The tubes were placed in a TH641 rotor and centrifuged 
(Sorvall Discovery 90SE) at 200,000 g for 3 hours at 18ºC with the brake off. The AAV9 
vectors were extracted between the 60 – 40% fractions with a 19-gauge needle, diluted 
in PBS and concentrated to 1 mL final volume in a Vivaspin 20 (100 kDa cut-off 
[Sartorius]) and filter sterilised.   
The capsid protein content and vector purity were assessed by visualisation of the capsid 
proteins VP1, VP2, and VP3 by SYPRO® Ruby Protein Gel Stain (Thermo Scientific) after 
SDS-PAGE. The genome titres of the concentrated vectors were determined using 
alkaline agarose gel electrophoresis. Alkaline gels were run at 20V overnight at 4ºC with 
0.05 M NaOH as running buffer, stained with nucleic acid stain 4x GelRed® in NaCl 0.1 
M (Biotium) for 2 hours, then imaged under ultraviolet light and quantified against the 




2.17 Statistical analysis 
All data sets were graphically and statistically analysed using GraphPad Prism software. 
All data is expressed as mean ± standard error of the mean (SEM) unless stated 
otherwise. Levels of significance are defined as: *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001.   
Samples for animal studies were randomly selected and assigned to the experimental 
groups, and analysed in a blinded fashion with regard to genotype during outcome 
assessment, where possible. No animals were excluded from analyses. The minimum 
sample sizes required to detect statistical significance between groups were estimated 
at α = 0.05 and Power (1 – β error probability) = 0.8.  
A normal distribution was assumed for all values in each data set, and so parametric 
tests were used for all statistical analyses. Analyses between 2 experimental groups 
were performed using an unpaired two-tailed t-test. A one-way analysis of variance 
(ANOVA) was used to compare the mean differences between 3 or more independent 
experimental groups against 1 variable, and a two-way ANOVA was used to compare 
the mean differences between experimental groups against 2 independent variables. All 
ANOVA analyses were completed with a Bonferroni’s multiple comparisons post-hoc test 
for comparison of individual groups. Linear regression was used to determine the 
relationship between a dependent an independent variable, and to assess the difference 
in slope and y-intercept between the regression lines of 2 experimental groups, shown 




Chapter 3 Baseline characterisation of 
the inducible cardiomyocyte-specific 





Although classically viewed as key drivers of oxidative stress, it is now widely recognised 
that ROS paradoxically also play important roles as reactive biomolecules in intracellular 
signalling cascades. In the heart, this is essential for the regulation of several 
pathophysiological processes including survival and stress response pathways, cellular 
differentiation and proliferation.131,139  
The Nox family are a crucial enzymatic source of regulated ROS production within 
defined subcellular compartments and are therefore critically involved in redox 
signalling.170,171 The Nox enzymes Nox1 – Nox5 are expressed in the cardiovascular 
system,143 of which Nox2 and Nox4 are expressed in cardiomyocytes.170,172 The 
myocardial expression level of Nox4 has been shown to rise in situations of cardiac 
stress, and studies published by our laboratory and others have found that this Nox 
isoform exerts several protective effects in the heart against adverse remodelling.149–
152,173–177 Although such extensive research has enhanced our understanding of the role 
of Nox4, it is likely that the complexities regarding the precise mechanisms of Nox4-
mediated redox signalling pathways in the heart are yet to be fully understood.172 
Moreover, it is of interest that different Nox4 isoforms are likely to be present in specific 
subcellular compartments,143 with potential implications for differences in functions in 
ROS-related cell signalling.153 However, the prevalence and functional roles of such 
variants remain to be explored.    
3.1.1 Initial characterisation of Nox4D 
As described in 1.5.2, the identification of 4 novel splice variants of Nox4 was originally 
reported in 2005. Compared to the other Nox4 splice variants, Nox4D represented the 
most intriguing as this 28-kDa isoform was found to be fully functional in terms of ROS 
generation due to retention of the FADH and NADPH binding domains, despite lacking 
most of the classical Nox transmembrane domain (Figure 1.5). The lack of this domain 
is a result of splicing at exons 3 – 11 of Nox4, suggesting that Nox4D may localise in 
non-membrane associated compartments.153    
Despite such a critical difference in structure in comparison to full-length Nox4, it was 
found that Nox4D is capable of NADPH oxidase activity and therefore distinct redox-
mediated effects due to compartmentalised ROS generation.153 Additional work in our 
laboratory further characterised the functional role of Nox4D, highlighting the potential 
for this splice variant to exert (patho)physiological effects by redox-modulation of 
nuclear-based signalling pathways.154   
76 
 
3.1.2 Nox4D is a potential regulator of cardiomyocyte proliferation 
We became interested in a potential role for Nox4D in cell cycle modulation during gain-
of-function experiments in neonatal rat cardiomyocytes. Isolated neonatal rat ventricular 
myocytes (NRVMs) were infected with recombinant adenovirus expressing either Nox4D 
(Ad.Nox4D) or β-galactosidase control (Ad.β-gal), then cultured for a further 48 hours. 
Splice variant-specific overexpression of the 28-kDa isoform was primarily associated 
with strong focal intranuclear immunostaining, whereas the nuclear expression of 
endogenous Nox4D was significantly lower in myocytes infected with Ad.β-gal (Figure 
3.1A). Interestingly, Nox4D-overexpressing neonatal cardiomyocytes showed changes 
in cell number and cell size characteristic of a greater rate of proliferation (Figure 3.1B 
and C). This led to further investigation for molecular readouts of cell proliferation, and 
later observed that such changes were accompanied by increased expression of 
markers of proliferation including Ki67 (Figure 3.1D), 5-bromo-2’-deoxyuridine (BrdU) 
incorporation (Figure 3.1E) and 3H-leucine incorporation (Figure 3.1F) as well as 




Figure 3.1. Overexpression of Nox4D increases proliferation of neonatal cardiac myocytes. 
Isolated neonatal rat cardiac myocytes were infected with adenovirus expressing Nox4D 
(Ad.Nox4D) or β-galactosidase control (Ad.β-gal) and cultured for 48 hours. (A) Western blot (left) 
and immunofluorescence (right) show overexpression and nuclear localisation of the 28-kDa 
splice variant. Nox4D-overexpressing myocytes show greater cell number (B) and smaller cell 
size (C) relative to Ad.β-gal control. Immunofluorescence staining also shows increased 
expression of the cell cycle marker Ki67 (D) and increased DNA synthesis by 5-bromo-2’-
deoxyuridine (BrDu) incorporation (E), in conjunction with increased protein synthesis by 3H-
leucine incorporation (F). (G) Western blot (left) and relative quantification (right) reveals Nox4D 
overexpression is associated with enhanced phosphorylation of the redox-sensitive kinase Akt, 
which has proliferative activity. Scale bars in (A), (D) and (E): 50 μm. n = 3 per group. Data 
represent mean ± SEM. *P<0.05 by unpaired two-tailed t-test. Work by Dr Narayana Anilkumar, 










































Collectively, these findings provided initial evidence that overexpression of Nox4D is able 
to enhance the proliferation of neonatal cardiomyocytes in vitro. Smaller cell size has 
previously been reported as a characteristic of proliferating neonatal cardiomyocytes,87 
and together with greater cell number, is suggestive of enhanced cell cycling. Positive 
Ki67 immunostaining is a marker for progression through the cell cycle as this detects 
cells that are actively in G1, S, G2 or M-phase81,178 More specifically, incorporation of the 
labelled thymidine analogue BrdU directly measures de novo DNA synthesis and is 
therefore a readout for detection of S-phase synthesis in the cell cycle.81 Similarly, 
incorporation of the labelled amino acid 3H-leucine is indicative of protein biosynthesis, 
which is essential for cell growth and translational control of the cell cycle. The active 
phases of the cell cycle during which most protein synthesis occurs are the gap phases 
G1 and G2, thus 3H-leucine incorporation functions as an additional readout of cell cycle 
progression.179,180  
Given that these changes occurred in conjunction with enhanced phosphorylation of Akt, 
it would appear that Nox4D overexpression increases neonatal cardiomyocyte 
proliferation in a redox-mediated, Akt-dependent manner. The PI3K-Akt pathway is 
known to be centrally involved in the regulation of cardiomyocyte proliferation and 
survival,119,181,182 and is also susceptible to ROS-driven redox modulation.183 Based on 
this, we reasoned that Nox4D may represent a novel redox regulator of cardiomyocyte 
cell cycle progression.  
As discussed in 1.2.4, adult mammalian cardiomyocytes possess a very limited 
regenerative capacity.78 Any intrinsic proliferative activity remains insufficient to achieve 
complete functional recovery following disease characterised by cardiomyocyte loss, and 
so the prospect that cardiomyocyte proliferation could be induced by appropriate 
therapeutic manipulation represents a major unmet clinical need.26,184 Thus, this formed 
the rationale for the present work as we wanted to investigate the potential of Nox4D to 
promote cardiomyocyte proliferation in the adult mammalian heart.  




The aims of this chapter were to generate and characterise a novel transgenic model of 
cardiac-targeted Nox4D overexpression, specifically with a view to investigate the effects 
of manipulation of Nox4D levels on cardiomyocyte cell cycle activity in the adult 




3.3 Summary of methods 
Ind-csNox4D Tg mice were generated by crossing female Nox4D Tg mice with male 
αMHC-MCM mice, as described in 2.2. For baseline characterisation of the Ind-csNox4D 
phenotype, cardiomyocyte-specific overexpression of Nox4D was selectively induced in 
male and female adult Ind-csNox4D mice by administration of tamoxifen at 20 mg/kg 
body weight once per day for 5 consecutive days. WT littermate controls were treated in 
parallel (section 2.3).  
Experiments were performed according to 2 protocols. During the initial protocol (Figure 
2.4), cardiac structure and function were serially monitored by echocardiography (section 
2.5), and cardiac tissues were harvested at 3 weeks following tamoxifen induction 
(section 2.7). The efficiency of the tamoxifen protocol to induce overexpression of Nox4D 
was evaluated by Western blotting (section 2.10). The subcellular localisation of 
endogenous and overexpressed Nox4D was initially assessed by immunohistochemistry 
with Nox4 antibody in cardiac cryosections (sections 2.11.1 & 2.11.2), but due to 
unsatisfactory results with the use of this antibody in tissue sections, this required further 
optimisation ex vivo in adult cardiomyocytes isolated from WT and Ind-csNox4D mice 2 
weeks after tamoxifen induction (sections 2.8 & 2.11.2). The potential for cardiac-specific 
Nox4D overexpression to target redox signalling pathways and promote cardiomyocyte 
cell cycle re-entry was investigated by Western blotting and immunohistochemistry, 
respectively. This was also investigated transcriptionally by qPCR screening for gene 
expression profiles associated with cell cycle modulation (section 2.9).  
To capture a potential immediate window of cardiomyocyte proliferation secondary to 
induction of Nox4D overexpression, a second cohort of Ind-csNox4D and WT animals 
were administered EdU and harvested 5 days following completion of tamoxifen 
induction (Figure 2.6). EdU incorporation, as a marker of S-phase activity, was measured 
in cardiac cryosections by fluorescent detection of EdU in conjunction with 
immunohistochemistry (sections 2.11.2 & 2.11.3). These tissues were also analysed by 






3.4.1 Induction of Nox4D overexpression in cardiomyocytes of adult Ind-
csNox4D mice 
To explore the role of Nox4D in the adult heart, Ind-csNox4D Tg (αMHC-MCM;Nox4D) 
mice were generated for selective induction of Nox4D overexpression in differentiated 
cardiomyocytes (as discussed in 2.2.1). Male and female Ind-csNox4D and WT (αMHC-
MCM-negative;Nox4D) littermate controls were treated in parallel with tamoxifen (20 
mg/kg body weight per day for 5 days) at 8 weeks of age, after which hearts were 
harvested 3 weeks later. 
To evaluate the efficiency of the tamoxifen protocol to induce αMHC-MCM-mediated 
recombination, the expression of Nox4D at protein level was measured by Western 
blotting. Overexpression of Nox4D was detected by a 10-fold increase in protein level 
compared to WT controls (Figure 3.2). This was accompanied by no change in the mRNA 
level of full-length Nox4, confirming the induction of Nox4D is splice variant-specific 
(Figure 3.3).  
Figure 3.2. Induction of Nox4D overexpression in the adult heart. Representative immunoblot 
(left) and relative quantification (right) of Nox4D protein expression in hearts of adult WT and Ind-
csNox4D transgenic (Tg) mice 3 weeks after tamoxifen administration. Tg mice show a 10-fold 
increase in cardiac Nox4D protein level compared to control mice. n = 4 per group. Data represent 



















Figure 3.3. Induction of Nox4D overexpression in the adult heart is splice variant-specific. 
qPCR analysis of relative Nox4 mRNA expression in hearts of WT and Ind-csNox4D mice 3 weeks 
after tamoxifen administration. Full-length Nox4 mRNA is unchanged in Ind-csNox4D compared 
to control mice. n = 4 per group. Data represent mean ± SEM. Statistical analysis by unpaired 
two-tailed t-test. 
Initial attempts were made to establish the subcellular localisation of overexpressed 
Nox4D compared to the endogenous protein in vivo by immunoreactivity, using a well-
validated, in-house prepared polyclonal antibody directed against the carboxy-terminal 
region of Nox4, which is preserved in Nox4D.154,185 However, it is recognised in our 
laboratory that this antibody performs less well for immunohistochemical applications, as 
demonstrated by the lack of specificity in signal in both WT and Ind-csNox4D hearts 
(Figure 3.4). Additional attempts to optimise immunofluorescence staining in vivo by 











Figure 3.4. Localisation of Nox4D after induction of overexpression in the adult heart. 
Representative images of initial attempt at immunofluorescence staining for Nox4 (green) with 
the cardiomyocyte marker α-actinin (red) and nuclear marker DAPI (blue) on cardiac cryosections 
of Ind-csNox4D and WT control hearts harvested 3 weeks after tamoxifen induction, for 
characterisation of cellular localisation of Nox4D within cardiomyocytes in vivo. Under standard 
immunohistochemical staining conditions, the Nox4 antibody performs suboptimally. Scale bars: 
10 μm. n = 4. 
Given that previous data in NRVMs showed positive Nox4D staining when used in vitro 
(Figure 3.1), further optimisation of immunostaining with the Nox4 antibody was carried 
out in isolated adult cardiomyocytes from Ind-csNox4D and WT mice 2 weeks after 
tamoxifen induction. However, under standard staining conditions, there was little 
improvement in signal from the Nox4 antibody and, as such, the determination of Nox4D 
localisation and difference in expression between WT and Ind-csNox4D myocytes 





























Figure 3.5. Optimisation of immunostaining of Nox4D localisation in isolated adult 
cardiomyocytes. Representative images of further optimisation of immunofluorescence staining 
of Nox4 (green) with α-actinin (red) and Hoechst as a nuclear stain (blue) in adult cardiomyocytes 
isolated from WT and Ind-csNox4D mice 2 weeks after tamoxifen induction. Striated 
cardiomyocytes are revealed by positive sarcomeric actinin staining whilst Nox4 staining remains 
suboptimal. Scale bars: 50 μm. 
Using the same model of isolated adult cardiomyocytes, the conditions for 
immunofluorescence staining of Nox4D were further optimised to enhance antibody 
penetration and binding (Figure 3.6). This equated to an improvement in the specificity 
of the green signal and indicated that Nox4D is localised to the nuclear and cytosolic 
cellular compartments, as such staining was absent in the primary antibody negative 
control. This staining pattern was observed at a low level of expression in 
cardiomyocytes isolated from WT tissue. In Ind-csNox4D Tg cardiomyocytes, increased 
Nox4D expression was observed with predominant subcellular localisation within the 















Figure 3.6. Final optimisation of immunostaining of Nox4D localisation in isolated adult 
cardiomyocytes. Representative images of finalised optimisation of immunofluorescence 
staining conditions for Nox4 (green) with α-actinin (red) and Hoechst as a nuclear stain (blue) in 
adult cardiomyocytes isolated from WT and Ind-csNox4D mice 2 weeks after tamoxifen induction. 
Negative control incubated with secondary antibodies and Hoechst only. The magnified portion 
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3.4.2 Induction of cardiomyocyte-specific Nox4D overexpression in vivo 
does not affect basal cardiac function, structure or morphology 
To investigate the basal phenotype of the mice secondary to induction of cardiomyocyte-
specific Nox4D overexpression, echocardiography was repeatedly performed in WT and 
Ind-csNox4D transgenic mice before and after induction. A series of time points were 
selected to permit functional monitoring and analysis during the first 2 weeks after 
tamoxifen induction as a relevant time frame for subsequent experiments.  
Echocardiographic image analysis demonstrated no abnormalities in systolic function, 
as indicated by no change in ejection fraction compared to WT mice. Similarly, cardiac 
structure was unaffected as shown by no change in left ventricular end-diastolic volume 
(LVEDV, as a marker of LV dilatation), or interventricular diastolic septum thickness (IVS, 
d) (Figure 3.7). These results collectively highlighted that cardiomyocyte-specific Nox4D 
overexpression did not affect cardiac functional or structural parameters over the time 
frame observed.     
In conjunction, the ratios of heart weight to body weight post-tamoxifen induction in Ind-
csNox4D transgenic mice were also unchanged in comparison to WT mice, suggesting 




Figure 3.7. Cardiac structure and function are unchanged in inducible cardiomyocyte-
specific Nox4D (Ind-csNox4D) transgenic mice. (A) Representative M-mode 
echocardiographic images of WT and Ind-csNox4D transgenic hearts at baseline and days 3, 5 
and 12 after tamoxifen induction. White and cyan arrows indicate left ventricular end-diastolic 
diameter (LVEDD) and left-ventricular end-systolic diameter (LVESD), respectively. Scale bars: 
200 ms, 4 mm. Echocardiographic images analysed within same range of heart rate (B) for 
measurement of ejection fraction (C), left ventricular end-diastolic volume (LVEDV) (D), and 
interventricular septum thickness at diastole (IVS, d) (E). n = 4 per group. Data represent mean 



























Figure 3.8. Inducible cardiomyocyte-specific Nox4D overexpression does not affect 
cardiac morphology. Heart weight to body weight ratio in WT and Ind-csNox4D transgenic mice 
indicates cardiac morphology is unchanged after tamoxifen induction. n = 8 per group. Data 
represent mean ± SEM. Statistical analysis by unpaired two-tailed t-test. 
3.4.3 Cardiac-specific Nox4D overexpression does not affect basal cell 
proliferation in adult mice 
The capacity for cardiac-specific Nox4D overexpression to induce proliferation of adult 
cardiomyocytes in the absence of injury was investigated immunohistochemically 3 
weeks after tamoxifen induction by confocal microscopy. The proliferation markers Ki67 
and phospho-histone H3 (pHH3) were utilised for the evaluation of cardiomyocyte cell 
cycling in adult hearts of Ind-csNox4D Tg mice compared to WT littermate controls. 
Cardiomyocytes indicative of proliferation were identified by nuclear expression of Ki67, 
highlighting G1, S, G2 and M-phase of the cell cycle, and histone H3 phosphorylation at 
serine 10, a marker of late G2/M-phase, in conjunction with positive cell immunostaining 
for sarcomeric α-actinin.  
Quantification of the number of α-actinin-positive cardiomyocytes with Ki67-positive 
nuclei per microscopic field revealed that despite a small trend showing greater number 
in Ind-csNox4D myocardium, overall there was no difference compared to WT controls 
(Figure 3.9A and B). Similarly, although the same trend was observed for the number of 
α-actinin-positive cardiomyocytes with pHH3-positive nuclei in Ind-csNox4D hearts, this 
was not statistically different from that in WT hearts (Figure 3.9C and D).   
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Figure 3.9. Cardiomyocyte-specific Nox4D overexpression induced in adult mice does not 
promote cardiomyocyte proliferation in the absence of injury. Representative images of 
immunofluorescence staining for cell proliferation markers Ki67 (A) and phospho-histone H3 
(pHH3) (C) (both green) with α-actinin (red) as a cardiomyocyte marker and DAPI (blue) as a 
nuclear marker on cardiac cryosections of Ind-csNox4D and WT control hearts harvested 3 weeks 
after tamoxifen induction. Scale bars: 250 μm (left), 10 μm (right). White arrows and higher 
magnification images indicate positive cardiomyocyte nuclei, defined by co-localisation of green 
and blue signal in α-actinin-positive cells. (B) and (D) Quantification of the number of positive 
cardiomyocytes per field. Five fields of view, each of consistent cardiomyocyte count, were 
imaged per heart. n = 4 per group. Individual data points are shown with mean ± SEM. Statistical 
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3.4.4 Cardiac-specific Nox4D overexpression does not affect redox 
signalling pathways or transcriptional profiles associated with cell 
cycle modulation 
Following the initial in vitro data in which Akt phosphorylation was shown to be enhanced 
in response to Nox4D overexpression (Figure 3.1G), this was further investigated to 
establish if the same response could be elicited in the adult heart. The capacity for basal 
cardiomyocyte-specific Nox4D overexpression to promote Akt phosphorylation in vivo 
was assessed by Western blotting of myocardial lysates of Ind-csNox4D and WT adult 
hearts, 3 weeks after tamoxifen induction.  
However, the level of phosphorylated Akt as a marker of activation of the PI3K-Akt 
pathway was shown to be unchanged in Ind-csNox4D hearts compared to WT controls, 
indicating no baseline activation of Akt secondary to induced cardiac-specific Nox4D 
overexpression (Figure 3.10A). Likewise, as the cell cycle inhibitor p27Kip1 is a direct 
target of Akt,119 this was also measured as a downstream readout of Akt activation. 
Consistent with the level of phosphorylated Akt, no changes were seen in the level of 
p27Kip1 in the Tg compared to WT hearts, suggesting no Akt-mediated effect on 
downstream targets (Figure 3.10B).  
Under normal physiological conditions, the mRNA expression of cell cycle activators and 
foetal contractile proteins or dedifferentiation markers in the heart would be expected to 
decrease after birth whilst the expression of cell cycle inhibitors would be predicted to 
rise, in line with the usual postnatal exit of cardiomyocytes from the cell cycle.186 
Therefore, in order to investigate the propensity of Nox4D-overexpressing adult 
cardiomyocytes to re-enter the cell cycle, a selection of these markers, as informed by 
recent reports in the literature,162,187 was screened by qPCR analysis of myocardial lysate 
collected from Ind-csNox4D and WT hearts at the same time point as above after 
tamoxifen induction. 
Overall, this screen revealed no changes in the mRNA expression levels of cell cycle 
activators (cyclins E1, A2 and D1), foetal contractile proteins (myosin heavy chain 7 
[Myh7] and slow skeletal troponin I [ssTNI]) or other dedifferentiation markers (Runx1, 
Dab2, GATA4 and ckit) in hearts of Ind-csNox4D transgenic compared to WT control 
mice (Figure 3.11). As such, this demonstrated no changes in either the differentiation 
status or proliferative capacity of adult cardiomyocytes overexpressing Nox4D under 




Figure 3.10. Cardiac-specific Nox4D overexpression does not enhance signalling of 
proliferative redox-sensitive pathway Akt. (A) and (B) Representative immunoblots (left) and 
relative quantification (right) of phosphorylated Akt (P-Akt,  serine 473) (A) and downstream target 
p27Kip1 (B) protein expression in hearts of WT and Ind-csNox4D transgenic mice 3 weeks after 













Figure 3.11. Nox4D overexpression in the adult heart does not affect gene expression 
profiles associated with dedifferentiation or cell cycle modulation. qPCR analysis of relative 
mRNA expression of markers of dedifferentiation in (A) myosin heavy chain 7 (Myh7), (B) Runx1, 
(C) slow skeletal troponin I (ssTNI), (D) Dab2, (E) GATA4, (F) ckit and markers of proliferation in 
(G) cyclin E1, (H) cyclin A2, and (I) cyclin D1, in hearts of WT and Ind-csNox4D mice 3 weeks 
after tamoxifen induction. n = 4 per group. Data represent mean ± SEM. Statistical analysis by 
unpaired two-tailed t-test. 
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3.4.5 Under baseline conditions, induction of cardiac-specific Nox4D 
overexpression does not provide an immediate proliferative window 
Given the lack of phenotype when Ind-csNox4D transgenic hearts were assessed at 3 
weeks post-tamoxifen induction, an alternative protocol was devised to determine 
whether the induction of cardiomyocyte-specific Nox4D overexpression would be 
associated with an immediate window of cardiomyocyte proliferation. To achieve this, 
Ind-csNox4D and WT mice were treated with tamoxifen again at 8 weeks of age, as 
described in 3.3.1. Following completion of tamoxifen induction on day 5, mice were 
further injected with the nucleoside thymidine analogue EdU at 50 mg/kg body weight on 
days 5 and 8 for pulse-chase analysis on day 10. The use of EdU was preferable here 
due to improved tissue sample preservation and reproducibility as compared to BrdU-
based assays that require a harsh DNA denaturation step prior to detection.188,189  
Cardiomyocyte proliferation was measured by fluorescent labelling of incorporated EdU 
in conjunction with sarcomeric α-actinin immunostaining to mark cardiomyocytes that 
have newly synthesised DNA and therefore proceeded through S-phase. The number of 
α-actinin-positive cardiomyocytes with EdU-positive nuclei were counted per microscopic 
field, as described in 3.3.3. Compared to WT hearts, although associated with a slight 
upward trend, the number of EdU-positive cardiomyocytes was shown to be unchanged 
in the hearts of Ind-csNox4D animals (Figure 3.12). This suggested no impact of Nox4D 







Figure 3.12. Induction of Nox4D in the adult heart is not associated with an immediate 
window for cardiomyocyte proliferation. To capture proliferation events, Ind-csNox4D and WT 
control animals were injected twice with 5-ethynyl-2’-deoxyuridine (EdU) during the 5-day period 
following tamoxifen induction and then harvested. (A) Representative images of 
immunofluorescence staining of EdU (green) incorporation, labelling cells that have synthesised 
DNA, with α-actinin (red) as a cardiomyocyte marker and Hoechst (blue) as a nuclear marker on 
cardiac cryosections of Ind-csNox4D and WT control hearts. Scale bars: 250 μm (left), 10 μm 
(right). White arrows and higher magnification images indicate positive cardiomyocyte nuclei, 
defined by co-localisation of green and blue signal in α-actinin-positive cells. (B) Quantification of 
the number of positive cardiomyocytes per field. Five fields of view, each of consistent 
cardiomyocyte count, were imaged per heart. n = 4 per group. Individual data points are shown 
with mean ± SEM. Statistical analysis by unpaired two-tailed t-test. 
To establish whether the induction of cardiomyocyte-specific Nox4D overexpression 
would have an early impact on transcriptional profiles associated with cell cycle 
modulation, the same qPCR screen was conducted (as described in 3.3.4) on WT and 
Ind-csNox4D hearts collected 5 days after tamoxifen induction.  
As was observed in Ind-csNox4D hearts 3 weeks after tamoxifen induction, no changes 
were found in the mRNA expression levels of cell cycle activators (cyclins E1, A2 and 
D1), foetal contractile proteins (Myh7 and ssTNI) or other dedifferentiation markers 
(Runx1, Dab2, GATA4 and ckit) in Ind-csNox4D compared with WT hearts 5 days after 
tamoxifen induction. This was consistent with the quantification of EdU incorporation 
above, collectively demonstrating no difference in phenotype even at an earlier time point 













Figure 3.13. Nox4D overexpression in the adult heart does not affect transcript expression 
of markers of dedifferentiation or cell cycle modulation immediately after induction. qPCR 
analysis of relative mRNA expression of markers of dedifferentiation in (A) myosin heavy chain 7 
(Myh7), (B) Runx1, (C) slow skeletal troponin I (ssTNI), (D) Dab2, (E) GATA4, (F) ckit and markers 
of proliferation in (G) cyclin E1, (H) cyclin A2, and (I) cyclin D1, in hearts of WT and Ind-csNox4D 
mice harvested 5 days after tamoxifen induction. n = 4 per group. Data represent mean ± SEM. 
Statistical analysis by unpaired two-tailed t-test. 
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3.5.1 Generation of an inducible cardiomyocyte-specific transgenic 
mouse model with Nox4D overexpression 
Transgenesis has repeatedly been proven as an invaluable tool in defining the function 
of a particular gene and its protein in vivo.158 Therefore, to explore the functional role of 
Nox4D in the adult heart, we employed a gain-of-function, tissue-specific Cre/LoxP-
mediated gene targeting strategy to generate an inducible transgenic mouse model of 
conditional cardiomyocyte-specific overexpression of Nox4D.  
The first step in the baseline characterisation of this novel model was to validate the 
induction of Nox4D overexpression in response to tamoxifen. Adult Ind-csNox4D mice 
demonstrate a 10-fold upregulation in Nox4D protein level in the heart, thereby 
reproducibly validating the efficiency of this tamoxifen protocol to induce the translocation 
of Cre recombinase to the nucleus.158,150 The overexpression of Nox4D in Ind-csNox4D 
hearts did not change the mRNA expression level of full-length Nox4, meaning that 
interpretation of its effects was not confounded by such changes. 
Due to the impact of compartmentalised ROS generation and redox signalling,154 a 
characteristic that we hypothesised to be important to the functional role of Nox4D in 
vitro is its nuclear localisation. This was previously predicted in the original identification 
of Nox4 splice variants, is consistent with its lack of transmembrane domain,153 and was 
further characterised in our laboratory.154 It was therefore of great interest to establish 
whether the subcellular localisation of endogenous and overexpressed Nox4D splice 
variant in cardiomyocytes would be the same in vivo, as this could be an important 
determinant for functional effect.  
Although the immunostaining of Nox4D in vivo gave rise to some technical difficulty and 
required optimisation, final staining ex vivo in isolated WT and Ind-csNox4D 
cardiomyocytes provided a strong indication that Nox4D is localised to the nuclear and 
cytosolic compartments, with predominant handling within the nucleus, which is similar 
to that seen in vitro. To substantiate this finding, additional methods would be needed to 
overcome the limitations encountered with immunostaining such as cell fractionation and 
nuclear isolation (discussed in 6.4).   
On a more global level, Ind-csNox4D hearts importantly show similar basal cardiac 
contractility, structure and gross morphology to WT littermates. Thus, the induction of 
cardiomyocyte-specific Nox4D overexpression in the adult mouse heart is well tolerated 
and does not appear to be associated with an obvious detrimental phenotype.  
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3.5.2 Impact of cardiomyocyte-targeted overexpression of Nox4D on cell 
cycle modulation in the adult heart 
The adult mammalian heart retains a very limited regenerative potential as the majority 
of cardiomyocytes demonstrate permanent cell cycle exit after birth.68,83,88 There now 
exist several reports of evidence to support a small capacity for pre-existing 
cardiomyocytes to re-enter the cell cycle in the adult heart, especially after injury such 
as MI.9,86 However, any intrinsic regenerative pathways mounted by the adult heart are 
insufficient to achieve meaningful restoration of contractile function following pathological 
cardiomyocyte loss.26,78   
In light of this, the ability to induce effective adult cardiomyocyte proliferation would 
represent both a novel and promising therapeutic strategy in the setting of cardiac 
injury.23,26,184 The use of genetically-modified mice has formed the basis for several 
studies assessing the potential of specific genes and pathways to promote 
cardiomyocyte proliferation in normal and diseased hearts.190 This has enabled recent 
findings showing that many developmental and signalling pathways are able to stimulate 
cell cycle re-entry in mature adult cardiomyocytes.23  
As discussed in 1.3.4, it is becoming increasingly recognised that cardiomyocyte cell 
cycle regulation may be sensitive to ROS-mediated redox signalling pathways.191 
However, this is likely a complex mechanism due to arguments that cardiomyocyte cell 
cycle arrest may be triggered by mitochondrial ROS-mediated oxidative stress,79 and 
conversely, that cardiomyocytes residing in microenvironments of hypoxia may be 
responsible for cellular turnover in the adult heart (discussed in more detail in 1.2.5).87 
As such, these studies suggest that ROS likely exert diverse functions in cell cycle 
modulation,191 the effects of which are critically dependent on the cellular source, spatial 
regulation, and amount released.131  
In pursuit of the above therapeutic strategy, the work described in this chapter 
demonstrates the impact of a novel transgenic model overexpressing a redox-active 
Nox4 splice variant to induce cardiomyocyte proliferation under baseline conditions. 
In the absence of injury, the Ind-csNox4D transgenic heart does not appear to be 
associated with the promotion of cardiomyocyte proliferation 3 weeks after the induction 
of Nox4D overexpression. This is primarily evidenced by no change in microscopic 
visualisation of markers of the cell cycle – Ki67 and pHH3. Ki67 is a nuclear protein and 
is commonly used in studies as a marker of cell cycle progression, highlighting all active 
phases of the cell cycle.192 As such, Ki67 is usually considered less specific and should 
not be used definitively.43,81 Histone H3 phosphorylation at serine 10 is also a commonly 
used marker for cell cycle activity, more specifically detected in late G2/early mitosis.193  
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Although commonly used markers, what is highly important to note are the investigative 
challenges associated with assessment of cardiomyocyte proliferation by microscopy. 
These include the obscurity of identification of cardiomyocyte nuclei due to the 
heterogeneity and dense spatial packaging of cardiomyocytes with neighbouring non-
myocytes in the myocardium.25,40 Furthermore, cardiomyocytes can exhibit non-
proliferative cell cycles by increasing their DNA content via polyploidisation and 
polynucleation without actually dividing.194–196 Therefore, the utilisation of such 
methodology reinforces the need for very careful analysis with the awareness that the 
detection of some markers alone does not provide conclusive proof of bona fide 
cardiomyocyte proliferation but rather an indication of proliferative potential.  
The baseline phenotype of the Ind-csNox4D heart was therefore investigated by 
additional methods for determination of activation of redox signalling and transcriptional 
regulators of cardiomyocyte cell cycling. Akt is involved in the regulation of cell cycle 
progression amongst other processes including cell death and migration.197 The 
phosphorylation state of Akt is susceptible to redox modulation and may be differentially 
regulated by specific thiol oxidations of cysteine residues within the activation loop or the 
N-terminal pleckstrin homology (PH) domain,132,183 or indirectly by oxidation of 
phosphatases.151,198  
Such post-translational modifications are able to modulate the nuclear translocation of 
activated Akt,183 the importance of such localisation was previously highlighted by a study 
in which cardiac-specific nuclear-targeted Akt was associated with increased 
cardiomyocyte cycling.124 Given that the nucleus is known to contain several 
phosphatases,199,200 we hypothesised that nuclear-localised Nox4D was associated with 
enhanced Akt kinase activation in vitro via redox-mediated inhibition of specific nuclear-
localised phosphatases. In contrast, this effect did not appear to transfer from the in vitro 
to in vivo setting in the adult heart, as evidenced by no change in the level of 
phosphorylated Akt after induction of cardiac-specific Nox4D overexpression. 
Furthermore, as p27Kip1 is a direct downstream target of Akt, in which Akt-mediated 
phosphorylation of p27Kip1 impairs nuclear import of p27Kip1 and leads to its 
degradation,119,121,201 we also saw no change in the levels of p27Kip1 in the Ind-csNox4D 
hearts, thus confirming no Akt-mediated proliferative signalling upregulation. However, it 
is worth remembering that the proportion of cycling cardiomyocytes would likely be small, 
and so there may have been Akt activation in small percentage of cardiomyocytes, but 
was difficult to detect in whole multicellular myocardial samples.   
Another element that is becoming increasingly recognised for its role in cardiomyocyte 
regeneration is the process of dedifferentiation. This argues that mature adult 
cardiomyocytes can re-enter the cell cycle and divide through a 3-step process of 
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dedifferentiation, proliferation, and redifferentiation,202 and was demonstrated by a 
coculture system with neonatal cardiomyocytes in which cytokinesis of adult 
cardiomyocytes was preceded by dedifferentiation.202 It is thought that the cellular 
morphological rearrangement and gain in plasticity associated with cardiomyocyte 
dedifferentiation is what allows cardiomyocytes to become permissive to cell cycle re-
entry.187 This is accompanied by an upregulation in genes typically expressed in 
embryonic and foetal hearts. Transcript markers re-expressed in dedifferentiated 
cardiomyocytes therefore include early transcription factors such as GATA4, foetal 
contractile proteins such as Myh7 and ssTnI, and also genes usually restricted to stem 
cells, including ckit, Runx1 and Dab2.162,187  
In light of this, we conducted a baseline screen for transcript markers of dedifferentiation 
and proliferation (cyclins E1, A2 and D1), but in agreement with our other findings, these 
proved to be unchanged. Alternatively, as stated above, it is also possible there were 
transcriptional changes in a minor subset of cardiomyocytes, but detection using whole 
myocardium was insufficiently sensitive.  
Given the lack of baseline phenotype when assessed 3 weeks after tamoxifen induction, 
we reassessed Ind-csNox4D hearts for an immediate window of cardiomyocyte 
proliferation by EdU pulse-chase analysis. The labelled thymidine analogue EdU is also 
commonly used to detect proliferating cells as it is stably incorporated into newly 
synthesised DNA during DNA replication.81 However, as with the above described 
problems associated with the use of antibodies raised against markers of the cell cycle, 
EdU incorporation does not exclusively identify cardiomyocytes that will divide due to 
non-proliferative cell cycles and incorporation during other cellular processes such as 
DNA repair.43,195  
We identified that induction of Nox4D overexpression is not associated with an 
immediate window of cardiomyocyte proliferation due to only small changes in EdU 
incorporation, suggesting that Ind-csNox4D confers little or no enhancement in 
proliferative potential. Likewise, Nox4D overexpression in the adult heart neither seems 
to affect gene expression patterns associated with cell cycle modulation during this 
period. 
Attempts to directly induce cardiomyocyte proliferation in the adult heart by temporal and 
spatial regulation of specific genetic pathways have been demonstrated by several 
studies, including cardiomyocyte-specific modification of Hippo/YAP,114,119 
microRNAs,100,203 developmental transcription factors,162 and ERBB2 receptor 
signalling.204 Such inducible expression systems activating, for example, YAP114 and the 
co-receptor ERBB2,204 in the adult mammalian heart have been able to stimulate 
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cardiomyocyte proliferation in the absence of myocardial injury. However, in the case of 
ERBB2, this was observed in conjunction with pathological changes characterised by 
cardiac hypertrophy.204 Collectively, these studies demonstrate the ability to enhance 
basal cardiomyocyte proliferation, but also the need for tight regulatory control.  
Here we show that induction of cardiomyocyte-targeted overexpression of Nox4D in adult 
mice does not translate to enhanced proliferative potential in the absence of injury. This 
was unexpected given the contrasting effects we previously observed in vitro using 
neonatal cardiomyocytes, despite being able to reproduce the nuclear localisation in 
vivo. Thus, the lack of translation of effect from in vitro to in vivo is likely multifactorial. 
The cardiomyocyte cell type studied represents a major difference as neonatal myocytes 
are already more proliferative in nature due to their developmental immaturity,40,205 
whereas the adult myocyte may not be permissive to this redox-mediated pathway. The 
level of transgene expression can be difficult to control in vivo and as such could also 
influence the therapeutic effect. Lastly, it could be postulated that the impact of cardiac-
specific Nox4D overexpression could become apparent in the setting of pathological 
stress, as this could provide the stimulus necessary for cardiomyocyte dedifferentiation 




Chapter 4 The impact of inducible 
cardiomyocyte-specific Nox4D 






Myocardial infarction is a prevalent major cardiovascular event and leading cause of 
mortality and morbidity.206 Owing to the insufficiency of cardiomyocyte self-renewal, the 
adult mammalian heart cannot compensate for the massive loss of functional 
cardiomyocytes caused by MI, resulting instead in compromised myocardial function and 
heart failure.10,11,18  
Small animal models of myocardial ischaemia and infarction are important tools in 
cardiovascular research. Despite obvious differences in organ size and heart rate, with 
some dissimilarities in cardiac haemodynamics and electrophysiology, overall the mouse 
heart is considered to resemble the human heart sufficiently well in terms of anatomy 
and physiology.207 Moreover, it has been demonstrated that adult mice show many of 
the clinical and haemodynamic features of heart failure seen in humans.208 Combined 
with the wide applicability of gene targeting to the mouse, these experimental models 
have enabled extensive study on the consequences of genetic manipulation on 
molecular pathways underlying the ischaemic tolerance of the myocardium.207,209 This 
aims to provide better mechanistic insight into the processes involved in cardiac repair 
and regeneration, with eventual translatability to the clinical setting for the prevention or 
treatment of heart failure.18,210  
4.1.1 The pathophysiology of permanent coronary artery ligation 
The mouse model of permanent ligation of the LAD coronary artery reliably induces 
infarctions involving the anterolateral, posterior, and apical regions of the heart, and is 
utilised to investigate cardiac function and long-term left ventricular (LV) remodelling 
post-myocardial infarction. This model fundamentally differs from models of transient 
ligation, in which the initial extent of the infarct is susceptible to modulation by factors 
that affect myocardial salvage upon reperfusion.211,212 In contrast, at 24 hours post-MI by 
permanent ligation, the infarct area becomes fixed due to the absence of reperfusion, 
such that the entire area-at-risk (AAR) is infarcted. This scenario translates to patients 
with acute ST segment elevation MI who are unable to receive timely or successful 
reperfusion therapy due to contraindications or delay.213,214 Cardiac function in this model 
is therefore subject to infarct expansion and healing, and the concomitant development 
of remodelling processes including LV hypertrophy and chamber dilatation.210,211  
Myocardial ischaemia occurs when the coronary blood flow to the myocardium is 
reduced, and leads to infarction when the duration is prolonged, causing profound 
electric, metabolic, functional, and structural consequences within the myocardium.215 
Coronary occlusion causes immediate cessation of mitochondrial oxidative 
phosphorylation, forcing cardiomyocytes to switch to alternative ATP-generating 
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pathways including mobilisation from creatine phosphate17 and anaerobic glycolysis.216 
The latter pathway results in a rapid increase in the levels of lactate in the ischaemic 
myocardium, leading to the onset of intracellular acidosis.17 Cumulatively, these 
mechanisms impact on the activity of contractile proteins as their function is depressed 
by inorganic phosphate derived from the metabolism of creatine phosphate,217 and 
decreased calcium binding secondary to acidosis.218 Thus, the rapid exhaustion of ATP 
stores and accumulation of metabolites caused by these energetic shifts manifest 
functionally as a severe deterioration in systolic contractility. Compared to humans, this 
may occur at a much faster rate in experimental small animal models, as contractile force 
is quickly suppressed within the first minute of the onset of ischaemia.17 
The metabolic effects described above cause further detriment to the ischaemic 
cardiomyocyte with marked perturbations in cellular ionic balance. Potassium efflux is 
increased whereas intracellular sodium and calcium are increased due to inhibition of 
ion channels by acidosis, collectively leading to excitation contraction uncoupling and 
increased susceptibility to ventricular arrhythmia.219,220 The resultant increased osmotic 
load eventually leads to irreversible changes in ultrastructural cardiomyocyte features 
including striking distortion of mitochondrial architecture and sarcolemmal 
blebbing.17,221,222 Deranged metabolism, sustained intracellular calcium overload, and 
oxidative stress collectively lead to advanced cardiomyocyte injury associated with 
progressive membrane damage, culminating in physical disruption of the sarcolemma 
and cardiomyocyte necrosis in the infarct environment.220,222  
Prolonged ischaemia causes irreversible death in an increasing number of 
cardiomyocytes. This paradigm describes a wavefront of cardiomyocyte death due to the 
heterogeneity of the myocardial response to ischaemia, extending in order of 
susceptibility from the subendocardium to the subepicardium as the duration of the 
ischaemic insult increases.17 Cardiomyocyte necrosis triggers an intense inflammatory 
reaction via the release of damage-associated molecular patterns (DAMPs), mediating 
leukocyte infiltration of the myocardial infarct that serves to clear dead cells and matrix 
debris, and initiate a reparative response.223,224     
4.1.2 Assessment of myocardial infarct size 
Despite standardisation of the permanent ligation protocol by maintenance of the 
consistency of the anatomical site at which the ligature is positioned, the model remains 
prone to variability in infarct size.210,225 This is considered one of the model’s principal 
limitations, and is reflective of the variability in the coronary circulation.226 The differences 
in the branching pattern of the murine LAD together with its supplied myocardial vascular 
territories prevent complete reproducibility of the AAR and thus the consistency of 
cardiac damage.207,227 Therefore, measurement of LV infarct size post-permanent 
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ligation is crucially important as it provides confirmation of the success of the surgical 
MI, and enables comparability of initial infarct injury across experimental groups for 
assessment of remodelling differences at later stages. If AAR is standardised, any 
differences observed in LV geometry and function are therefore independent of acute 
cardiomyocyte injury and are reflective of differences in recovery.210  
Several techniques are available for the determination of myocardial infarct size, 
including late gadolinium-enhanced magnetic resonance imaging, histological staining, 
and plasma sampling.226 In animal studies, triphenyltetrazolium chloride (TTC) staining 
is considered the gold standard technique for demarcation of the fractions of viable and 
non-viable tissue zones, and is used by many laboratories.207,228–230 However, the major 
limiting factor associated with this technique is that it is an end-point evaluation, 
precluding long-term analysis of LV function and remodelling.207  
The measurement of biomarkers by plasma sampling represents another index of 
cardiac injury. Due to their high specificity and sensitivity, cardiac troponins, particularly 
the I and T isoforms, are well-evaluated clinical biomarkers for the diagnosis and 
prognosis of myocardial injury.231,232 Most troponin is localised within the 3-unit complex 
of the myofibrillar contractile apparatus, consisting of troponin I, T, and C. There is only 
one isoform of cardiac troponin I (cTnI) expressed in the myocardium, which is also-
tissue-specific. This has allowed the generation of highly specific monoclonal antibodies 
that do not exhibit cross-reactivity with other non-cardiac isoforms.233 Using these 
antibody-based assays, cardiac troponin I release from the injured myocardium is 
detectable early post-MI, the magnitude of elevation of which serves as a predictor of 
the extent of myocardial necrosis.226 Furthermore, the prognostic value of cTnI release 
has also been demonstrated in small mouse models of permanent LAD ligation, showing 
a rapid rise in plasma levels following ligation and a peak between 24 and 48 hours, with 
significant correlation to histological infarct size and cardiac function. Thus, cTnI is also 
a valuable biomarker for the confirmation of MI and prediction of infarct size in small 
animal models.226,234  
4.1.3 Postinfarction left ventricular adverse remodelling 
The adult mammalian heart responds to the acute loss of myocardium induced by severe 
ischaemic damage through formation of a scar.17 This refers to the unique pattern of 
remodelling events, involving the infarct zone, the encircling border zone of viable 
myocytes, and the remote non-infarcted zone, that are triggered in response to the 
abrupt increase in loading conditions caused by MI.235 The interplay between all 3 
integrated components of the myocardium, namely the cardiomyocytes, ECM, and 
capillary microvasculature, has important multifactorial roles in the postinfarction 
remodelling process.236,237 This describes specific changes in the structure, size and 
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shape of the left ventricle, culminating in significant alteration of chamber architecture, 
which profoundly impacts on cardiac function and the development of heart failure.238 
The loss of myocardial tissue post-MI causes an immediate decrease in ejection 
fraction.210 During the early phase of remodelling, infarct expansion results from the 
degradation of the interstitial matrix and cardiomyocyte slippage through activation of 
matrix metalloproteinases (MMPs) released from neutrophils.239 This promotes 
disproportionate LV wall thinning and chamber dilatation, which effectuates an increase 
in LVEDV. This alters the Frank-Starling relation in the infarct border zone and remote 
myocardium, and may preserve stroke volume by augmenting shortening in non-
infarcted LV segments and therefore the pressure developed during systole.240 
Neurohormonal mechanisms are also invoked in response to disturbances in vascular 
haemodynamics, which yield transient functional compensation in the immediate phase 
post-MI. This is mediated by increased sympathetic nerve activation and catecholamine 
synthesis, leading to enhanced activation of the renin-angiotensin-aldosterone system 
and increased systemic vascular resistance.235 In conjunction with myocardial stretch, 
these pathways also trigger the transcription and release of atrial and brain natriuretic 
peptides (ANP and BNP), which modulate activation of the renin-angiotensin-
aldosterone system, normalise ventricular filling and improve pump function.235,241 
Elevations in the synthesis of ANP and BNP consequently function as molecular markers 
of remodelling or failure.242   
However, the increased LVEDV induced by infarct expansion also concomitantly leads 
to an elevation of diastolic and systolic wall stress, which acts as a powerful stimulus for 
regional hypertrophy of the non-infarcted segment.235 Increased wall stress triggers a 
complex network of intracellular signalling cascades, which initiate increased synthesis 
of contractile units through neurohormonal agonist-mediated activation of cell membrane 
receptors by angiotensin II, catecholamines, and endothelin,243,244 as well as activation 
of mechanoreceptors. Cardiomyocyte hypertrophy, demonstrated by a significant 
increase in cell volume, develops to establish a more even distribution of the increased 
wall stresses. This represents another adaptive remodelling response that initially 
stabilises contractile function by offsetting increased load and attenuating further 
dilatation.238 
As the remodelling phenotype progresses, the postinfarction heart becomes 
characterised by hallmark changes in global LV geometry.241 Cardiomyocytes in viable 
remodelling segments may undergo apoptosis second to inflammatory signalling and 
biomechanical stress.245 Due to chamber dilatation, remodelling post-MI is primarily a 
state of volume-overload and thus leads to myocyte lengthening and eccentric 
hypertrophy. Major targets of hypertrophic intracellular signalling pathways are 
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transcriptional regulators that drive the reinduction of a gene expression programme 
comparable to that seen during foetal development.246 Myocyte enhancer factor 2 
(MEF2),247 nuclear factor of activated T cells (NFAT),247 GATA4,248 and myocardin249 are 
transcription factors that have all been shown to be centrally involved both in early 
cardiac development and in the hypertrophic response to cardiac stress. Importantly, this 
complex response is subject to careful control through integration of other pathways that 
limit pro-hypertrophic signalling, such as those mediated by nitric oxide and natriuretic 
peptides.242  
During infarct healing, the initial inflammatory phase is superseded by the proliferative 
phase, associated with suppression of pro-inflammatory pathways and infiltration and 
proliferation of interstitial fibroblasts.17 Growth factor release and neurohormonal 
signalling stimulate the phenotypic transformation of fibroblasts into myofibroblasts, 
characterised by upregulated expression of contractile stress fibres and α-smooth 
muscle actin.17,250 Activated myofibroblasts critically serve to enrich the ECM by 
deposition of matricellular proteins and initiate tissue repair by collagen synthesis.235,251 
Collagens type I and III are predominantly deposited in the infarct zone, and also in the 
remote zone if potentiated by extensive myocyte death.235 Formation of a structural 
network of matrix proteins in the infarct region transitions into the maturation phase of 
infarct healing, signified by strengthening of fibrillar collagen by cross-linking and 
reduction of cellular content.17,252 Stabilisation of the wound is aided by important 
maturation of the infarct vasculature.253 The resultant fibrous tissue forms a scar that has 
been shown to replace the loss of myocytes by 4 weeks after MI.254  
Postinfarction remodelling therefore does not only involve the cellular and molecular 
events associated with infarct healing, but is also intertwined with alterations including 
hypertrophy and fibrosis in the non-infarcted myocardial segments. Experimental models 
of MI have shown that the severity of these alterations is largely dependent on the size 
of the infarct.17 Although initially adaptive, the events of ventricular remodelling 
collectively lead to progressive contractile dysfunction, increased incidence of 
arrhythmia, and increased mortality.242 Compared to less severe models of myocardial 
infarction, permanent ligation typically yields accentuated dilated remodelling and 
exacerbated contractile dysfunction.210 Cardiomyocyte replacement with a noncontractile 
scar may maintain the structural integrity of the ventricle and prevent rupture,17 but also 
increases myocardial stiffness, resulting in a loss of elasticity and impairment in diastolic 
filling.255 Failure to normalise increased wall stresses due to chronic volume-overload 
results in progressive chamber dilatation and a further increase in cardiac workload.238 
Thus, it is may be more appropriate to consider the sequence of processes involved in 
107 
 
postinfarction healing and repair as maladaptive remodelling that fails to compensate for 
the loss of essential cardiomyocytes.242  
In light of this, it is extremely clear that the adult mammalian heart is unable to mount a 
substantial renewal response to counteract the increased demand imposed by infarctive 
injury.18 Although current therapies have significantly improved prognosis, the burden of 
heart failure post-MI remains high.256 Therapeutic harnessing of the mechanisms that 
influence regeneration is a visionary goal in the cardiovascular research field and is 
under extensive investigation through the use of preclinical animal models of myocardial 
infarction.21 The proliferative potential of inducible Nox4D in the adult heart remains to 





The primary aim of this chapter is to investigate the impact of inducible cardiomyocyte-
specific Nox4D overexpression on functional recovery post permanent ligation of the left 
anterior descending coronary artery. The effects on long-term ventricular remodelling will 
also be examined, with a specific focus on the ability of Nox4D to enhance the 
proliferative capacity of the myocardium after ischaemic injury. Regional effects will be 




4.3 Summary of methods 
The impact of the Ind-csNox4D Tg model in the setting of pathological stress was 
investigated by induction of MI by permanent LAD coronary artery ligation. Female adult 
WT and Ind-csNox4D mice were administered tamoxifen at 8 weeks of age (section 2.3), 
then randomised to undergo MI or sham ligation at 10 – 12 weeks of age, followed by 
plasma sampling at 24 hours post-surgery for measurement of cTnI for quantification of 
myocardial injury (section 2.4 & 2.12). Echocardiography was performed at baseline, 
within 1 week of surgery, then at 1, 2, and 4 weeks post-surgery for assessment of global 
and regional cardiac contractile function by strain analysis (section 2.5). Cardiac tissues 
were harvested after 4 weeks (section 2.7) for regional infarct zone analysis of cell cycle 
markers and postinfarction remodelling processes at the cellular and transcript levels by 
several staining methods (section 2.11) and qPCR (section 2.9), respectively (Figure 
2.5).  
A separate cohort of animals was also used for assessment of EdU incorporation post-
MI. As above, tamoxifen-treated adult WT and Ind-csNox4D Tg mice were subjected to 
MI or sham surgery, and harvested after 2 weeks during which a total of 4 doses of EdU 
were administered (Figure 2.7). EdU labelling was detected by fluorescence staining in 
conjunction with immunohistochemistry (sections 2.11.2 & 2.11.3). 
For investigation of the potential negative effects of nuclear-localised ROS generation, a 
tamoxifen dose response experiment was performed. Male and female adult Ind-
csNox4D were injected with tamoxifen, but randomised to receive one of the following 
doses: 5 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg, and harvested after 2 weeks (as 
described in section 2.3). Cardiac tissues were analysed by HPLC for quantification of 






4.4.1 Induction of cardiomyocyte-targeted Nox4D overexpression elicits a 
differential temporal functional response post-myocardial infarction 
To investigate the impact of inducible Nox4D overexpression in the adult heart on the 
functional response to myocardial ischaemic injury, female Ind-csNox4D transgenic mice 
and WT littermate controls were treated with tamoxifen at 8 weeks of age, then subjected 
to either MI by permanent LAD coronary artery ligation or sham ligation at 10 – 12 weeks 
of age. To assess functional recovery post-MI, animals were serially monitored by 
advanced ultrasound cardiac imaging and analysed by myocardial using strain once at 
baseline, within 1 week prior to surgery, and then at 1, 2, and 4 weeks after injury, at 
which point animals were sacrificed.  
Baseline echocardiography in tamoxifen-treated animals prior to MI further confirmed the 
absence of abnormality in systolic function or structure secondary to the induction of 
cardiac-specific Nox4D overexpression, as demonstrated by no change compared to WT 
hearts in ejection fraction, LVEDV, LVESV, global longitudinal strain (GLS, as a more 
advanced index of systolic function), or end-diastolic left ventricular mass (LVM) (Figure 




Figure 4.1. Systolic function is unchanged in Inducible cardiomyocyte-specific Nox4D 
animals prior to myocardial infarction. Baseline strain analysis, within 1 week prior to 
myocardial infarction or sham surgery, of B-mode parasternal long axis echocardiographic 
images of WT and Ind-csNox4D hearts within same range of heart rate (A) for measurement of 
ejection fraction (B), left ventricular end-diastolic volume (LVEDV) (C), left ventricular end-systolic 
volume (LVESV) (D), global longitudinal strain (GLS) (E), and left ventricular mass (LVM) (F). n = 
20 (WT), 21 (Ind-csNox4D). Data represent mean ± SEM. Statistical analysis by unpaired two-
tailed t-test. 
To reliably assess the functional response of the Ind-csNox4D model compared to WT 
after MI, it was crucially important to employ a readout that permitted quantification of 
the initial injury. This was achieved by measurement of plasma cTnI at 24 hours post-MI 
as a biomarker for myocardial injury. There was no difference in the 24-hour release of 
cTnI in Ind-csNox4D mice compared to WT controls, suggesting no difference in the 
acute response to myocardial ischaemia (Figure 4.2). All sham ligation mice yielded cTnI 













Figure 4.2. Cardiac troponin I release 24 hours post-myocardial infarction estimates similar 
myocardial injury in Inducible cardiomyocyte-specific Nox4D mice. ELISA-based detection 
of plasma cardiac troponin I (cTnI) 24 hours post-myocardial infarction as a biomarker for cardiac 
injury. The concentration of cTnI is unchanged in Ind-csNox4D relative to WT mice. n = 15 (WT), 
16 (Ind-csNox4D). Data represent mean ± SEM. Statistical analysis by unpaired two-tailed t-test. 
As mentioned above, 2D echocardiographic imaging was analysed by myocardial strain 
before and after MI for advanced assessment of traditional left ventricle (LV) functional 
parameters as well as global longitudinal strain (GLS). Representative analysis of an 
infarcted LV is shown in Figure 4.3, the accuracy of which relies on careful tracing of the 











Figure 4.3. Analysis of cardiac contractility by Vevo Strain Software. Representative strain 
analysis of an infarcted heart in B-mode parasternal long axis view by Vevo® Strain technology. 
Left ventricular tracing (green) outlines endocardial border (inner) and epicardial border (outer) 
over two cardiac cycles for advanced assessment of traditional LV functional parameters and 
global deformation by strain (cyan).  
To overcome the experimental variability associated with the permanent LAD ligation MI 
model and subsequent difficulty in interpretation of functional response, all functional 
readouts post-MI were individually plotted relative to the initial ischaemic injury as 
quantified by 24-hour cTnI.  
At 2 weeks post-MI, LV function was initially assessed using volume-dependent 
parameters. Generally, ejection fraction and LVESV tended to deteriorate with increasing 
24-hour cTnI as a consequence of the severity of the MI, whilst LVEDV and LVM 
remained more stable. Interestingly, for any given cTnI, Ind-csNox4D animals 
demonstrated a better functional response compared to WT animals in terms of ejection 
fraction, as shown by a statistical difference between the intercept of the regression lines. 
No significant difference between genotypes was observed for similar analyses of 
LVEDV and LVESV. Additionally, there was no difference in LVM, which, together with 
the lack of trend against increasing cTnI, suggests minimal development of LV 










Figure 4.4. Cardiomyocyte-specific Nox4D overexpression in adult mice demonstrates 
functional improvement 2 weeks after myocardial infarction. Strain analysis of 
echocardiographic images of WT and Ind-csNox4D hearts 2 weeks after myocardial infarction by 
permanent left anterior descending coronary artery ligation for measurement of volume-based 
parameters relative to 24h cardiac troponin I (cTnI) - ejection fraction (A), left ventricular end-
diastolic volume (LVEDV) (B), left ventricular end-systolic volume (LVESV) (C), and left ventricular 
mass (LVM) (D). n = 10 (WT), 11 (Ind-csNox4D). Individual data points are shown. Statistical 
analysis by linear regression, represented by regression lines (solid lines) with 95% confidence 
intervals (dotted lines), with comparison of the lines by slope and y-intercept. 
We next assessed the response of the mice at 2 weeks post-MI in terms of GLS as a 
well-evaluated, volume-independent indicator of LV contractility. Strain is a 
measurement of deformation that refers to the change in length of the myocardium within 
a certain direction relative to its baseline length, and is calculated by speckle tracking 
algorithms that follow the motion of specific myocardial patterns. GLS reflects the 
shortening of the LV wall in a longitudinal direction, and is therefore negative in value. 
Compared to traditional parameters such as ejection fraction, GLS is considered a more 





Whereas WT animals showed an increase in GLS in conjunction with increasing cTnI, 
denoting worsening LV function as the GLS becomes more positive, this was improved 
in Ind-csNox4D animals as the data points lay in a separate population at higher cTnI, 
resulting in a significant difference between the slopes of the regression lines (Figure 
4.5). This suggested that cardiac-specific Nox4D overexpression was associated with 








Figure 4.5. Induction of cardiomyocyte-specific Nox4D overexpression limits deterioration 
in global longitudinal strain 2 weeks after myocardial infarction. Strain analysis of 
echocardiographic images of WT and Ind-csNox4D hearts 2 weeks after myocardial infarction for 
assessment of global longitudinal strain (GLS) relative to 24h cardiac troponin I (cTnI), as an 
advanced measure of systolic function. n = 10 (WT), 11 (Ind-csNox4D). Individual data points are 
shown. Statistical analysis by linear regression, represented by regression lines (solid lines) with 
95% confidence intervals (dotted lines), with comparison of the lines by slope and y-intercept. 
Whereas GLS is a global indicator of function, derived from the average across all LV 
segments, speckle tracking echocardiography is also an ideal tool to measure regional 
contractile function.258 Therefore, to investigate the effects of induced cardiac-specific 
Nox4D overexpression on the pattern of GLS observed at 2 weeks post-MI in further 
detail, myocardial strain was analysed regionally to permit understanding of LV function 
relative to zone. This was done using the segmental analysis component of the Vevo® 
Strain software, which calculates the relative strain in 6 regions of the LV, including the 
base, mid and apex of both the anterior and posterior surfaces of the chamber (Figure 
4.6A). This is particularly pertinent as MI is a regional form of cardiac injury, and so these 
strain segments translate to the infarct zones created by MI, notably remote (base), 
border/remote (mid), and infarct (apex) (Figure 4.6B). Thus, regional strain analysis 





Figure 4.6. Segmental strain analysis of regional cardiac contractility by Vevo Strain 
Software. (A) Representative Segmental Synchronicity analysis of an infarcted heart in B-mode 
parasternal long axis view by Vevo® Strain technology. Parameters including strain and strain 
rate are measured in each left ventricular zone: posterior base, posterior mid, posterior apex, 
anterior base, anterior mid, and anterior apex. (B) Schematic representation of the left ventricle 
in long axis view after myocardial infarction. Regional zones are depicted: remote zone (anterior 
base and posterior base), border zone and remote zone (anterior mid and posterior mid), and 
infarct zone (anterior apex and posterior apex).  
As well as longitudinal, segmental strain analysis also examines the regional radial 
strain, which describes the thickening of myocardial tissue in a transverse direction, and, 
as such, is positive in value. It is important to note that whilst strain describes the absolute 
deformation, strain rate is an additional readout that describes the rate at which the 
deformation occurs.257,258 We therefore assessed the longitudinal and radial strain rate 
within each defined LV segment of Ind-csNox4D compared to WT hearts to establish 
potential differences in the contractile properties of the myocardial tissue. 
The mean data describing the longitudinal strain rate and the radial strain rate in each 
Ind-csNox4D and WT LV region is shown in Figure 4.7A and B, respectively. As 
expected, this confirmed the decline in LV function on a zone-dependent level as shown 
by a relative deterioration in both directions of strain rate from the base to the apex, 
equating to the remote zone versus the infarct zone. This was particularly demonstrated 
by the longitudinal strain rate, which remained significantly greater in the anterior base 
compared to the anterior apex in WT as well as Ind-csNox4D hearts. Interestingly, both 












contractility in each LV segment of Ind-csNox4D compared to WT control hearts, which 
was in agreement with the enhanced GLS in Ind-csNox4D hearts at this time point 
(Figure 4.5).  
The regional functional effects of MI were next analysed relative to 24-hour cTnI. The 
anterior mid segment of the LV was first chosen, as any proliferative mechanisms 
involved in functional recovery might be expected to be preferentially localised to the 
border zone.162 However, this showed little difference in longitudinal and radial strain rate 
between Ind-csNox4D and WT animals relative to 24-hour cTnI (Figure 4.7C and D). 
Equally, there was little difference between the same comparison within the anterior base 





Figure 4.7. Inducible cardiomyocyte-specific Nox4D mice show similar strain rates in 
specific left ventricular segments 2 weeks after myocardial infarction. Segmental strain 
analysis of echocardiographic images of WT and Ind-csNox4D hearts 2 weeks after myocardial 
infarction for assessment of longitudinal strain rate (A) and radial strain rate (B) in 6 regional 
zones of the left ventricle: posterior base (post base), posterior mid (post mid), posterior apex 
(post apex), anterior base (ant base), anterior mid (ant mid), and anterior apex (ant apex). n = 10 
(WT), 11 (Ind-csNox4D). Data represent mean ± SEM. ***P<0.001, ****P<0.0001 by two-way 
ANOVA with Bonferroni’s post hoc correction. Further assessment of strain rate relative to 24h 






base zone in (E) longitudinal and (F) radial. n = 10 (WT), 11 (Ind-csNox4D). Individual data points 
are shown. Statistical analysis by linear regression, represented by regression lines (solid lines) 
with 95% confidence intervals (dotted lines), with comparison of the lines by slope and y-intercept.  
At 4 weeks post-MI, 2D echocardiographic image assessment of LV function 
demonstrated the classical physical features of decline secondary to MI, characterised 
by LV dilatation and apical dyskinesis due to extensive scarring and wall thinning (Figure 
4.8A). Compared to 2 weeks post-MI, all volume-dependent parameters as well as LVM 
showed more progressive decline with a greater relationship to increasing 24-hour cTnI 
and therefore MI severity. The structure and function observed in the echocardiographic 
images were mirrored in the analyses, showing that by 4 weeks, cardiac-specific Nox4D 
overexpression was insufficient to maintain the functional improvement seen at 2 weeks, 
suggesting a transient response. Despite a slight trend for some of the Ind-csNox4D 
animals to demonstrate better ejection fraction, for a given cTnI this was largely 
unchanged. Accordingly, the same pattern was also observed for LVEDV (suggesting 
minor or no attenuation of LV chamber dilatation), LVESV, and LVM (suggesting minimal 
attenuation of LV hypertrophy) (Figure 4.8B – E). Animal survival was also monitored 
over the 28-day experimental period, in which the only case of death post-MI occurred 
in the Ind-csNox4D group (1 case in total 17), and no death occurred in either sham 





Figure 4.8. Cardiac-specific Nox4D overexpression does not sustain improvement in 
volume-dependent functional parameters 4 weeks after myocardial infarction. (A) 
Representative B-mode parasternal long axis echocardiographic images of WT and Ind-csNox4D 
hearts 4 weeks after myocardial infarction. Scale bar: 4 mm. Quantification of function by strain 
analysis of volume-based parameters relative to 24h cardiac troponin I (cTnI) – ejection fraction 
(B) left ventricular end-diastolic volume (LVEDV) (C), left ventricular end-systolic volume (LVESV) 
(D), and left ventricular mass (LVM) (E). n = 15 (WT), 16 (Ind-csNox4D). Individual data points 
are shown. Statistical analysis by linear regression, represented by regression lines (solid lines) 


















The potential temporal functional effects elicited by induction of cardiomyocyte-specific 
Nox4D overexpression in the adult heart were further demonstrated globally by 
longitudinal strain. Unlike the distinct improvement in GLS seen in Ind-csNox4D 
compared to WT mice at 2 weeks, at 4 weeks the trend for improved GLS in Ind-csNox4D 
animals was much smaller. Although a small subset of Ind-csNox4D animals were able 
to retain better GLS, several were comparable to the WT animals relative to the same 
initial injury, which was therefore insufficient to achieve significant functional recovery 
(Figure 4.9A). Furthermore, the functional response of the Ind-csNox4D model to MI in 
terms of mean GLS, without normalisation to 24-hour cTnI, was also analysed by time-
course in comparison to WT control, for assessment of overall significance. This showed 
that by 4 weeks post-MI, both WT and IndcsNox4D animals demonstrated significant 
decline in GLS relative to respective baseline control. No differences were found in GLS 
between WT and IndcsNox4D animals at any of the time points examined. Taken 
together, this suggests that whilst Ind-csNox4D animals may confer a functional benefit 
at 2 weeks post-MI when analysed relative to initial myocardial injury, this benefit is not 
maintained at 4 weeks, and, in light of the mean data, indicates that any functional benefit 
detected would be unlikely to lead to a clinically meaningful result (Figure 4.9B).  
 
Figure 4.9. Induction of cardiomyocyte-specific Nox4D overexpression does not prevent 
deterioration in global longitudinal strain 4 weeks after myocardial infarction. (A) Strain 
analysis of echocardiographic images of WT and Ind-csNox4D hearts 4 weeks after myocardial 
infarction for assessment of global longitudinal strain (GLS) relative to 24h cardiac troponin I 
(cTnI). n = 15 (WT), 16 (Ind-csNox4D). Individual data points are shown. Statistical analysis by 
linear regression, represented by regression lines (solid lines) with 95% confidence intervals 
(dotted lines), with comparison of the lines by slope and y-intercept. (B) Strain analysis of 
echocardiographic images of WT and Ind-csNox4D hearts for assessment of mean GLS, without 
normalisation to 24h cTnI, at baseline, and 1 week, 2 weeks, and 4 weeks after myocardial 




WT Baseline versus 4-Week; ####P<0.0001: Ind-csNox4D Baseline versus 4-Week by two-way 
ANOVA with Bonferroni’s post hoc correction. 
The strain rate at 4 weeks post-MI was also evaluated on a regional level by segmental 
analysis. Interestingly, in Ind-csNox4D hearts this again identified clear zone-specific 
differences between the anterior base and the anterior apex in both directions of strain 
rate, as well as in WT hearts between the posterior base and the posterior apex by 
longitudinal strain rate. However, the longitudinal strain rate of the anterior base of WT 
hearts had also declined to a comparable level to that of the anterior apex, meaning that 
the longitudinal strain rate of the anterior base of Ind-csNox4D hearts remained 
significantly better than the anterior base of WT hearts (Figure 4.10A and B).  
Analysis of the regional functional differences relative to 24-hour cTnI showed little 
difference in both the longitudinal and radial strain rate of the anterior mid segment 
between WT and Ind-csNox4D hearts (Figure 4.10C and D). However, in agreement with 
the mean data, the longitudinal strain rate of the anterior base was improved in several 
Ind-csNox4D animals, resulting in a statistical difference between the intercept of the 
regression lines. Additionally, this region-specific result was further evidenced by a 
significant difference between groups in the radial strain rate, thus overall suggesting 
enhanced regional contractile properties in hearts overexpressing cardiac-targeted 





Figure 4.10. Inducible cardiomyocyte-specific Nox4D mice show regional improvement in 
strain rate 4 weeks after myocardial infarction. Segmental strain analysis of 
echocardiographic images of WT and Ind-csNox4D hearts 4 weeks after myocardial infarction for 
assessment of longitudinal strain rate (A) and radial strain rate (B) in 6 regional zones of the left 
ventricle: posterior base (post base), posterior mid (post mid), posterior apex (post apex), anterior 
base (ant base), anterior mid (ant mid), and anterior apex (ant apex). n = 15 (WT), 16 (Ind-
csNox4D). Data represent mean ± SEM. *P<0.05, **P<0.01, ****P<0.0001 by two-way ANOVA 
with Bonferroni’s post hoc correction. Further assessment of strain rate relative to 24h cardiac 






in (E) longitudinal and (F) radial. n = 15 (WT), 16 (Ind-csNox4D). Individual data points are shown. 
Statistical analysis by linear regression, represented by regression lines (solid lines) with 95% 
confidence intervals (dotted lines), with comparison of the lines by slope and y-intercept. 
To control for the induction of MI by permanent LAD ligation, a smaller group of WT and 
Ind-csNox4D animals were subjected to sham ligation and monitored functionally over 
the same 28-day period. At 4-weeks post-sham, echocardiographic imaging showed no 
LV structural abnormalities (Figure 4.11A). Images were analysed by the same technique 
as described for animals subjected to MI, demonstrating no decline in cardiac function in 
Ind-csNox4D compared to WT animals from baseline to 4 weeks post-sham, shown by 





Figure 4.11. Inducible cardiomyocyte-specific Nox4D mice subjected to sham myocardial 
infarction show no change in cardiac structure and function 4 weeks after surgery. (A) 
Representative B-mode parasternal long axis echocardiographic images of WT and Ind-csNox4D 
hearts 4 weeks after sham myocardial infarction control surgery. Scale bar: 4 mm. 
Echocardiographic images analysed by strain for measurement of volume-based parameters – 
ejection fraction (B) left ventricular end-diastolic volume (LVEDV) (C), left ventricular end-systolic 
volume (LVESV) (D), and left ventricular mass (LVM) (E). n = 7 per group. Data represent mean 




















4.4.2 The localised protective effects of cardiac-specific Nox4D 
overexpression are insufficient to fully limit postinfarction 
remodelling processes 
WT and Ind-csNox4D hearts were harvested 4 weeks post-MI or sham ligation for 
analysis of cellular and molecular processes involved in adverse cardiac remodelling. As 
expected, post-mortem morphometric analysis showed that MI induced a significant 
increase in heart weight to body weight ratio in both WT and Ind-csNox4D mice 
compared with sham. However, this was not rescued by Nox4D overexpression as there 









Figure 4.12. Cardiomyocyte-targeted Nox4D overexpression induced in adult mice does 
not protect against myocardial infarction-induced changes in cardiac morphology. Heart 
weight to body weight ratio measured 4 weeks after sham or myocardial infarction (MI) is 
significantly increased in both WT and Ind-csNox4D transgenic mice but not rescued in Ind-
csNox4D mice. Sham; n = 7 per group, MI; n = 17 (WT), 19 (Ind-csNox4D). Individual data points 





Similarly, this was further evidenced at transcript level where molecular markers of heart 
failure – ANP, BNP, and Myh7 – were raised in the infarct border zone and, to a lesser 
degree, the infarct remote zone of WT hearts relative to sham. Despite a trend for the 
expression of these markers to be reduced in Ind-csNox4D hearts after MI, this did not 
prove to be significant. The expression of myosin heavy chain 6 (Myh6) can be expected 
to decrease in the context of failure due to a shift in expression of the Myh7 isoform; this 
was largely unchanged in the WT hearts relative to sham, but may have demonstrated 












Figure 4.13. Cardiac-specific Nox4D overexpression does not prevent increased transcript 
expression of markers of hypertrophy 4 weeks after myocardial infarction. Regional zone 
qPCR analysis of relative mRNA expression of markers of hypertrophy 4 weeks after myocardial 
infarction (MI), in the infarct border zone (BZ), infarct remote zone (RZ), and sham control in (A) 
atrial natriuretic peptide (ANP), (B) brain natriuretic peptide (BNP), (C) myosin heavy chain 6 
(Myh6), and (D) myosin heavy chain 7 (Myh7), in hearts of WT and Ind-csNox4D mice. n = 6 per 









The capacity for induced Nox4D overexpression to mediate protective effects in the adult 
heart after ischaemic injury was further measured histochemically by the development 
of fibrosis as another hallmark pathological feature of adverse remodelling. The total 
content of collagen, predominantly the fibrillar types I and III, deposited in cardiac tissues 
was visualised by picrosirius red and quantified as an indicator of fibrosis coverage.259 
This confirmed a significant increase in fibrosis after MI, the greatest proportion of which 
was localised to the site of the scar. Interestingly, the development of fibrosis was 
unchanged between WT and Ind-csNox4D hearts after sham, but was significantly 
reduced in Ind-csNox4D hearts after MI (Figure 4.14A and B). Furthermore, picrosirius 
red staining can also function as an indicator of the structure of the collagen network due 
to the birefringent properties of mature collagen, the cross-linked fibres of which can be 
detected using polarised light.259 In agreement with total fibrosis coverage, Ind-csNox4D 
hearts also revealed a reduction in the fraction of cross-linked deposited collagen, 




Figure 4.14. Cardiomyocyte-specific Nox4D overexpression induced in adult mice results 
in reduced fibrosis coverage 4 weeks after ischaemic injury. (A) Representative images of 
picrosirius red staining by standard light microscopy for analysis of fibrosis (dark red) on 
equivalent cardiac apical cryosections of WT and Ind-csNox4D hearts harvested 4 weeks after 
myocardial infarction (MI) or sham surgery. Muscle fibres and cytoplasm stain yellow. Staining is 
shown in the sham left ventricle, MI border zone (BZ) – same field also under polarised light, and 
MI remote zone (RZ). Scale bars: 250 μm. Quantification as a % of the whole cross-section of (A) 
total cardiac fibrosis coverage and (B) total collagen deposition as assessed by yellow/orange 
birefringence under polarised light. n = 4 per group. Data represent mean ± SEM. *P<0.05, 
















The hypertrophic response of Ind-csNox4D compared to WT cardiomyocytes was further 
analysed at the cellular level by WGA staining, which binds to the glycoproteins of cell 
membranes. MI induced a significant increase in cardiomyocyte cross-sectional area in 
both the infarct border zone and remote zone of WT hearts compared to WT sham 
controls. This was increased to a lesser degree in Ind-csNox4D hearts, although there 
was no statistical difference compared to WT hearts after MI (Figure 4.15). Moreover, 
staining of endothelial cells by isolectin B4 revealed a significant reduction in capillary 
density in the border zone of infarcted WT hearts compared to WT sham hearts. Similar 
to the trend observed in cardiomyocyte hypertrophy, infarcted Ind-csNox4D hearts 
demonstrated a smaller decrease in capillary density relative to Ind-csNox4D sham 
controls, however this was insufficient to fully rescue the response observed after MI in 
WT animals (Figure 4.16).  
131 
 
Figure 4.15. Inducible cardiomyocyte-specific Nox4D mice show equivalent cardiac 
hypertrophy 4 weeks after myocardial infarction. (A) Representative images of fluorescence 
staining of wheat germ agglutinin (WGA) (red) for visualisation of cell membranes on cardiac 
cryosections of WT and Ind-csNox4D hearts harvested 4 weeks after myocardial infarction (MI) 
or sham surgery. Staining is shown in the sham left ventricle, MI border zone (BZ), and MI remote 
zone (RZ). Scale bars: 50 μm. (B) Quantification of cardiomyocyte cross-sectional area. n = 4 per 
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Figure 4.16. Inducible cardiomyocyte-specific Nox4D mice show equivalent cardiac 
capillary density 4 weeks after myocardial infarction. (A) Representative images of 
fluorescence staining of Isolectin B4 (green), marking endothelial cells, on cardiac cryosections 
of WT and Ind-csNox4D hearts harvested 4 weeks after myocardial infarction (MI) or sham 
surgery. Staining is shown in the sham left ventricle, MI border zone (BZ), and MI remote zone 
(RZ). Scale bars: 50 μm. (B) Quantification of capillary density. n = 4 per group. Data represent 
















Apoptotic cardiomyocyte cell death was measured 4 weeks post-MI and sham by TUNEL 
assay. This technique utilises enzymatic in situ detection of DNA fragmentation, which 
represents a hallmark characteristic of apoptosis.166 MI demonstrated the presence of 
positive TUNEL staining in both cardiomyocytes and non-cardiomyocytes. MI was 
associated with a trend showing an increase in the number of TUNEL-positive, α-actinin-
positive cardiomyocytes observed after sham in WT control hearts. This was more 
elevated in the border zone of WT infarcted hearts compared to the remote zone. The 
number of apoptotic cardiomyocytes in Ind-csNox4D hearts also tended to increase in 
the border zone of infarcted hearts relative to sham. Although this remained lower 






Figure 4.17. Inducible cardiomyocyte-specific Nox4D mice show trend for reduced 
cardiomyocyte apoptosis 4 weeks after myocardial infarction. Representative images of 
immunofluorescence staining for TUNEL (red), marking cells that are undergoing apoptosis, with 
α-actinin (green) as a cardiomyocyte marker and Hoechst (blue) as a nuclear marker on cardiac 
cryosections of WT and Ind-csNox4D hearts in (A) positive control with DNase treatment, and (B) 
4 weeks after myocardial infarction (MI) or sham surgery. Staining is shown in the sham left 
ventricle, MI border zone (BZ) with lower magnification images of TUNEL-positive cells (upper) to 
demonstrate low frequency (arrows indicate positive cardiomyocyte nuclei, arrowheads indicate 
non-myocytes), and MI remote zone (RZ). Scale bars: 50 μm. (C) Quantification of the number of 
positive cardiomyocytes as a percentage of total number of cardiomyocytes counted in each zone. 
n = 4 per group. Data represent mean ± SEM. Statistical analysis by two-way ANOVA with 


























4.4.3 Cardiac-specific Nox4D overexpression does not enhance 
proliferative capacity in the infarct border or remote zones 
To determine the impact of cardiomyocyte-specific Nox4D overexpression on 
cardiomyocyte proliferation in the setting of ischaemic stress, the expression of 
proliferation markers Ki67 and pHH3 was evaluated immunohistochemically in the 
border and remote zones of infarcted WT and Ind-csNox4D hearts. The cardiomyocyte 
identity of cells with positive nuclear expression of Ki67 or pHH3 in conjunction with 
positive sarcomeric α-actinin immunostaining was further verified by Z-stack confocal 
imaging, and quantified as a percentage of total cardiomyocytes counted in each relative 
zone.  
Compared to sham controls, a small increase in the percent of cardiomyocytes with Ki67-
positive nuclei was found in the border zones of both WT and Ind-csNox4D hearts after 
MI. However, this was not enhanced in Ind-csNox4D hearts as there was no difference 
in the border zone compared to WT hearts. Furthermore, there was little difference 
between the number of Ki67-positive cardiomyocytes in the remote zones of WT and 
Ind-csNox4D hearts, suggesting no change in the proliferative response of non-infarcted 
myocardium (Figure 4.18). Likewise, a similar trend was observed in the percent of 
cardiomyocytes positive for nuclear expression of pHH3, indicative of late G2/M-phase, 
showing that MI was associated with just a marginal increase in WT hearts. However, 
this was associated with was no difference versus Ind-csNox4D hearts in either the 




Figure 4.18. Cardiomyocyte-specific Nox4D overexpression induced in adult mice does 
not promote cardiomyocyte cell cycle activity in the infarct border or remote zone. (A) 
Representative images of immunofluorescence staining as negative control, incubated with 
secondary antibodies and Hoechst (blue) only for validation of primary antibody signal. Scale 

















bars: 50 μm. (B) Representative images of immunofluorescence staining for cell cycle progression 
marker Ki67 (green) with α-actinin (red) as a cardiomyocyte marker and Hoechst as a nuclear 
marker in the infarct border zone (BZ) of cardiac cryosections of WT and Ind-csNox4D hearts 
harvested 4 weeks after myocardial infarction (MI). Boxes (left) indicate images of higher 
magnification containing positive cardiomyocyte nuclei, shown by Z-stack maximum fluorescence 
intensity projection (middle) and orthogonal view (right) to confirm co-localisation of green and 
blue signal in α-actinin-positive cells. Scale bars: 50 μm (left), 25 μm (middle and right). (C) 
Quantification of the number of positive cardiomyocytes as a percentage of total number of 
cardiomyocytes counted in each zone. n = 4 per group. Data represent mean ± SEM. Statistical 




Figure 4.19. Cardiomyocyte-specific Nox4D overexpression induced in adult mice does 
not promote cardiomyocyte proliferation in the infarct border or remote zone. (A) 
Representative images of immunofluorescence staining for cell proliferation marker phospho-
histone H3 (pHH3) (green) with α-actinin (red) as a cardiomyocyte marker and Hoechst as a 
nuclear marker in the infarct border zone (BZ) of cardiac cryosections of WT and Ind-csNox4D 
hearts harvested 4 weeks after myocardial infarction (MI). Boxes (left) indicate images of higher 
magnification containing positive cardiomyocyte nuclei, shown by Z-stack maximum fluorescence 
intensity projection (middle) and orthogonal view (right) to confirm co-localisation of green and 
blue signal in α-actinin-positive cells. Scale bars: 50 μm (left), 25 μm (middle and right). (C) 
Quantification of the number of positive cardiomyocytes as a percentage of total number of 
cardiomyocytes counted in each zone. n = 4 per group. Data represent mean ± SEM. Statistical 
analysis by two-way ANOVA with Bonferroni’s post hoc correction. 
  














In an attempt to provide some mechanistic basis for the effects of cardiac-specific Nox4D 
overexpression in the adult heart in response to MI, this was further investigated at 
transcript level by regional zone qPCR analysis. This screen targeted functional groups 
of genes that are likely important regulators of the regenerative potential of the heart. 
Overall, this revealed no changes in the mRNA expression levels of cell cycle activators, 
including cyclins (E1, A2 and D1), Cdks (Cdk2, Cdk4), and the mitosis marker aurora 
kinase B (Aurkb), or cell cycle inhibitors (p27Kip1, p21Cip1) in the infarct border zone or 
remote zones of WT and Ind-csNox4D hearts relative to respective sham controls. 
Equally, no differences were found in either the border zone or remote zone between 
Ind-csNox4D and WT hearts after MI (Figure 4.20).     
The mRNA expression levels of markers re-expressed in dedifferentiated 
cardiomyocytes, which might contribute to the enhanced propensity for cell cycle re-entry 
in dedifferentiated cardiomyocytes,187 were also analysed (as originally investigated in 
Chapter 3). Some zone-dependent changes in the transcript expression of markers of 
dedifferentiation were detected in WT hearts after MI. Runx1 showed an upward trend in 
only the border zone, whereas Dab2 was slightly increased in the border zone but 
significantly increased in the remote zone. GATA4 tended to be upregulated in both 
infarct zones whilst ssTNI and ckit were unchanged compared to WT sham controls. This 
response was not seen in Ind-csNox4D hearts, which demonstrated little change in the 
expression of these markers after MI compared to sham baseline. However, no 
significant differences were found between WT and Ind-csNox4D hearts in either infarct 

























Figure 4.20. Nox4D overexpression in the adult heart does not affect transcript expression 
of markers of proliferation 4 weeks after myocardial infarction. Regional zone qPCR analysis 
of relative mRNA expression of markers of proliferation 4 weeks after myocardial infarction (MI), 
in the infarct border zone (BZ), infarct remote zone (RZ), and sham control in (A) cyclin E1, (B) 











p27Kip1, and (H) aurora kinase B (Aurkb) in hearts of WT and Ind-csNox4D mice. n = 6 per group. 



















Figure 4.21. Nox4D overexpression in the adult heart does not affect transcript expression 
of markers of dedifferentiation 4 weeks after myocardial infarction. Regional zone qPCR 
analysis of relative mRNA expression of markers of proliferation 4 weeks after myocardial 
infarction (MI), in the infarct border zone (BZ), infarct remote zone (RZ), and sham control in (A) 
Runx1, (B) Dab2, (C) GATA4, (D) slow skeletal troponin I (ssTnI), and (E) ckit in hearts of WT 
and Ind-csNox4D mice. n = 6 per group. Data represent mean ± SEM. *P<0.05 by two-way 










Angiogenesis represents another important mechanistic process that has been shown 
to enhance the regenerative response and functional recovery post-MI.260 As infarcted 
Ind-csNox4D hearts showed a trend for increased maintenance of capillary density and 
vascular abundance, the expression of proangiogenesis factors (vascular endothelial 
growth factor A [Vegfa]261,262 and angiopoietin 2 [Angpt2]263) was also screened by qPCR. 
After MI, this revealed an upward trend in Ind-csNox4D compared to WT hearts, 







Figure 4.22. Cardiac-specific Nox4D overexpression does not significantly affect transcript 
expression of markers of angiogenesis 4 weeks after myocardial infarction. Regional zone 
qPCR analysis of relative mRNA expression of markers of angiogenesis 4 weeks after myocardial 
infarction (MI), in the infarct border zone (BZ), infarct remote zone (RZ), and sham control in (A) 
vascular endothelial growth factor A (Vegfa), (B) angiopoietin 2 (Angpt2) in hearts of WT and Ind-
csNox4D mice. n = 6 per group. Data represent mean ± SEM. Statistical analysis by two-way 






Lastly, as Nox4D is a ROS-generating isoform, to evaluate the possibility of deleterious 
effects as a result of nuclear-localised ROS release we screened for a potential 
upregulation in genes that form part of the Nrf2 antioxidant response element 
transcriptional pathway. However, at 4 weeks post-MI, we saw no changes in the 
expression of Nrf2 target genes264,265 - glutamate-cysteine ligase catalytic subunit (Gclc) 
or glutathione S-transferase, alpha 2 (Gsta2) -  between WT and Ind-csNox4D hearts. 
This was neither changed compared to sham-operated controls, suggesting no Nrf2-
dependent upregulation in antioxidant genes in response to induced cardiomyocyte-








Figure 4.23. Cardiac-specific Nox4D overexpression does not affect transcript expression 
of Nrf2 target genes 4 weeks after myocardial infarction. Regional zone qPCR analysis of 
relative mRNA expression of target genes of the Nrf2 antioxidant pathway 4 weeks after 
myocardial infarction (MI), in the infarct border zone (BZ), infarct remote zone (RZ), and sham 
control in (A) glutamate-cysteine ligase, catalytic subunit (Gclc), (B) glutathione S-transferase, 
alpha 2 (Gsta2) in hearts of WT and Ind-csNox4D mice. n = 6 per group. Data represent mean ± 






To capture DNA replication events as a marker of proliferation at an earlier phase after 
MI, WT and Ind-csNox4D mice were injected with EdU (50 mg/kg body weight) every 4 
days for 2 weeks, commencing 24 hours post-ligation. Cardiomyocyte proliferation was 
quantified as the percentage of α-actinin-positive cells with positive nuclear fluorescent 
labelling of incorporated EdU, the identity of which was again confirmed by Z-stack 
confocal imaging.  
Interestingly, this technique was able to demonstrate that the percent of EdU-positive 
cardiomyocytes was significantly increased in the MI border zone of both WT and Ind-
csNox4D hearts compared to WT and Ind-csNox4D sham-operated controls, 
respectively. In WT hearts, this was also significantly higher than the MI remote zone. 
These data provided additional evidence to suggest that the induction of cardiomyocyte-
specific Nox4D overexpression plays no detectable role in enhancing the proliferative 
reserve of cardiomyocytes in response to MI, as there was no difference in the number 





Figure 4.24. Cardiomyocyte-specific Nox4D overexpression induced in adult mice does 
not promote cardiomyocyte proliferation in the infarct border or remote zone 2 weeks after 
myocardial infarction. (A) Representative images of immunofluorescence staining of 5-ethynyl-
2’-deoxyuridine (EdU) (green) incorporation, labelling cells that have synthesised DNA, with α-
actinin (red) as a cardiomyocyte marker and Hoechst as a nuclear marker in the infarct border 
zone (BZ) of cardiac cryosections of WT and Ind-csNox4D hearts harvested 2 weeks after 
myocardial infarction (MI). Boxes (left) indicate images of higher magnification containing positive 
cardiomyocyte nuclei, shown by Z-stack maximum fluorescence intensity projection (middle) and 
orthogonal view (right) to confirm co-localisation of green and blue signal in α-actinin-positive 
cells. Scale bars: 50 μm (left), 25 μm (middle and right). (C) Quantification of the number of 
positive cardiomyocytes as a percentage of total number of cardiomyocytes counted in each zone. 
n = 4 per group (MI) and 3 per group (sham). Data represent mean ± SEM. *P<0.05, ***P<0.001  
by two-way ANOVA with Bonferroni’s post hoc correction. 















To date, there are no published studies regarding the role of cardiomyocyte Nox4D in 
MI, and so the results described in this chapter represent the first report investigating the 
effects of inducible overexpression of a nuclear-localised, redox-active Nox4 splice 
variant on functional recovery and myocardial regenerative capacity post-ischaemic 
injury in the adult mammalian heart.  
4.5.1 Verification of the permanent LAD ligation model 
Our use of the permanent LAD coronary artery ligation model reproducibly induced 
myocardial infarction in WT and Ind-csNox4D transgenic animals, characterised by the 
classical physical and geometric signs of LV apical wall thinning, elevations in LV 
dimensions and volumes, and progressive functional decline.210,211,266 Furthermore, this 
study also demonstrates the translatable importance of plasma cTnI as a major 
biomarker for ischaemic cardiac injury in mice. The 24-hour plasma cTnI levels were 
shown to be closely related to functional parameters in order of increasing severity at 2 
and 4 weeks post-ligation. No elevations in cTnI were observed after sham ligation, 
suggesting that generalised muscle injury sustained from surgery does not contribute to 
detectable release.226  
Despite occlusion at the same anatomical level, a widely recognised limitation of the LAD 
ligation model is the intrinsic variability of MI infarct size.225,227 Many preclinical studies 
assess the efficacy of their interventions by measurement of infarct size as an end-point 
outcome. Without early evaluation of infarct size, the resulting comparisons between 
experimental groups may be impaired by inter-animal variability.210,226 In agreement with 
this limitation, variability in initial myocardial injury was encountered in the present study 
as evidenced by the acquired range of cTnI levels. However, this was circumvented in 
part by overall comparability of the mean 24-hour cTnI between WT and Ind-csNox4D 
groups, and analysis of functional parameters relative to 24-hour cTnI, which would not 
be permissible with other traditional staining methodologies.228 For analysis of 
histological and transcriptional readouts of remodelling and proliferation, mice were 
selected within a similar range of 24-hour cTnI and therefore a comparable degree of 
injury.  
4.5.2 Cardiac-specific Nox4D transgenic mice show a transient 
improvement in functional response after myocardial infarction 
At 2 weeks post-MI, we found that Ind-csNox4D mice are able to demonstrate enhanced 
preservation of ejection fraction and GLS. However, by 4 weeks after MI, Ind-csNox4D 
mice show only little evidence of sustained improvement as indicated by minor or no 
changes in ejection fraction, LV volumes, LV mass or GLS, thereby suggesting a 
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transient improvement in functional response, insufficient to fully rescue recovery. As 
myocardial strain and strain rate are particularly suited for the measurement of regional 
myocardial contractile function, they represent the ideal parameters for quantification of 
the segmental LV dysfunction that is induced by postinfarction scarring.161,257,258 
Therefore, we next evaluated the regional longitudinal and radial strain rate as higher 
sensitivity indices of contractility in an aim to gain greater understanding of the temporal 
functional response elicited by Ind-csNox4D mice in response to MI. At 2 weeks post-
MI, it would appear that the beneficial contractile effects seen in Ind-csNox4D hearts are 
more globally distributed across the LV, as both the longitudinal and radial strain rates 
demonstrate general improvement in all segments, thus contributing to the overall 
enhancement in GLS without major differences compared to WT hearts relative to cTnI 
in the anterior border (mid) or remote (base) zones. However, at 4 weeks post-MI, 
although Ind-csNox4D mice do not maintain the significant improvement in GLS, regional 
strain analysis enabled the identification of localised enhanced longitudinal and radial 
strain rate specifically within the anterior base of the LV. In light of this, it would appear 
that this difference in contractility confers some localised compensatory enhancement of 
function, but is insufficient to offset the global deterioration as demonstrated by ejection 
fraction and LV chamber dilatation, and therefore unlikely to achieve a clinically 
significant recovery . 
However, the patterns of this functional response strongly suggest regional differences 
in Ind-csNox4D versus WT hearts in response to MI. An enhanced rate of myocardial 
deformation within the anterior base of Ind-csNox4D hearts suggests enhanced 
compensatory contractile function within the anterior border or remote non-infarcted 
regions. Interestingly, this is supported by studies in small animal models that have 
reported specific compensatory improvements in regional LV contractility 4 weeks post-
permanent ligation secondary to distinct differences in postinfarction remodelling 
(discussed in more detail in section 4.5.3).261,267 Therefore, the potential mechanisms 
underlying the response seen in the present study could be reflective of differences in 
the repair process of the remaining viable myocardium.17  
4.5.3 Inducible cardiomyocyte-specific Nox4D overexpression confers a 
partial reparative response during postinfarction remodelling 
This was investigated further by regional zone pathological analysis of the infarcted 
tissues. Delineation of the MI regions is crucial for the study of the response to MI as the 
infarct zone is demonstrative of processes relating to scar formation and maturation, 
whilst the border and remote zones importantly reveal cellular events in still-viable 
myocytes as well as remote remodelling changes.210  
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As demonstrated previously in mice,254 echocardiographic assessment of LV chamber 
dimensions and volumes revealed the progressive development of dilated ventricular 
remodelling by 4 weeks post-MI, as evidenced by a greater trend of LVM and LVEDV 
relative to 24-hour cTnI compared to that seen at 2 weeks post-MI. As expected, the WT 
response to infarctive injury is characterised by multiple features of remodelling. At 4 
weeks post-MI, WT mice develop LV cardiomyocyte hypertrophy, as collectively 
evidenced by elevations in LV mass, heart weight to body weight ratio, cardiomyocyte 
cross-sectional area in conjunction with raised molecular markers indicative of pro-
hypertrophic signalling. This is coupled with extensive fibrous scar formation and 
maturation, and cardiomyocyte apoptosis in the infarct border zone and remote non-
infarcted myocardium.   
In contrast, Ind-csNox4D transgenic mice appear to demonstrate a partially reduced 
remodelling response following MI, which could be in keeping with the observed effects 
on regional contractile function. Whilst there is no overall morphometric change in heart 
weight to body weight, Ind-csNox4D mice show some trends for reduction in LV mass 
relative to initial injury, smaller cardiomyocyte area, and downregulation of expression of 
markers of failure in both the border and remote zones. This is particularly interesting in 
light of previous research that established preserved cardiac function in an adult rat 
model of permanent ligation following AAV-mediated overexpression of Vegfb.261 This 
aforementioned study reported improved regional function within the border zone of the 
anterior wall attributable to the induction of compensatory hypertrophy. This 
physiological-like hypertrophic response was characterised by the activation of 
contractile genes such as Myh6 in conjunction with repression of foetal genes of 
pathological hypertrophy, including Myh7, skeletal α-actin, and the cardiac natriuretic 
peptides. Furthermore, it was also found that the mechanism for enhanced contractile 
function was in part elicited by preservation of viable myocardial tissue through protection 
of cardiomyocytes from apoptosis, as opposed to promotion of proliferation.261  
Regional qPCR analysis showed that Ind-csNox4D hearts are associated with 
comparatively less activation of Myh7, ANP and BNP particularly in the remote non-
infarcted LV. However, this was not coupled with an upregulation in Myh6. As discussed 
in 4.2.3, GATA4 has been shown to function as one of the target transcription factors 
that represent key points of convergence for many stress-induced hypertrophic signalling 
cascades.242,248 Therefore, it is pertinent to note that in WT mice, we found an 
incremental transcript expression of GATA4 in the border and remote zone of infarcted 
hearts compared to sham-operated hearts, whereas in Ind-csNox4D hearts we observed 
reduced expression in both the infarct border and remote zones.  
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Moreover, experimental models have shown that occasional cardiomyocytes may 
undergo programmed cell death by apoptosis in the remodelling viable segments of the 
myocardium weeks or even months after infarction.245 As such, cell viability is also 
considered a feature of the remodelling phenotype, as further loss of myocardium 
contributes to progressive functional decline.235,242 This may be driven by molecular 
signals as part of intrinsic pathways, involving mitochondrial signalling, or extrinsic 
pathways via ligand binding to cell surface death receptors.17 It is evident that Ind-
csNox4D hearts may demonstrate increased propensity for anti-apoptotic or survival 
signalling, as shown by an initial trend for reduced apoptotic cardiomyocytes in both the 
infarct border and remote zones. 
Therefore, given the collective potential trends on hypertrophic gene programmes in 
conjunction with cardiomyocyte area, LV mass, and apoptotic signalling, it is possible to 
speculate that the induction of Nox4D overexpression may exert a degree of redox-
mediated attenuation of pathological hypertrophy and enhancement of postinfarction 
cardiomyocyte survival, with a potential shift towards a more compensatory or adaptive 
hypertrophy in localised segments of the infarcted LV. Thus, the regionalised pattern of 
effects is emphasised here as this could account for the observed lack of detectable 
effect on the global parameter heart to body weight ratio.  
In addition, the potential for Ind-csNox4D mice to demonstrate enhanced reparative 
recovery is further evidenced by a significant reduction in total cardiac fibrosis at 4 weeks 
post-ligation, and a trend for reduction in the maturation of deposited cross-linked fibrillar 
collagen. However, these changes still proved insufficient to achieve significant rescue 
of overall global function. The described study on AAV-mediated delivery of Vegfb also 
reported enhanced repair through a reduction in fibrotic scar area. However, it is 
important to note that this study also reported that the regional contractile effects were 
able to equate to a significant improvement in global LV function, which, compared to 
the present study, in the absence of meaningful cardiomyocyte regeneration, is therefore 
likely reflective of a greater magnitude of effect on hypertrophic gene expression profiles 
and anti-apoptotic signalling pathways.   
4.5.4 Cardiomyocyte-targeted Nox4D overexpression does not elicit 
regenerative recovery in response to myocardial infarction 
A major endpoint of this study was to establish the proliferative potential of induced 
cardiac-specific Nox4D overexpression in the adult heart in the setting of myocardial 
infarctive injury. Unfortunately, within this study design, we found that following 
ischaemic stress, adult Ind-csNox4D transgenic mice do not mount a substantial 
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proliferative response to achieve meaningful restoration of cardiac structure and, 
ultimately, function. 
Previous research in the adult mouse heart has demonstrated that 8 weeks after 
permanent LAD ligation, approximately 3% of cardiomyocytes adjacent to the infarct area 
show evidence of cell division, with minimal contribution from progenitor cells, whereas 
most DNA synthesis occurs in polyploid, multinucleate cells without cytokinesis, 
consistent with a hypertrophic response.86 We were able to identify a very small increase 
in cardiomyocyte cell cycle activity in WT hearts after MI, as evidenced by microscopic 
visualisation of Ki67 and pHH3 expression at 4 weeks, and EdU incorporation at 2 
weeks, indicative of G1 – M phase, late G2/early mitosis, and DNA replication, 
respectively. It is known that not only cardiomyocytes in the infarct border zone 
demonstrate cell cycle activity, but also cardiomyocytes in the remote non-infarcted 
region, which implies some activation of intercellular signalling pathways throughout the 
myocardium.268 Consistent with this, although greatest in the infarct border zone, WT 
infarcted hearts also revealed an upward trend in the proportion of cardiomyocytes 
positive for these markers in the remote region, suggesting a level of zone dependency. 
Interestingly, the percentage of WT border zone cardiomyocytes indicative of active DNA 
synthesis by incorporation of EdU is in keeping with that found by a recent study which 
examined proliferation events over a similar duration.98 Assuming a comparable rate and 
linearity of incorporation, the final quantity of EdU-positive cardiomyocytes demonstrates 
the same order of proportionality to the dose used as that found in the present study.  
The minimal regenerative contribution of the adult heart to postinfarction recovery is 
further demonstrated here by transcript analysis of cell cycle markers. At 4 weeks post-
MI, we found that WT hearts show no changes in mRNAs encoding genes critical for cell 
cycle progression (cyclins and Cdks), cytokinesis (aurora kinase B), or cell cycle 
inhibition.43 This is in agreement with recent research that extensively profiled the 
transcriptional networks in multiple cardiac cell populations during cardiac development, 
repair and regeneration.269 This work importantly identified that adult P56 
cardiomyocytes failed to reactivate a proliferative gene programme characteristic of 
neonatal P1 myocytes following infarction but rather deployed a distinct injury-responsive 
gene profile, consistent with adverse remodelling, and further identified a crucial 
realisation that, in whole-heart transcriptomic studies, reversion to an early 
developmental proliferative phenotype under pathological conditions could in fact be 
attributable to contaminating non-myocyte populations.269   
Extensive assessment of the above microscopic and transcript markers of cell cycle 
modulation in the Ind-csNox4D transgenic heart demonstrated that cardiac-specific 
Nox4D overexpression does not lead to an increase in the intrinsic regenerative capacity 
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of the adult heart after MI. This is in contrast to other studies of regeneration post-
permanent ligation in response to genetic manipulation of, for example, transcription 
factors,162 microRNAs,98 cell cycle components,93 and Hippo signalling,113 which have 
reported rescue of function through activation of renewal mechanisms leading to 
enhanced cardiomyocyte proliferation in addition to reduced remodelling, suggesting that 
cell cycle activation was able to counteract the postinfarction adverse ventricular 
remodelling.  
Because the stimulation of cardiomyocyte proliferation is likely to involve a partial 
dedifferentiation step, the expression levels of markers of dedifferentiation were also 
investigated. Cardiomyocyte dedifferentiation is characterised at the cellular level by 
rearrangement of the contractile apparatus and cytoskeleton alongside changes in 
energy metabolism. Closely connected with remodelling, dedifferentiation is induced in 
response to pathological stimuli in the heart, and driven by reciprocal changes in the 
expression pattern of mature and immature cardiomyocyte-specific genes. It is proposed 
that sarcomeric disassembly and reduced energy demand might provide cardiomyocytes 
with the additional plasticity necessary to re-enter the cell cycle and survive in conditions 
of hypoxia.187,270 Given the parallel with remodelling, it may not be surprising that several 
of the gene expression changes associated with each process overlap, such as GATA4 
and Myh7.  
Interestingly, at 4 weeks post-MI, whilst WT hearts demonstrated evidence of zone-
dependent elevations in Runx1, Dab2, and GATA4 (as highlighted above), this was not 
mirrored in Ind-csNox4D hearts. In contrast, infarcted Ind-csNox4D hearts demonstrate 
little change in the expression of these markers as compared to their sham counterparts, 
the interpretations of which could either relate to reduced induction of dedifferentiation, 
or that due to the time point at which markers were assessed, may in fact reflect 
enhanced completion of the dedifferentiation cycle with a greater proportion of 
redifferentiated functional myocytes.202 The latter mechanism is vital for functional 
recovery as the extended presence of dedifferentiation signals leads to a compromise in 
contractility and thus promotes adverse remodelling.187 However, given the absence of 
effect of Nox4D overexpression on proliferation, this remains somewhat inconclusive, 
and so may better relate to the proposed regionalised preservations in function via 
restriction of adverse remodelling.  
An additional possibility that may contribute to the partial recovery seen in the Ind-
csNox4D heart is increased vascular abundance. The process of postinfarction repair is 
normally accompanied by an early increase in angiogenesis.271 qPCR analysis revealed 
a potential trend for increased expression of the proangiogenesis factors Vegfa and 
Angpt2, which, in combination with the trend for increased maintenance of capillary 
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density in the infarct border and remote zones, may be suggestive of increased 
myocardial vascularity.  
In an aim to investigate the possible reasons underlying the observed lack of effect of 
inducible Nox4D overexpression on cardiomyocyte proliferation after MI, we conducted 
a dose response experiment to determine whether the induction of Nox4D transgene 
expression is susceptible to modulation by incremental tamoxifen administration, and 
whether the subsequent effects on ROS generation negatively impact on the resulting 
phenotype.  
HPLC analysis of DHE-derived oxidation products 2 weeks after tamoxifen induction 
revealed a generalised upward trend in the release of superoxide (Figure 4.25A) and 
hydrogen peroxide and other reactive species (Figure 4.25B) in Ind-csNox4D tissues in 
order of increasing tamoxifen dosage, although this was not significant.168 This 
suggested that the levels of localised ROS release, as an indirect marker of the level of 
Nox4D expression induced, may demonstrate a dose response relationship with 
tamoxifen, although this is not fully definitive given the relative decrease seen with the 
greatest dose.  
 
Figure 4.25. Incremental dosage of tamoxifen appears to be associated with a trend for 
greater reactive oxygen species generation. High-performance liquid chromatography (HPLC) 
analysis of dihydroethidium (DHE)-derived oxidation products for measurement of ROS 
generation in hearts of Ind-csNox4D mice harvested 2 weeks after administration of tamoxifen at 
doses of 5, 10, 15 and 20 mg/kg body weight in (A) 2-hydroxyethidium (EOH) for superoxide, and 
(B) ethidium (E) for hydrogen peroxide and other ROS. n = 3 per group. Data represent mean ± 
SEM. Statistical analysis by one-way ANOVA with Bonferroni’s post hoc correction. HPLC by Dr 





Given the potential for excessive ROS production to be associated with oxidative 
damage,131 it was important to establish the propensity of Nox4D overexpression to elicit 
detrimental cellular effects in vivo. This was assessed immunohistochemically by 
utilisation of the DNA damage response marker γ-H2AX (serine-139-phosphorylated 
H2AX). If the DNA damage is too extensive for repair, cells usually undergo permanent 
cell cycle exit or apoptosis.272 This is regulated by multiple effector proteins, of which 
persistent phosphorylation of H2AX Y142 (tyrosine 142) has been shown to be a 
component of the pathways that leads to increased apoptotic cell death.273 This is 
particularly pertinent in light of previous research demonstrating that postnatal 
cardiomyocyte cell cycle withdrawal is driven by increasing oxygen tension post-birth, 
leading to increased ROS generation and oxidative DNA damage.79  
The proportion of cardiomyocytes positive for γ-H2AX showed a steady increase in 
response to increasing dosage of tamoxifen, which could therefore be suggestive of 
increasing Nox4D-derived ROS generation or enhanced nuclear translocation of Cre 
recombinase (Figure 4.26). Tamoxifen-induced αMHC-MCM activity has previously been 
linked to myocardial toxicity via activation of a DNA damage response, leading to 
cardiomyocyte death and dysfunction. However, these effects were observed at 
tamoxifen doses much greater than those employed here.274 Even so, the level of γ-
H2AX observed in the Ind-csNox4D heart after administration of the greatest dose of 
tamoxifen is comparable to that in the WT control. Therefore, it would seem less likely 
that this effect is solely dependent on the induction of Nox4D expression or Cre activity, 
and, as such, would need to be fully elucidated with further experiments using untreated 
controls.  
Importantly, despite the possibility for increased ROS production in Ind-csNox4D hearts 
subjected to a greater tamoxifen dosage, together with increased DDR signalling, 
cardiomyocyte-specific Nox4D overexpression does not appear to be associated with 
increased Nrf2-mediated antioxidant signalling or cardiomyocyte apoptosis, as observed 




Figure 4.26. Incremental dosage of tamoxifen appears to be associated with a trend for 
greater cardiomyocyte DNA damage. Representative images of immunofluorescence staining 
for γ-H2AX (green) as a marker for DNA damage in (A) positive control in neonatal rat 
cardiomyocytes after 3-hour incubation with cytotoxic drug etoposide 10 µM or dimethyl sulfoxide 
(DMSO) with α-actinin (red) and DAPI (blue). Scale bars: 25 μm. (B) With α-actinin (red) and 
Hoechst (blue) on cardiac cryosections of Ind-csNox4D hearts harvested 2 weeks after 
administration of tamoxifen at doses of 5, 10, 15 and 20 mg/kg body weight, compared to WT 
mice also administered tamoxifen 20 mg/kg body weight. Boxes indicate areas of higher 
magnification containing positive cardiomyocyte nuclei. Scale bars: 50 μm. (C) Quantification of 
the number of positive cardiomyocytes as a % of total number of cardiomyocytes counted in each 




































zone. n = 3 per group. Data represent mean ± SEM. Statistical analysis by one-way ANOVA with 
Bonferroni’s post hoc correction. 
In conclusion, Ind-csNox4D transgenic mice demonstrate region-specific preservation of 
contractile function, which correlates with a partial reparative rescue of the remodelling 
response primarily, within the remote non-infarcted zone of the myocardium. Although 
we were not able to attribute this response to an increased cardiomyocyte proliferative 
capacity, the Ind-csNox4D heart does not appear to be associated with detrimental 
effects of excessive ROS exposure, however this warrants further investigation.  
In agreement with the effects of inducible cardiomyocyte-specific Nox4D overexpression 
elicited in response to MI, it is known that various signalling networks that impact on 
several key features of the cardiac remodelling process are redox-sensitive, including 
contractile dysfunction, hypertrophy, interstitial fibrosis, capillary density, and cell 
survival. Such pathways can contribute in a protective or detrimental manner, the effects 
of which are likely highly dependent on the source and compartmentalisation of the 
signalling ROS.131,275 Thus, it is possible to speculate that nuclear-localised, Nox4D-
derived ROS may target compartment-specific signalling or transcriptional pathways 
involved in the modulation of the remodelling response to MI.  
Overall, the findings of this study show that cardiomyocyte-targeted Nox4D 
overexpression induced in the adult heart has the potential to enhance recovery after MI, 
although the underlying mechanism remains to be discerned. There exist several 
possibilities to account for the insufficiency of this model to achieve significant rescue of 
functional recovery, and these relate to the optimal level of overexpression required for 
therapeutic effect, the susceptibility of the adult heart to this pathway, and the potential 
inability of Nox4D to promote proliferation of differentiated cardiomyocytes. Alternatively, 
redox signalling pathways mediated by Nox4D in this setting may be reflective of survival 
as opposed to proliferation. Thus, in order to gain a deeper insight into the 
pathophysiological response of inducible Nox4D overexpression to MI, it would be 
important to understand whether the proliferative effects seen previously in the neonatal 
myocyte can in principal be recapitulated in the adult myocyte. This will be investigated 




Chapter 5 The manipulation of Nox4D in 





Given the results of the previous chapter on the study of Nox4D overexpression in 
response to MI, it is important to note here that the work of the present chapter was 
undertaken in parallel, as driven by the original aims of the project in relation to the 
greater understanding of the potential role of Nox4D in cardiomyocyte proliferation.  
It has become increasingly recognised that cardiac remodelling in response to both acute 
and chronic disease processes is intimately connected with partial dedifferentiation of 
cardiomyocytes. This describes the reversion to a less mature phenotype characterised 
by greater plasticity with important implications for cell cycle progression. Although 
remodelling describes a complex process of multicellular interplay, in vitro experiments 
with isolated adult cardiomyocytes are invaluable for delineation of the underlying 
molecular mechanisms.187  
5.1.1 Dedifferentiation of cardiomyocytes in vivo and in vitro 
Cardiomyocytes need to be able to adjust their metabolic and contractile activities in 
order to adapt under pathophysiological conditions.187 The concept of cardiomyocyte 
dedifferentiation following myocardial injury has been reported in lower vertebrate 
species such as the zebrafish,276,277 defined by key features including electric uncoupling, 
disassembly of sarcomeric structures, and reciprocal changes in the expression of 
mature versus immature cardiomyocyte-specific markers, resulting in the re-expression 
of genes typically expressed during embryonic or foetal developmental stages.270,276–278 
Dedifferentiation has also been observed in adult mammalian cardiomyocytes by 
structural rearrangement and sarcomeric disassembly.75,109,279 Thus, it follows that 
dedifferentiation might serve as a pre-programmed survival mechanism for 
cardiomyocytes subjected to stress such as hypoxia, by providing resistance to altered 
metabolic states through inactivation of energy-intensive functions.280,281  
Whilst neonatal cardiomyocytes have been widely used to study processes of 
remodelling due to their accessibility and ease of culturing, they remain limited by 
substantial differences to terminally differentiated adult cardiomyocytes in terms of 
morphology and response to stimuli.279,281 Indeed, freshly isolated adult cardiomyocytes 
are classically characterised by their highly ordered three-dimensional sarcomeric 
structure. As such, the resulting susceptibility of these cells to the mechanical stress 
imposed by the isolation procedure is demonstrative of their typical fragility post-isolation, 
thus reflecting the need for the ability to adapt to changes in architecture to maintain 
viability.187 The progressive active remodelling, or dedifferentiation, of isolated adult 
cardiomyocytes in long-term culture is well recognised.282–284 Enhanced in the presence 
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of FBS, cardiomyocytes show rounding up of cell edges and outward spreading to re-
establish cell-to-cell contacts, consistent with a loss of cross-striated appearance.187  
This is in agreement with more recent observations of loss of angular morphology and 
sarcomeric structures within 7 days of culture, culminating in cells with distinctive 
formation of pseudopodia and partial redifferentiation associated with synchronous 
contraction in regions of higher density by 21 days. Thus the traditional parameter of rod-
shaped morphology does not necessarily remain equatable with cell viability after 
extended periods of culture.163 These observations collectively imply that reorganisation 
of the contractile and cytoskeletal apparatus are reversible features of dedifferentiation, 
and function to enable cardiac remodelling in the settings of myocardial injury or 
disease.285   
5.1.2 Regulation of cardiomyocyte dedifferentiation by oncostatin M 
Several factors have shown involvement in the modulation of cardiac remodelling in 
vivo.187 A previous study aimed to characterise the signals that transduce cardiomyocyte 
dedifferentiation and remodelling in the adult heart, and discovered a consistent 
upregulation of the inflammatory cytokine oncostatin M (OSM) and positive correlation 
with dedifferentiation of cardiomyocytes in the hearts of human patients with 
cardiovascular disease in both the acute (MI border zone) and chronic (end-stage heart 
failure) setting. Interestingly, recapitulation of these findings in functional studies on adult 
mouse models showed that OSM exerts protective effects after acute myocardial injury 
but paradoxically promotes functional deterioration and lethality when chronically 
activated in heart failure, suggesting that dedifferentiation of cardiomyocytes is most 
beneficially important for survival under conditions of stress when transiently induced.286  
OSM belongs to the interleukin-6 (IL-6) subfamily of cytokines, and has been termed a 
multifunctional cytokine with evidence of biological activity in various inflammatory, 
haematopoietic, and developmental processes.287 Due to activation of the common 
coreceptor gp130, the cardiac functions of members of this class of cytokines have been 
mostly implicated in cardiomyocyte survival and hypertrophy.288,289 However, important 
differences exist in the signalling properties between individual members due to 
utilisation of other receptors. OSM induces heterodimerisation of the gp130 coreceptor 
with either the leukaemia inhibitory factor (LIF) receptor (LIFR) or OSM receptor (Oβ), 
and therefore elicits its effects via the type I or type II receptor complexes, respectively.290  
The role of OSM in cardiomyocyte dedifferentiation was substantiated by further 
experiments with isolated adult myocytes in vitro. Stimulation of cardiomyocyte cell 
cultures with OSM resulted in striking morphological changes characterised by 
elongation, reformation of contact with neighbouring cells, and massive loss of 
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sarcomeric structures consistent with activation of foetal gene markers.286 Biochemical 
analysis revealed that the mechanism by which these effects are mediated is 
transduction of the Ras/Raf/MEK/ERK signalling cascade through activation of the type 
II OSM receptor. This involves recruitment of the serine-threonine protein kinase Raf by 
Ras, which promotes MEK1/2 (MAPK/ERK kinase) dual-specificity kinase, which in turn 
phosphorylates the effector kinase ERK1/2.291   
Importantly, the dedifferentiation of cardiomyocytes induced by OSM is considered 
partially reversible, since the stimulation of OSM-treated adult cardiomyocytes with 
insulin-like growth factor 1 (IGF1) as a hypertrophic signal results in sarcomerogenesis 
in vitro.187,281,292 Together with greater plasticity, the reversibility of cardiomyocyte 
dedifferentiation has significant implications for myocardial regeneration.286  
5.1.3 Partial dedifferentiation of cardiomyocytes may promote 
proliferative potential 
The premise that cardiomyocyte dedifferentiation may facilitate proliferation is supported 
by recent important findings that OSM-treated cardiomyocytes in vitro have 
demonstrated greater cell cycle progression as signified by elevated DNA synthesis as 
a marker of S-phase entry.286 This is corroborated by additional evidence gained from 
experiments based on a coculture system of isolated adult and neonatal cardiomyocytes 
demonstrating cytokinesis of adult myocytes following an initial dedifferentiation step. 
The important finding of this study is the observation that redifferentiation of adult 
myocyte-derived daughter cells was essential for the restoration of contractile function. 
The stimulus for redifferentiation was delivered by intercellular propagation of calcium 
transients from neighbouring neonatal myocytes, which was proven inhibitable by 
hypoxia-mediated impairment of gap junction function. This 3-step process of 
dedifferentiation, proliferation, and redifferentiation describing cell cycle re-entry of 
mature adult cardiomyocytes was also shown in an in vivo model of acute MI, primarily 
at the site of the border zone. Redifferentiation of pre-existing adult-derived, newly 
formed myocytes was enhanced in an ischaemia-resistant gap junction mutant via 
promotion of cell-to-cell electric recoupling between cardiomyocytes of the infarct border 
zone and surviving myocardium.202   
These findings further support the concept that partial dedifferentiation of 
cardiomyocytes represents an adaptive mechanism in contexts of stress such as 
hypoxia, whilst the heart remodels in an effort to reconstitute functionality. However, 
whilst dedifferentiation may provide the plasticity needed for cardiomyocyte proliferation, 
it is evident that the extended presence of dedifferentiation signals may compromise 
contractility as a result of irregularly arranged and reduced expression of myofilament 
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proteins, and thus, in the absence of redifferentiation, may compound the development 
of adverse ventricular remodelling.281,286   
In spite of this, given the apparent priming effect of dedifferentiation on cardiomyocyte 
proliferation, it remains an interesting approach to utilise in the study of the proliferative 
potential of Nox4D. This is especially pertinent in light of the disparity of results 
encountered so far on the effects of Nox4D overexpression on proliferation of neonatal 
myocytes in vitro versus adult myocytes in vivo. As such, the potential functional role of 




The aims of this chapter are to investigate the effects of Nox4D overexpression on the 
proliferation of cardiomyocytes in the setting of oncostatin M-induced dedifferentiation 
using an ex vivo model of cultured isolated adult cardiomyocytes. To establish a 
complementary loss-of-function approach, an siRNA-mediated technique will also be 




5.3 Summary of methods 
To develop a complementary loss-of-function approach, siRNA designed to target 
Nox4D splice variant was optimised in vitro using the H9c2 cell line. This required several 
optimisation steps due to the difficulties associated with splice variant-specific targeting 
(as discussed in sections 2.15 & 5.4.1). Nox4D knockdown was verified at mRNA and 
protein levels by qPCR (section 2.9) and Western blotting (section 2.10), respectively. 
The proliferative potential of Nox4D was further investigated ex vivo using a protocol for 
the isolation and culture of adult mouse cardiomyocytes (section 2.8). Cell viability was 
assessed at 72 hours post-isolation by dye exclusion methods (section 2.8.4). The 
effects of Nox4D overexpression on cardiomyocyte proliferation in the setting of 
dedifferentiation were assessed using OSM as a potent mediator of cardiomyocyte 
dedifferentiation and FGF2 as a stimulus for S-phase entry (section 2.8.5). For these 
culture experiments, adult cardiomyocytes were isolated from WT and csNox4D Tg mice. 
This was considered preferable compared to the Ind-csNox4D Tg model as the 
constitutive csNox4D model may demonstrate more uniformly distributed overexpression 
of Nox4D and also circumvents the requirement for tamoxifen administration. In brief, 
adult male and female WT and csNox4D cardiomyocytes were isolated in parallel and 
plated on the same day, then allowed to recover for 2 days (Figure 2.10). Cells were then 
treated with OSM and FGF2, and cell cycle progression events were quantified by 
positive incorporation of EdU or expression of proliferation markers (sections 2.11.2 & 
2.11.3). Quantification of stitched, fixed field confocal images was performed manually 







5.4.1 Development of splice variant-targeted Nox4D knockdown  
To gain greater understanding of the physiological role of endogenous Nox4D, it was 
necessary to establish a loss-of-function approach by generation of a knockdown tool. 
However, due to the technical difficulties associated with splice variant-specific targeting 
without affecting the expression of the parent sequence, this required careful 
optimisation. Therefore, a series of steps were taken to sequentially achieve reliable 
Nox4D knockdown in vitro using the H9c2 cell line.  
The transfection protocol was first designed according to a transfection reagent 
optimised for siRNA delivery, and validated against commercially available siRNA 
targeted against Nox4 as a positive control. Compared to untargeted siRNA control, this 
was associated with approximately 80% knockdown in Nox4 mRNA expression. This 
effect was abrogated when cells were treated with transfection reagent alone or 
untreated as additional controls (Figure 5.1A).  
As previously mentioned, the only difference in sequence between Nox4D and full-length 
Nox4 is situated within the exon 2/12 junction.153 As such, siRNA and primers were 
designed to target this site to enable specificity for Nox4D. An siRNA sequence with 
preliminary Nox4D knockdown efficacy was transfected and trialled against a series of 5 
primer sets, the most optimal of which were primers 1 and 3, as determined by 
assessment of qPCR products for specific amplification of Nox4D only, confirmed by 
nucleotide sequencing (Figure 5.1B). These primer sets were then further optimised in 
conjunction with the qPCR reaction conditions, by reduction of primer concentration and 
an increase in template volume, for enhancement of Nox4D detection (Figure 5.1C & D). 
Finally, titration of the concentration of Nox4D siRNA to be transfected revealed that 10 
nM was the optimal concentration associated with maximal knockdown efficacy and 
minimal cytotoxicity (Figure 5.1E), and was used for further experiments.  
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Figure 5.1. Optimisation of siRNA-mediated Nox4D knockdown in vitro. siRNA-mediated 
Nox4D knockdown and detection was progressively optimised in H9c2 cells and analysed by 
qPCR 72 hours post-transfection. (A) Relative Nox4 mRNA expression after transfection of pre-
validated siRNA targeted to exon 3 of Nox4 (siNox4), untargeted siRNA control (siCtrl), and 
transfection reagent (TR) and untreated (UT) controls, as positive control of transfection protocol. 
(B) Relative Nox4D expression analysed against a series of 5 primer sets designed to target rat 
Nox4D after transfection of Nox4D siRNA sequence (siNox4D), normalised to respective siCtrl. 
Relative Nox4D expression after transfection of siNox4D against (C) primer set 1, and (D) primer 
set 3 in conjunction with optimisation of qPCR reaction conditions. (E) Relative Nox4D expression 
analysed against selected primer set 1 after transfection of siNox4D concentration gradient, 






Following optimisation of the technique, siRNA-mediated silencing of Nox4D finally 
resulted in nearly 80% knockdown of Nox4D mRNA expression levels compared to 
siRNA control (Figure 5.2A). Importantly, this was accompanied by no significant change 
in the mRNA expression level of Nox4, suggesting greater selectivity of the designed 
siRNA sequence for its splice variant target (Figure 5.2B).  Knockdown of Nox4D was 
also verified at protein level by approximately 50% depletion of the 28-kDa band 
compared to siRNA control (Figure 5.3). 
To further develop the utility of this knockdown tool and test the functional significance 
of Nox4D in different settings, the corresponding short hairpin RNA (shRNA) sequences 
were produced and cloned to generate both an adenovirus (AV) and an adeno-
associated virus serotype 9 (AAV9) as vectors for shRNA expression and Nox4D 
knockdown in vitro and in vivo, respectively. However, due to the initial challenges 
associated with the establishment of Nox4D knockdown, we were unable to undertake 
further experiments with these viral delivery tools in addition to the time taken for their 
generation.  
Figure 5.2. Targeted siRNA mediates Nox4D knockdown. qPCR analysis of relative mRNA 
expression of Nox4D (A) and Nox4 (B) in H9c2 cells 72 hours post-transfection of siRNA designed 
to specifically target Nox4D (siNox4D) or untargeted siRNA control sequence (siCtrl). Nox4D is 
preferentially silenced over full-length Nox4. n = 4 per group. Data represent mean ± SEM. 






Figure 5.3. Targeted siRNA mediates Nox4D knockdown at protein level. Representative 
immunoblot (left) and relative quantification (right) of Nox4D protein expression in H9c2 cells 72 
hours post-transfection of siRNA designed to specifically target Nox4D (siNox4D) or untargeted 
siRNA control sequence (siCtrl). n = 3 per group. Data represent mean ± SEM. **P<0.01 by 









5.4.2 Establishment of model of cultured isolated adult mouse 
cardiomyocytes 
In parallel, extensive work was undertaken to adopt and establish in-house a recently 
published protocol for the isolation and culture of adult mouse cardiomyocytes for the 
study of the proliferative potential of Nox4D ex vivo.163 Several attempts were made to 
develop the technique required to achieve satisfactory yield of viable cardiac myocytes. 
This led to an average yield of 70% rod-shaped myocytes that adhered to laminin-coated 
culture surfaces after calcium reintroduction and displayed characteristic angular 
morphology and organised sarcomeric architecture (Figure 5.4). This highly ordered 
sarcomeric striation pattern was further demonstrated in fixed myocytes on the same day 
as isolation by immunostaining for the actin-binding protein α-actinin, which localises to 
the sarcomeric Z-disk.293 Staining of the nuclei also indicated that several myocytes 







Figure 5.4. Isolation of rod-shaped cardiomyocytes from the adult mouse heart. 
Representative brightfield images of adult mouse whole heart digestion products on laminin-
coated culture surfaces 1 hour after plating, demonstrating approximate yields of 70% rod-














Figure 5.5. Isolated adult mouse cardiomyocytes have organised sarcomeric structures. 
Representative images of immunofluorescence staining of fixed WT adult mouse cardiomyocytes 
on day of isolation with α-actinin (red) as a sarcomeric marker and Hoechst (blue) as a nuclear 
marker. Scale bars: 50 μm. n = 2.  
Isolated cardiac myocytes were maintained in the same culture medium supplemented 
with a defined lipid mixture and insulin-transferrin-selenium, as established previously. 
To validate the viability of cultured isolated cardiac myocytes in our hands before 
conducting experiments over a prolonged culture period, cells were stained by 2 methods 
at 72 hours post-isolation. Application of the dyes trypan blue and 7-AAD were excluded 
by rod-shaped cardiomyocytes, confirming viability by the presence of intact cell 
membranes, whereas cells that stained positive for each respective dye were considered 
non-viable (Figure 5.6). Non-viable cells were generally rounded in morphology and/or 
displayed irregular membranes. As such, although decreased in  number, 
cardiomyocytes with rod-shaped, square-edged morphology represented a good 
indicator of viability at this time point.  
  




Figure 5.6. Isolated adult cardiomyocytes remain viable after three days in culture. Survival 
of isolated adult mouse cardiomyocytes was assessed after 72 hours in culture. (A) 
Representative brightfield images of myocytes stained with trypan blue, in which cells permeable 
to the dye are stained blue and considered dead. Scale bars: 100 μm. (B) Representative 
brightfield and fluorescence stitched images of myocytes stained with Hoechst (blue), labelling 
nuclei and 7-aminoactinomycin D (7-AAD; red), labelling DNA in cells with disrupted membranes 
only. Co-localisation of blue and red signal is indicative of non-viable cells. Scale bars: 250 μm. 
n = 1.  
  
  







5.4.3 Nox4D overexpression is associated with modulation of cell cycle 
progression of dedifferentiated adult mouse cardiomyocytes  
In keeping with the hypothesis that dedifferentiated cardiomyocytes show enhanced 
propensity to re-enter the cell cycle, we utilised a known mediator of cardiomyocyte 
dedifferentiation – OSM – to explore whether adult cardiac myocytes can in principle be 
induced to proliferate by Nox4D overexpression.  
Multiple attempts were required to establish a robust model of dedifferentiated adult 
myocytes in vitro. The key factor that enabled the realisation of dedifferentiation was the 
removal of the myosin II ATPase inhibitor BDM294 from the medium after 48 hours in 
culture. Thus, isolated cardiomyocytes were cultured in BDM-containing medium for the 
initial recovery period only as it was observed that this was associated with increased 
viability.   
Isolated WT adult mouse cardiomyocytes were initially treated with an incremental 
concentration of OSM 48 hours post-isolation for determination of the optimal conditions 
for the proposed dedifferentiation protocol. Compared to untreated control cells, 
incubation with OSM was associated with striking morphological changes characterised 
by a substantial increase in cell size and expansion by formation of multiple extensions 
from the cell body. Visualisation by brightfield microscopy revealed the first changes of 
rounding and extension in individual myocytes within 2 days of exposure to OSM. By 6 
days, nearly all cardiomyocytes showed transformation to a dedifferentiated phenotype. 
This was accompanied by a concentration-dependent downregulation in sarcomeric 
structures and re-expression of dedifferentiation markers, as observed by 
immunofluorescence staining for α-actinin and α-smooth muscle actin after 8 days of 
treatment with OSM, respectively. The lowest effective concentration of OSM (50 ng/mL) 
was selected as the optimum concentration for further experiments. Untreated 
cardiomyocytes also progressively demonstrated cellular expansion and some structural 
rearrangement during the defined culture period, although considerably less pronounced 
in conjunction with greater retention of expression of α-actinin in comparison to OSM-




Figure 5.7. Oncostatin M induces dedifferentiation of adult mouse cardiomyocytes. 
Representative images of immunofluorescence staining for dedifferentiation marker α-smooth 
muscle actin (green) with α-actinin (red) as a cardiomyocyte marker and DAPI (blue) as a nuclear 
marker in isolated WT adult mouse cardiomyocytes after 8 days in culture, during which cells 
were treated with an oncostatin M (OSM) dose response (at 20, 50, and 100 ng/mL) for 6 days 
after an initial 48-hour recovery period. Scale bars: 250 μm (upper), 50 μm (lower). n = 1.    
To explore the effects of Nox4D overexpression on the cell cycle progression of 
dedifferentiated adult myocytes, we employed and adapted a protocol previously shown 
to promote proliferation of dedifferentiated neonatal myocytes. Cardiomyocytes were 
isolated from adult male and female WT and constitutive  csNox4D Tg mice, plated and 
allowed to recover for 2 days, then treated with OSM for 6 days before final exposure to 
FGF2 as a stimulus for S-phase entry. The culture medium was supplemented with EdU 
for the final 2 days to capture S-phase events.  
Cell size was measured as an initial readout to assess the potential effects of Nox4D 
overexpression on the morphological properties of dedifferentiated cardiomyocytes. 
Compared to untreated controls, treatment with OSM alone and OSM plus FGF2 induced 
a significant increase in the cell size of cardiomyocytes isolated from WT mice. The same 
response was also elicited in cardiomyocytes isolated from csNox4D Tg mice. Treatment 
with FGF2 alone was also associated with a trend for increased cell size in both WT and 
csNox4D cardiomyocytes compared to respective control, although not significant. No 
differences were observed between cultured WT and csNox4D cardiomyocytes in any of 
the experimental conditions (Figure 5.8).   
Untreated OSM 20 OSM 50 OSM 100
DAPI  Sarcomeric α-actinin  α-Smooth muscle actin
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Figure 5.8. Cell size is unchanged in dedifferentiated Nox4D-overexpressing 
cardiomyocytes. (A) Representative images of immunofluorescence staining for cardiomyocyte 
marker α-actinin (red) with Hoechst (blue) as a nuclear marker in isolated WT adult mouse 
cardiomyocytes cultured in the presence of oncostatin M (OSM) 50 ng/mL for 6 days after an 
initial 48-hour recovery period, followed by further treatment with fibroblast growth factor 2 (FGF2) 
100 ng/mL for an additional 2 days. Cardiomyocytes treated with only FGF2 for the final 2 days 
served as controls. Scale bars: 50 μm. (B) Quantification of cell area of adult cardiomyocytes 
isolated from WT and csNox4D transgenic mice cultured as in (A). Cell area is unchanged in 
Nox4D-overexpressing cardiomyocytes. n = 3 (WT), 4 (csNox4D). Data represent mean ± SEM. 
***P<0.001 by two-way ANOVA with Bonferroni’s post hoc correction. 
A
B
Ctrl OSM FGF2 OSM + FGF2
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The capacity for Nox4D overexpression to promote proliferation of adult cardiomyocytes 
in the setting of dedifferentiation was primarily quantified by EdU incorporation as a 
marker of cells that have demonstrated cycling through S-phase of the cell cycle. Cells 
were also immunostained with sarcomeric α-actinin to verify cardiomyocyte identity.  
Interestingly, in the absence of treatment, the number of EdU-positive csNox4D 
cardiomyocytes showed an upward trend compared to that in WT cardiomyocytes, 
suggesting the possibility of a Nox4D-related effect even without OSM-induced 
dedifferentiation. Surprisingly, compared to control cells, pretreatment with OSM alone 
was not associated with an increase in EdU incorporation in either WT or csNox4D 
myocytes, and additional treatment with FGF2 neither conferred an additive effect. 
However, it was generally observed that prior incubation with OSM seemed to be 
associated with a greater preservation of viable cardiomyocytes for the duration of the 
culture protocol, as observed by a reduced increase in the number of rounded dead cells 
compared to that in untreated cells by microscopy. A somewhat unexpected  result was 
observed in csNox4D cardiomyocytes after incubation with FGF2 alone for the final 2 
days. In this condition, the number of csNox4D cardiomyocytes with EdU positivity 
showed a strong upward trend in comparison to WT cardiomyocytes, although this 
individual comparison was not significant (overall two-way ANOVA source of variation: 
genotype; P < 0.05). The number of FGF2-treated, EdU-positive csNox4D 
cardiomyocytes was also significantly greater than when pretreated with OSM (Figure 
5.9).  
Overall, it is also important to note certain morphological observations that in some 
cases, EdU-positive nuclei demonstrated an appearance possibly indicative of mitotic 
division, such as that in the micrograph shown for OSM-treated csNox4D myocytes. 
Furthermore, EdU-positivity was often seen in myocytes with reduced α-actinin 
expression, potentially suggesting greater sarcomeric disassembly as an important 




Figure 5.9. Nox4D overexpression increases DNA synthesis in dedifferentiated 
cardiomyocytes. (A) Representative images of immunofluorescence staining of 5-ethynyl-2’-
deoxyuridine (EdU) (green) incorporation, labelling cells that have synthesised DNA, with α-
actinin (red) as a cardiomyocyte marker and Hoechst (blue) as a nuclear marker in isolated WT 
control and csNox4D adult mouse cardiomyocytes cultured in the presence of oncostatin M 
(OSM) 50 ng/mL for 6 days after an initial 48-hour recovery period, followed by further treatment 
with fibroblast growth factor 2 (FGF2) 100 ng/mL and supplementation of all conditions with EdU 
10 µM for an additional 2 days. Cardiomyocytes treated with only FGF2 for the final 2 days served 
as controls. Scale bars: 50 μm. (B) Quantification of the number of EdU-positive cardiomyocytes 
as a percentage of the total number of cardiomyocytes counted per defined area. n = 3 (WT), 4 
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To gain further evidence to support the proliferative potential of isolated cardiomyocytes 
with Nox4D overexpression, myocytes treated with the same protocol were 
immunostained with additional proliferation markers Ki67 and pHH3 to evaluate the 
proportion of cells with general cell cycling activity and the propensity to undergo division, 
respectively. Whilst data could not be analysed in all experimental conditions due to 
technical limitations, this provided a preliminary insight.   
There was little difference in the number of untreated Ki67-positive WT and csNox4D 
cardiomyocytes. Similar to the pattern of observed EdU incorporation, neither 
pretreatment with OSM alone or plus FGF2 was associated with increased expression 
of Ki67 in WT or csNox4D dedifferentiated cardiomyocytes compared to respective 
control. Interestingly, a large increase in the percentage of FGF2-treated csNox4D 
myocytes positive for expression of Ki67 was observed in comparison to FGF2-treated 
WT myocytes. However, this comparison was not proven significant, likely due to the 
requirement for additional replicates (overall two-way ANOVA source of variation: 
treatment stimulus; P = 0.0771) (Figure 5.10). Likewise, although partially a limited 
analysis, the pattern of data for expression of pHH3 was in agreement with that for Ki67 
and EdU incorporation. Compared to WT control myocytes, active stimulation of 
dedifferentiation with OSM or OSM plus further treatment with FGF2 was associated with 
no change in the percentage of pHH3-positive cells. The same rise was seen in csNox4D 
myocytes treated with FGF2, demonstrating that these cells were also positive for pHH3, 
suggestive of active G2/M-phase transition (Figure 5.11).  
Again, similar morphological patterns were observed in that dedifferentiated 
cardiomyocytes demonstrating nuclear positivity for Ki67 or pHH3 often in conjunction 
showed reduced expression of sarcomeric α-actinin. Notably, some clustered formations 
of positive cells often of smaller size were observed, such as those in the micrograph 
shown for FGF2-treated, Ki67-expressing csNox4D myocytes (Figure 5.10A), and FGF2-
treated, pHH3-expressing csNox4D myocytes (Figure 5.11A).  
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Figure 5.10. Nox4D overexpression promotes cell cycling in dedifferentiated 
cardiomyocytes. (A) Representative images of immunofluorescence staining of cell proliferation 
marker Ki67 (green) with α-actinin (red) as a cardiomyocyte marker and Hoechst (blue) as a 
nuclear marker in isolated csNox4D and WT control adult mouse cardiomyocytes cultured in the 
presence of oncostatin M (OSM) 50 ng/mL for 6 days after an initial 48-hour recovery period, 
followed by further treatment with fibroblast growth factor 2 (FGF2) 100 ng/mL for an additional 2 
days. Cardiomyocytes treated with only FGF2 for the final 2 days served as controls. Scale bars: 
50 μm. (B) Quantification of the number of Ki67-positive cardiomyocytes as a percentage of the 
total number of cardiomyocytes counted per defined area. n = 2 (WT), 3 (csNox4D). Data 
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Figure 5.11. Nox4D overexpression is associated with enhanced proliferation in 
dedifferentiated cardiomyocytes. (A) Representative images of immunofluorescence staining 
of cell proliferation marker phospho-histone H3 (pHH3) (green) with α-actinin (red) as a 
cardiomyocyte marker and Hoechst (blue) as a nuclear marker in isolated csNox4D and WT 
control adult mouse cardiomyocytes cultured in the presence of oncostatin M (OSM) 50 ng/mL 
for 6 days after an initial 48-hour recovery period, followed by further treatment with fibroblast 
growth factor 2 (FGF2) 100 ng/mL for an additional 2 days. Cardiomyocytes treated with only 
FGF2 for the final 2 days served as controls. Scale bars: 50 μm. (B) Quantification of the number 
of pHH3-positive cardiomyocytes as a percentage of the total number of cardiomyocytes counted 
per defined area. n = 2 (WT), 3 (csNox4D). Data represent mean ± SEM. Statistical analysis by 















The work of this chapter collectively details the techniques developed for the 
manipulation of Nox4D in vitro. Here, we provide further data based on a gain-of-function 
approach outlining a role for Nox4D in the modulation of cell cycle progression of adult 
cardiomyocytes when subjected to dedifferentiation. We also demonstrate the 
susceptibility of Nox4D expression to silencing in the long-term development of converse 
studies on the effects of loss-of-function.  
5.5.1 Targeted siRNA mediates Nox4D knockdown  
RNA interference has become a widely applied approach for target-specific knockdown 
of gene expression.295 In this study, the establishment of siRNA-mediated Nox4D 
knockdown presented several technical challenges that required extensive optimisation. 
Given that the proper selection of a target sequence for a chosen gene of interest 
represents one of the most critical components of successful gene silencing,296 the 
specific targeting of Nox4D splice variant is fundamentally limited by its lack of 
uniqueness in base sequence in comparison to full-length Nox4.153 This is compounded 
by the relatively low levels of abundance of endogenous Nox4D, impeding its detection. 
Nevertheless, careful optimisation of these limiting factors enabled the successful 
targeting and assessment of Nox4D expression, demonstrating reliable evidence of 
Nox4D knockdown at both mRNA and protein level.  
Direct translation of the designed siRNA sequence to the corresponding shRNA 
expression construct was undertaken for incorporation into AV and AAV9 delivery 
vectors as a means of obtaining enhanced transduction efficiency and prolonged gene 
transfer297 in cardiomyocytes and other cell types for further study on the functional 
effects of endogenous Nox4D. This is especially pertinent for adult cardiomyocytes since 
these cells are generally considered poorly permissive to non-viral transfection 
techniques, especially in their terminally differentiated phenotype.284 As such, 
adenoviral298–300 and AAV9-based techniques301 are associated with much more efficient 
transduction of adult myocytes, mainly in vitro and in vivo, respectively. Attempts were 
initially made to validate the resulting shRNA sequence, since conversion from siRNA to 
shRNA does not guarantee the retention of silencing efficacy,295 however this was limited 
by poor tolerability of the AAV2-shRNA plasmid in vitro, and so will directly be 





5.5.2 Isolated adult cardiomyocytes adapt to maintain viability in culture 
We employed a recently published, Langendorff-free method for the isolation of viable 
cardiac myocytes from the adult mouse heart for their study ex vivo.163 After an initial 
period of in-house optimisation and development of the required technique, this was able 
to reproducibly achieve average yields of 70% rod-shaped cells, leading to highly pure 
myocyte fractions of calcium-tolerant, healthy cells with organised sarcomeric striations. 
This is conducive to attainment of the key goal of primary adult cardiomyocyte culture, 
defined as the production of a homogeneous cell population that is amenable to 
maintenance over an extended time frame in exceedance of the acute isolation.284 This 
also importantly enables a period of recovery from the stresses of the isolation procedure 
induced by enzymatic digestion and physical disruption.302 Thus, for our adult myocyte 
cultures to be sufficiently successful to allow the measurement of parameters after a 
prolonged duration, it was paramount for the initial quality and myocyte yield of the 
isolation procedure to be as high as possible in order to overcome the significant loss in 
total myocyte number seen during the first week of culture.299,303 The viability of isolated 
cardiomyocytes in culture over the duration of the protocol was validated after recovery 
in the presence of BDM, as evidenced by exclusion of the dyes trypan blue and 7-AAD 
at 72 hours post-isolation, as well as 8 days after removal of BDM from the medium as 
shown by morphological adaptation.  
It is known that after successful isolation, plating and culture, isolated adult cardiac 
myocytes undergo extensive morphological rearrangement in adaptation to culture 
conditions.282–284 We reproducibly demonstrated the induction of dedifferentiation in 
cultured adult cardiomyocytes, both untreated and actively stimulated by OSM; an 
important observation that was only realised after removal of BDM from the culture 
medium. Such a finding has also been observed by other groups,163,299 and implies some 
information regarding the mechanism by which cardiomyocytes begin to dedifferentiate. 
Inhibition of myosin II ATPase by BDM prevents strong cross-bridge formation and 
damage due to terminal contracture and energy expenditure.284,294 Although addition of 
BDM to the culture medium has been shown to improve the number and morphology of 
isolated cells,304,305 it is essential that it is removed from the medium before measurement 
of parameters such as those relating to contractility or calcium transients. The 
disadvantage of its removal is that several myocytes are lost due to hypercontraction,163 
but given that rearrangement of the contractile apparatus is a hallmark feature of 
cardiomyocyte dedifferentiation, it follows that this would seem dependent on the 
mobilisation of contractile proteins enabled by relief of myosin II ATPase inhibition.   
We observed that dedifferentiation of adult cardiomyocytes ex vivo is associated with 
enhanced viability, as cells adapt to the culture environment through outward spreading 
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and expansion in order to re-establish contact with adjacent cells.187 This is agreeable 
with the published observation that the viability marker of angular rod-shaped 
morphology is only useful during the immediate phase of culture, as dedifferentiation 
commences by rounding of cellular edges during the first few days of culture (although 
subject to culture medium constituents and conditions).163,306 This pattern of 
cardiomyocyte biology is therefore consistent with the theory that dedifferentiation 
represents a pre-programmed survival mechanism that enables protection under 
stress.202 The cytokine OSM was recently identified as a major signal for the induction of 
cardiomyocyte dedifferentiation.286 Consistent with the effects reported by this study,286 
we found that incubation of adult cardiomyocyte cultures with OSM was associated with 
significantly greater and accelerated dedifferentiation, characterised by the massive loss 
of sarcomeric structures and increased expression of α-smooth muscle actin coupled 
with  enhanced formation of pseudopodia-like extensions. Compared to untreated 
myocytes, it was observed that OSM-treated cells were associated with a greater 
preservation in viability, as shown visually by a reduced loss of cells relative to the 
original plating number, suggesting that accelerated stimulation of dedifferentiation 
increases the rate of adaptation in culture.  
5.5.3 The role of Nox4D in the proliferation of dedifferentiated adult 
cardiomyocytes in vitro 
Isolated adult cardiomyocytes subjected to dedifferentiation in culture demonstrate the 
ability to enter the cell cycle, as primarily evidenced by EdU incorporation as a marker of 
S-phase activity. The clear cardiomyocyte identity of these cells is supported by 2 
observations; that the isolation procedure produces a highly pure myocyte fraction which 
is clearly identifiable in culture,163 and that they stain positive for expression of 
sarcomeric α-actinin.307 This is in contrast to the obscurities encountered in vivo due to 
the cellular heterogeneity and close spatial packing within the myocardium.81  
Whilst we were able to reproduce the characteristic OSM-induced marked elevations in 
cell size and changes in morphology, we surprisingly found that treatment of both WT 
and Nox4D-overexpressing adult cardiomyocytes with OSM alone or with FGF2 is not 
associated with an enhanced ability to enter the cell cycle. This was confirmed by 
visualisation of Ki67 and pHH3 expression in addition to EdU incorporation, and is in 
contrast to recent findings despite similarities in the treatment protocol and FBS 
inclusion.286 However, an important difference that could account for the disparity 
between results is that the previously demonstrated OSM-induced increase in EdU 
incorporation, further increased with the addition of FGF2, was seen in neonatal 
cardiomyocytes.286 The authors of this study attributed this finding to the partial induction 
of a cardiac-progenitor-like state, since they also found an increase in the expression of 
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typical progenitor cell markers, including Runx1,308 Dab2,309 and ckit310 in OSM-treated 
cardiomyocytes.286 Previous reports have shown that basic FGF (FGF2) signalling 
promotes DNA synthesis and proliferation of embryonic311 and neonatal312 myocytes, 
however in adult cardiomyocytes may be more associated with the induction of 
hypertrophy.187 It is also known that the progression of neonatal to adult cardiomyocytes 
is characterised by a transition from proliferative to hypertrophic growth, usually termed 
terminal differentiation.101 As such, one could argue that the differences in proliferation 
rate seen here in OSM-treated adult myocytes versus that in neonatal myocytes could 
be reflective of the intrinsic proliferative potential of the developmental stage of the 
myocyte in conjunction with the differential response to stimulation by FGF2.27 This 
means that, despite OSM-mediated reversion to a more immature phenotype, 
dedifferentiated adult myocytes may not be able to sufficiently harness the same 
response to proliferative signals as elicited by neonatal myocytes, and so may be limited 
in response to an overall maintenance in survival, as observed here by a reduction in 
cell loss, as opposed to significant generation of new myocytes. Alternatively, this could 
also imply that dedifferentiated adult myocytes do show enhanced proliferation but at a 
slower rate, and so the final 2-day EdU incubation period may have been of insufficient 
duration for detection of maximum events.  
It is important to remember that we detected that a small subpopulation of OSM-treated 
myocytes show evidence of potential for mitosis by expression of pHH3, also supported 
by microscopic observations of cellular morphology suggestive of mitosis. This illustrates 
that some OSM-treated myocytes show evidence of progression through the cell cycle, 
as opposed to events of only non-proliferative cell cycles characterised by DNA synthesis 
with or without karyokinesis in the absence of cell division.81 However, this would need 
to be substantiated by evidence of cytokinesis. 
In the study of the effects of Nox4D overexpression on the proliferation of dedifferentiated 
adult myocytes, the only difference detected was the consistent pattern of enhanced 
expression of all proliferation markers in csNox4D myocytes treated with FGF2. Although 
this would need to be corroborated by further work, it is intriguing that this effect was 
greater than when co-stimulated with OSM. FGF2 exerts many of its effects in 
cardiomyocytes through interaction with the high affinity type 1 FGF receptor (FGFR1). 
As described above, it is known that in adult myocytes, FGF2 is a potent stimulus of 
growth and cytoskeletal remodelling, mediating re-expression of α-smooth muscle actin 
whilst maintaining contractile capacity, whereas its stimulation of proliferation has been 
shown to occur by activation of the Ras/MAPK signalling pathway.313–316  
Furthermore, specific morphological patterns were noted not exclusively, but more 
frequently in cardiomyocytes treated with FGF2. We observed 2 distinct morphological 
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states defined by the level and arrangement of sarcomeric α-actinin expression. The 
morphological state that often coincided with positive incorporation of EdU or expression 
of Ki67 or pHH3 is described by very diffuse and reduced expression of α-actinin (this 
contrast is demonstrated in the micrograph shown for FGF2-treated, EdU-positive 
csNox4D myocytes, Figure 5.9A). This was particularly noted in csNox4D myocytes, and 
is suggestive of an increase in sarcomeric disassembly, providing additional plasticity in 
order to overcome steric hindrance and progress through M-phase and cytokinesis.317,318 
FGF2-treated csNox4D myocytes with positivity for a proliferation marker were also often 
observed in clustered formations, possibly indicative of a greater rate of expansion.  
As such, the finding that endogenously dedifferentiated csNox4D myocytes stimulated 
with FGF2 in vitro show enhanced cell cycle progression with evidence of M-phase 
transition is demonstrative of a Nox4D-mediated effect. This could be reflective of a 
greater sensitivity to FGF2-mediated signalling via nuclear-localised, ROS-mediated 
potentiation of kinase activation.154,198 It would also seem that the extent of 
dedifferentiation is important as the effect is much greater than with dual treatment with 
OSM and FGF2. For greater translatability to the in vivo setting, it would be necessary 
to study whether the proliferation of dedifferentiated csNox4D cardiomyocytes equates 
to redifferentiation to a functional phenotype with restoration of contractility. Based on 
previous reports, it is likely that this would require a longer culture period or a trigger 
such as a hypertrophic signal187 or intercellular gap junction communication.202 For a 
deeper understanding of the mechanisms underlying these findings, it would be essential 
to employ the developed adenoviral vector for establishment of Nox4D knockdown in 
isolated WT cardiomyocytes as a loss-of-function approach.  
In conclusion, the findings of this chapter are supportive to existing evidence that 
dedifferentiation of adult cardiomyocytes provides the stability to survive under situations 
of stress. Logically, it would seem to play an important role in cardiomyocyte cell cycle 
progression since the process of sarcomeric breakdown must be necessary for 
proliferation. However, it remains to be understood how the effects and extent of 
dedifferentiation may be modulated to provide the optimal balance for proliferation of 








6.1 Summary of findings 
The pathophysiology of heart failure is underscored by the inability of the adult 
mammalian heart to regenerate lost or damaged myocardium.78 The classical paradigm 
that the adult heart is a terminally differentiated organ has been convincingly overturned 
by an increasing body of evidence suggesting that postnatal and mature cardiomyocytes 
are capable of renewal, albeit at a low level.42 However, heart failure remains a global 
public health problem as this level of intrinsic cardiomyocyte turnover is insufficient for 
the restoration of contractile function.21,78 Whilst current interventions, including 
angiotensin-converting enzyme inhibitors, beta blockers, and cardiac resynchronisation 
therapy, reduce mortality, they fail to address the underlying damage such as that 
caused by a major cardiac event, and are therefore non-curative.21 At present, the only 
established method to replace lost cardiomyocytes is cardiac transplantation, which is 
usually reserved for severe heart failure. Given the insufficient availability of donor 
organs and significant complications associated with organ rejection, the development 
of novel therapeutic strategies that restore functional and structural integrity by 
repopulation of the damaged heart with replacement cardiomyocytes has been a long-
standing goal of the cardiovascular field.26,81  
The stimulation of endogenous mechanisms of proliferation within the resident 
cardiomyocyte pool as a means of sourcing viable cardiomyocytes has emerged as an 
attractive strategy for cardiac regeneration.41 Therefore, in order to therapeutically target 
pathways that control cardiac regeneration, it is crucial to understand the endogenous 
mechanisms which underlie the regulation of the cardiomyocyte cell cycle.21 In pursuit of 
this, we sought to investigate the effects of a novel, nuclear-localised regulator of redox 
signalling on cardiomyocyte cell cycle progression in the adult heart.  
The work presented here describes the impact of a transgenic model of inducible 
cardiomyocyte-specific Nox4D overexpression at baseline and after myocardial injury. 
The basal characterisation of this model validated the splice variant-specific induction of 
Nox4D overexpression in response to tamoxifen, as confirmed by a significant increase 
in Nox4D protein levels in the heart. Consistent with previously published work on the 
characterisation of Nox4D in vitro154 and further work in neonatal cardiomyocytes, we 
found that overexpressed Nox4D in vivo is localised to the nuclear and cytosolic 
compartments, with predominant handling within the nucleus. Ind-csNox4D mice 
demonstrate a similar cardiac phenotype to their WT counterparts in terms of 
contractility, structure, and gross morphology, suggesting that this level of Nox4D 
expression is well-tolerated in the adult heart. However, in the absence of injury, the Ind-
csNox4D model is not overtly associated with an enhanced propensity for cardiomyocyte 
dedifferentiation or proliferation.  
185 
 
Next, to investigate whether the role of cardiomyocyte-targeted Nox4D would become 
apparent in the context of injury, Ind-csNox4D mice were subjected to permanent LAD 
coronary artery ligation to induce MI. We selected this model of injury as MI is a prevalent 
major cardiovascular event associated with significant cardiomyocyte loss and robust 
long-term remodelling, and is therefore a clinically relevant model for the development 
of heart failure.210,319 The LV functional responses of the mice to MI were analysed in 
detail by speckle-tracking echocardiography, starting with simple volume-dependent 
indices and global measurement of longitudinal strain, then progressing to more sensitive 
indices at the regional level by segmental analysis of longitudinal and radial strain rate.258 
Interestingly, Ind-csNox4D mice show an improved functional response after MI, as 
signified by enhanced ejection fraction and GLS at 2 weeks, but this effect is transient 
and no longer present at 4 weeks. However, although a global improvement in function 
is not maintained, Ind-csNox4D mice do show evidence of region-specific differences in 
longitudinal and radial strain rate 4 weeks post-MI compared to WT controls within the 
anterior base of the LV, demonstrative of localised enhanced contractility.  
This mode of functional recovery seen in Ind-csNox4D mice correlated with a partial 
reparative response during postinfarction remodelling, consisting of trends for reduction 
in LV mass, decreased cardiomyocyte area, and downregulated transcript expression of 
markers of failure in the infarct border and remote zones in the absence of morphometric 
changes. Furthermore, Ind-csNox4D hearts demonstrate a trend for enhanced 
propensity for anti-apoptotic signalling and increased myocardial capillarisation in 
conjunction with a significant reduction in cardiac fibrosis. However, this collective 
pattern of seemingly regionalised effects is not coupled with, or mediated by, an 
augmentation in cardiomyocyte proliferation. We were not able to detect a role for Nox4D 
to promote cardiomyocyte dedifferentiation and cell cycle re-entry in the adult 
mammalian heart even when primed with an injurious stimulus.  
Given the lack of effect on cardiomyocyte renewal in vivo, we conducted further study to 
address the possibility that too high a level of overexpression of a ROS-generating 
enzyme within the nucleus may be linked to deleterious consequences.131,154 However, 
despite the potential dose dependency association between tamoxifen with ROS 
production and DDR signalling, this does not appear attributable to the levels of MCM 
activation or Nox4D induction, and neither do these effects seem to be associated with 
enhanced antioxidant signalling or cell death. As such, this would imply that the partial 
nature of the response afforded by cardiomyocyte-specific Nox4D overexpression after 
MI is not due to inhibitory effects of excessive ROS exposure, and may involve 
contribution from other factors.    
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In an attempt to assess in a more controlled model whether Nox4D is able to stimulate 
proliferation of cardiomyocytes in the adult versus the neonatal setting, this was tested 
further in vitro. We utilised an ex vivo model of isolated adult cardiomyocytes for the 
induction of dedifferentiation in culture as a means to assess the capacity of Nox4D to 
enhance their proliferative potential, and provide an experimental platform that would 
facilitate elucidation of the underlying ROS-dependent molecular mechanisms involved 
at the cellular level.  
Consistent with previous studies,163,284 the induction of dedifferentiation of adult 
cardiomyocytes in vitro, both without treatment and actively stimulated by OSM, is 
associated with prolonged viability, enabling protection from the stress of isolation as 
cells undergo morphological adaptation to the culture environment in order to avoid 
unfavourable mechanical distortion.187 Adult cardiomyocyte dedifferentiation is 
accelerated in culture by incubation with OSM, which regulates reversion to a more 
immature state characterised by loss of pre-existing sarcomeric structures in conjunction 
with re-expression of foetal genes and elongation towards neighbouring cells for re-
establishment of cell-to-cell contacts.286 We found that dedifferentiated adult myocytes 
demonstrate the capacity to re-enter the cell cycle, as primarily evidenced by DNA 
synthesis.81 Whilst we observed that treatment of both WT and Nox4D-overexpressing 
adult cardiomyocytes with OSM alone or with FGF2 is not associated with enhanced 
proliferative capacity in comparison to control untreated myocytes, we found a consistent 
pattern of enhanced expression of proliferation markers in Nox4D myocytes treated with 
FGF2. This effect is therefore likely suggestive of a redox interaction between FGF2-
mediated proliferative signalling pathways and compartmentalised ROS release by 
Nox4D.  
6.2 Physiological impact of inducible Nox4D 
overexpression in the adult mammalian heart 
6.2.1 Nox4D is linked to cardiomyocyte proliferation in a context-
dependent manner 
Our preliminary findings indicate that Nox4D increases the proliferation of neonatal 
cardiac myocytes. By overexpressing Nox4D in vitro, neonatal myocytes show enhanced 
proliferative capacity by characteristic changes in cell size and cell number, increased 
expression of markers of cell cycle progression, and increased activation of the PI3K/Akt 
signalling pathway and downstream targets.    
The NADPH oxidase enzyme complex uses NADPH as an electron donor to produce 
O2●− and H2O2 from molecular oxygen. Compared to other redox enzymes that produce 
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ROS as by-products, Noxs are the only known mammalian enzyme system dedicated to 
the generation of ROS.131,145 It is now recognised that ROS generated by Nox enzymes 
are involved in intracellular signalling processes that regulate cellular differentiation and 
proliferation.145 Nox4D has been demonstrated to be localised to the nucleus in neonatal 
myocytes and other cardiovascular cell types, although the mechanisms underlying its 
intracellular trafficking remain unclear,154 but could reflect differences in the subcellular 
targeting of Nox isoforms as a function of site-specific requirements for ROS.153 As 
discussed in 3.4.2, it is of interest that many protein phosphatases are highly enriched 
in, or even exclusive to, the nuclear subcellular compartment, where they regulate 
various processes by dephosphorylation of key substrates. A number of roles of nuclear 
protein phosphatases have been outlined, such as modulation of stress response 
pathways, RNA processing, and gene transcription. Also, many nuclear protein 
phosphatases, including protein phosphatase 1 (PP1), PP2A, Cdc25, and Cdc14, have 
pivotal roles in the regulation of cell cycle progression, as this is highly controlled by 
reversible protein phosphorylation.320 The susceptibility of phosphatases as protein 
sensors to Nox-derived signalling ROS is well recognised,151,198 and so the redox 
modulation of nuclear protein phosphatases would seem a likely target for nuclear-
localised Nox4D.  
Akt is a key player in signal transduction pathways that are activated in response to 
various stimuli, including growth factors and cytokines, and is therefore considered to be 
centrally involved in numerous cellular functions including proliferation and survival. The 
activation of downstream effectors that mediate such pathways is dependent on the 
translocation of phosphorylated Akt to the nucleus, where it may be inactivated by 
dephosphorylation of threonine residues by PP2A.321 Indeed, the impact of nuclear Akt 
has been demonstrated in the myocardium, in which cardiac-specific expression of 
nuclear-targeted Akt was associated with increased cardiomyocyte cycling.124 In light of 
these findings, it is plausible to reason that the Nox4D-dependent activation of Akt seen 
in neonatal cardiomyocytes may represent a potentiation mechanism for downstream 
proliferative signalling within the nucleus via redox-inhibition of Akt dephosphorylation.  
However, given that overexpressed Nox4D is also localised in part within the cytosol, the 
effects on proliferation may also be mediated by cytosolic redox pathways.154 Nox-
mediated signal transduction mechanisms involved in proliferation may also function 
through amplification of receptor tyrosine kinase (RTK)-mediated processes by inhibition 
of another class of phosphatases, the PTPs. This would therefore seem complementary 
to the proposed mode of Nox4D-mediated nuclear Akt activation, since Akt may be 
phosphorylated downstream of RTK stimulation.145,321 H2O2 is a mild oxidant and has 
been shown to target PTPs as they contain sensitive cysteine residues that are 
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vulnerable to oxidation. All PTPs contain an essential cysteine residue within the 
signature active site motif that is essential for their catalytic function, oxidation of which 
leads to enzymatic inactivation and potentiation of proliferative signalling cascades 
mediated by RTKs.322  
PTEN is an important redox-regulated PTP that plays a negative regulatory role in 
signalling pathways involved in cell growth,323 inhibition of which has been shown to 
mediate cardiomyocyte proliferation in embryonic, postnatal, and adult hearts.100 PTEN 
cleaves the phosphoinositide second messenger – phosphatidylinositol 3,4,5-
triphosphate (PIP3) – as its substrate to reverse the action of PI3K.323 Interestingly, the 
potentiation of Akt activation secondary to PTEN inhibition by Nox-derived ROS has 
been directly shown in a cellular model of Nox1 overexpression.324 Thus, it could be 
postulated that oxidative inhibition of PTEN represents a complementary mechanism 
underlying enhanced proliferation in Nox4D-overexpressing neonatal myocytes by 
increasing the proportion of activated Akt that can translocate to the nucleus.  
Moreover, it is intriguing that RTK activation in response to growth factor stimulation can 
induce the rapid and transient production of ROS, as ROS are required for growth factor-
induced tyrosine phosphorylation.323,325 Furthermore, ROS have been found to activate 
RTKs in a ligand-independent manner through transactivation,322 such that addition of 
H2O2 has been shown to augment intracellular tyrosine phosphorylation levels and 
induce cell proliferation in the absence of growth factor.326 Therefore, it may follow that 
increased intracellular generation of H2O2 by overexpression of Nox4D may amplify Akt 
activation by negative regulation of PTEN independently of receptor-ligand binding. 
Taken together, overexpressed Nox4D may serve to potentiate signal transduction 
pathways downstream of Akt at multiple cellular levels.   
However, when we investigated cardiomyocyte-targeted overexpression of Nox4D in the 
setting of the adult mouse heart, we were not able to reproduce the same effects on 
proliferation either at baseline or after ischaemic injury. We reasoned that this loss of 
phenotype could be caused by a number of factors: (i) the potential mislocalisation of 
Nox4D protein when overexpressed in adult cardiomyocytes; (ii) the level of Nox4D 
induced in this model in relation to the presumed therapeutic window of expression; (iii) 
the potential association between an overexpressed Nox enzyme and the deleterious 
effects of excessive ROS exposure; and (iv) the age at which Nox4D overexpression is 
induced and the susceptibility of the adult heart to redox regulation of proliferation.  
Immunostaining of adult cardiomyocytes isolated from Ind-csNox4D mice revealed that 
the induction of Nox4D overexpression in vivo results in similar intracellular location to 
that in neonatal myocytes in vitro, although the precise localisation within the nucleus 
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and cytosol remains to be determined. To address the physiological relevance of the 
relative level of Nox4D protein induced in the Ind-csNox4D model by αMHC-MCM, we 
conducted a tamoxifen dose response experiment to investigate the potential association 
between Nox4D expression and harmful effects due to excessive ROS production. 
Mitochondrial ROS are known for their ability to cause cellular toxicity by promoting 
damage of macromolecules such as DNA base oxidation and single- or double-strand 
breaks,327,328 and so we reasoned that an overexpressed nuclear source of ROS could 
be associated with the same effects if expressed too highly. Indeed, activation of the 
DNA damage response secondary to Nox4D overexpression was shown previously in 
cultured VSMCs by increased phosphorylation of H2AX at serine 139 in an oxidative-
dependent manner.154  
However, we found that this effect was not replicated in vivo in response to increasing 
Nox4D expression, suggesting that elevation of nuclear ROS release does not negatively 
regulate cardiomyocyte proliferation as a result of oxidative DNA damage, which is in 
contrast to what might be predicted by current theory regarding the effects of increased 
ROS on postnatal cardiomyocyte cell cycle withdrawal.79,87 DDR signalling usually results 
in cell cycle arrest or apoptosis if the damage is too extensive to be repaired.327 
Therefore, in view of the low rates of cardiomyocyte apoptosis in sham-operated WT or 
Ind-csNox4D hearts, it is possible that the incidence of γ-H2AX positivity could be 
causally associated with cell cycle arrest if DNA damage accumulation occurs without 
recruitment of repair mechanisms. It would be interesting to investigate whether the 
association between Nox4D expression and DDR signalling changes after MI, as cardiac 
stress would be expected to be associated with further increased ROS production, which 
has previously been linked to single-strand breaks in the setting of pressure overload-
induced heart failure.272   
Lastly, to address the possibility that the lack of efficacy of Nox4D to stimulate 
cardiomyocyte proliferation in the adult heart is due to key differences in the 
developmental stage of the heart, or the age at which Nox4D overexpression is induced, 
we evaluated the ex vivo culture model of adult cardiomyocytes for the study of 
proliferation in the setting of dedifferentiation. This is especially relevant since 
cardiomyocyte renewal in the adult mammalian heart may not necessarily recapitulate 
the events of development, meaning that the capacity of certain factors that stimulate 
myocardial proliferation during embryonic and early neonatal life may be lost in the adult 
heart.89  
Cardiomyocyte dedifferentiation is considered to enable a reduction in energy 
consumption due to changes in metabolism and inactivation of energy-intensive 
processes, thus providing protection from situations of stress such as ischaemia.281 
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Therefore, the dedifferentiation of adult cardiomyocytes in culture may permit simulation 
of the in vivo ischaemic environment of the infarct border zone in which surviving 
myocytes have uncoupled from the myocardium and are at high risk of cell death.202 In 
this setting, our findings on cultured cardiomyocytes provide evidence to support a role 
for Nox4D in the potentiation of FGF2-induced adult cardiomyocyte proliferation.  
Based on this observation, it could be speculated that Nox4D may either promote the 
dedifferentiation process itself, or enhance proliferation through FGF2-mediated 
signalling. In agreement with the proposed mechanism of action in neonatal 
cardiomyocytes, the latter pathway would seem more likely. The capacity of diffusible 
factors such as FGF2 to exert a mitogenic effect on cardiomyocytes has been mostly 
obtained in neonatal cardiomyocytes, as these cells maintain a transient proliferative 
capacity after isolation.27 In contrast, the proliferative activity of FGF2 in the adult heart 
is largely opposed by FGF16, a member of the FGF family that is preferentially 
expressed postnatally with a possible role in cardiomyocyte cell cycle withdrawal after 
birth.329 In support of this, we found that FGF2 is able to stimulate cell cycle activity in 
dedifferentiated adult cardiomyocytes, likely as a result of their reversion to a more 
immature state.187 Interestingly, FGF2 is known to exert its biological effects in 
cardiomyocytes through interaction with the tyrosine kinase receptor FGFR1.330 An 
important signal transduction pathway downstream of RTKs that mediates cell 
proliferation in response to growth factor stimulation is the MAPK pathway, in particular 
ERK1/2.331 This pathway is activated in response to FGF2 stimulation and is therefore 
implicated in its mitogenic activity.315,332 Furthermore, the activation of ERK1/2 by Nox-
derived ROS has been widely reported in numerous cell types,145 and was the first redox-
sensitive signalling pathway demonstrated to be modulated within the nuclei of VSMCs 
by Nox4D.154 It has also been shown that Nox4D is capable of H2O2 production,154 which 
is the major oxidant species implicated in redox regulation of cell proliferation.145  
Therefore, as postulated in neonatal myocytes, it follows that Nox4D may act as an 
intracellular signal amplifier in adult cardiomyocytes subjected to gradual 
dedifferentiation in culture that potentiates proliferative signalling through FGF2 via redox 
inhibition of PTPs. Further work is required to understand whether this effect is mediated 
through ERK1/2 signalling or whether additional growth factor-stimulated pathways such 
as PI3K/Akt are involved, which will also enable elucidation of the differential response 
seen in dedifferentiated myocytes actively induced by OSM.      
Although this model may recapitulate dedifferentiating cardiomyocytes in the ischaemic 
environment in vivo, we were only able to detect some evidence for a role for Nox4D in 
the proliferation of dedifferentiated adult myocytes ex vivo. One reason for this could be 
the severity of the permanent LAD ligation model used to induce MI.210 Another reason 
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for this could be an important difference in the strategies used to generate Nox4D 
overexpression. For our adult cardiomyocyte isolation studies, we utilised a constitutive 
model of cardiomyocyte-specific Nox4D overexpression in which Nox4D is 
overexpressed  under the regulation of the Mlc2v promoter, which directs Cre 
recombinase expression starting at approximately E8.160 This was preferable as we 
reasoned that the constitutive model may have more uniform overexpression of Nox4D 
whereas the inducible model may be subject to greater variation depending on the 
myocardial absorption and distribution of tamoxifen. However, it was later realised that 
in comparison to the Ind-csNox4D model, the expression level of Nox4D protein is 5-fold 
lower in the csNox4D model (Figure 2.8). This could have important implications for the 
difference in effect due to the developmental stage and relative level at which Nox4D is 
overexpressed. Therefore, it could be concluded overall that the capacity of Nox4D to 
enhance proliferative signalling pathways and cell cycle re-entry in cardiomyocytes is 
likely dependent on the level of expression and resulting impact on local redox balance, 
and possibly the maturity level of the cardiomyocyte.    
6.2.2 Induction of Nox4D in the adult heart may regulate redox-dependent 
prosurvival signalling pathways after ischaemic injury  
Our findings on the study of the response of Ind-csNox4D mice to MI suggest that Nox4D 
exerts partial beneficial actions in the heart characterised by locally enhanced contractile 
function and modulation of hypertrophy, apoptosis, fibrosis, and capillarisation. Although 
associated with incomplete preservation of cardiac function and recovery, these data are 
not coupled with a regenerative response and may instead reflect a potential prosurvival 
role for Nox4D in the amelioration of postinfarction remodelling.   
At present, descriptions of the effects of Nox4D, or other Nox4 splice variants, in the 
healthy or diseased heart in the literature are very limited. A recent study aimed to 
characterise Nox4 expression in human explant samples from healthy and failing hearts 
of ischaemic or dilated origin.333 RNA sequencing of the cardiac transcriptome revealed 
that the Nox4 gene is extensively spliced in heart failure with the suggestion that Nox4D 
may be downregulated in the ischaemic failing heart. However, this study is based on a 
limited sample set with significant differences in the age of the patients from which the 
tissues were sampled. The quantitative assessment of the detected protein isoforms may 
have been affected by the lack of direct sequencing evidence for their identification and 
discrimination from other isoforms, and the functional characterisation of these variants 
was neither investigated. As such, the interpretations of this study may be limited to the 
implication that Nox4D is expressed in the human heart.333  
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The development of cardiac remodelling in response to disease or injury involves a 
complex rearrangement of cardiomyocyte structure and function as well as the 
restructuring of the non-myocyte compartment through hallmark changes in the ECM 
and vasculature.275 Maladaptive remodelling is characterised by pathological 
hypertrophy accompanied by disproportionate interstitial fibrosis, cardiomyocyte death, 
vascular dysfunction, energy deficit, and chamber dilatation.334 Several different 
molecular targets of redox signalling in cardiac remodelling processes have been 
identified.138 Such redox-dependent modifications can affect the structural conformation, 
stability, and function of signalling proteins, and have been shown to include protein 
kinases (e.g. MAPKs, calcium-calmodulin kinase II [CaMKII], protein kinase A [PKA], 
protein kinase G [PKG]), class II histone deacetylases (HDACs), and transcription factors 
(Figure 6.1).275    
Cardiac hypertrophy is driven by a reprogramming of the normal pattern of 
cardiomyocyte gene expression, in which a number of transcription factors are involved, 
which are in turn regulated by a multitude of interacting signalling pathways.242,244 
Increasing evidence suggests that spatially confined ROS release may specifically target 
these signalling pathways, such as ERK1/2 and Akt, or may influence transcription factor 
binding directly, such as the dis-inhibition of Mef2-dependent prohypertrophic gene 
transcription via oxidation of HDACs.131,335,336 The impact of redox pathways on fibrosis 
has also been demonstrated in multiple cell types, in which activation of TGF-β by ROS 
has been shown to promote myofibroblast transformation as well as the transcription of 
profibrotic factors.131,337 Furthermore, cardiomyocyte apoptosis may in part be subject to 
modulation by the local redox environment.335 ROS-dependent activation of c-Jun N-
terminal kinase (JNK) in response to β-adrenoceptor stimulation in adult rat 
cardiomyocytes has been shown to activate the mitochondrial death pathway and 
cytochrome c release,338 whilst apoptosis signal-regulating kinase 1 (ASK1) may be 
redox-activated upstream of p38MAPK and JNK to induce cardiomyocyte apoptosis 
(Figure 6.1).339  
Likewise, redox pathways during cardiac remodelling are also activated to augment 
important protective effects. Notably, it has been shown that full-length Nox4 is capable 
of mediating numerous distinct prosurvival processes.335 In response to chronic pressure 
overload, Nox4 was found to facilitate functional adaptation to stress by enhancement of 
cardiomyocyte Hif1α-Vegf signalling, which was associated with enhanced myocardial 
capillary density through elevated paracrine angiogenic activity.149 This pathway is 
important for protection in this disease model as it is known to drive coordinated cardiac 
hypertrophy and angiogenesis, which are vital for the preservation of cardiac function.340 
Other targets of Nox4 in chronic cardiac stress may also involve the Nrf2-dependent 
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upregulation of cytoprotective genes,152 and induction of activating transcription factor 4 
(ATF4) via inhibition of PP1 to enhance cardiomyocyte survival.151 Furthermore, studies 
in non-cardiomyocyte cells have shown an inhibitory role for Nox4-derived ROS in 
apoptosis, the mechanisms involved in which may include activation of survival kinases 
such as Akt (Figure 6.1).341 
 
Figure 6.1. Redox regulation of stress response signalling cascades in the heart. The major 
stress stimuli that induce cardiac remodelling include neurohormonal agonists, mechanical 
forces, cytokines, growth factors, and hypoxia. Key pathways with evidence for redox regulation 
may affect protein translation and metabolism, but ultimately control gene expression, leading to 
important effects that determine whether the remodelling response is adaptive or maladaptive, 
including cardiomyocyte hypertrophy, survival, paracrine angiogenic signalling, and fibrosis. 
Redox modifications by reactive oxygen species (ROS), and source where known, of specific 
molecular targets are shown in red. OH, hydroxylation; Ox, oxidation; P, phosphorylation; ASK1, 
apoptosis signal-regulating kinase 1; CaMKII, calcium calmodulin-dependent kinase; GSK3, 
glycogen synthase-3; GPCR, G-protein coupled receptor; HDACs, histone deacetylases; HIF, 
hypoxia-inducible factor; IGF, insulin-like growth factor; MAPKs, mitogen-activated protein 
kinases; mTOR, mammalian target of rapamycin; NPR, natriuretic peptide receptors; NOS, nitric 
oxide synthases; PDE5, phosphodiesterase type 5; PI3K, phosphoinositide 3-kinase; PHD, HIF 
prolyl hydroxylase; PKA/C/D/G, protein kinase; RTK, receptor tyrosine kinases; SR, sarcoplasmic 
reticulum; Trx-1, thioredoxin-1; XO, xanthine oxidase. Adapted from Burgoyne et al, 2012.131  
These findings reinforce the importance of source- and compartment-specific ROS 
signalling as functional determinants of the resulting remodelling phenotype.342 The 
specificity of such signalling pathways is likely to be highly dependent on the confinement 
to which ROS are released, as this is lost upon excessive cellular exposure to ROS or 
mislocalisation of the ROS source, leading to aberrant biochemical function.275 
Interestingly, expression of a specific RTK protein in acute myeloid leukaemia (AML) 













patient samples and cell lines were found to correlate with elevated ROS levels.343 These 
cells showed upregulated expression of the Nox4D isoform at the nuclear membrane 
with increased production of H2O2 downstream of RTK-mediated activation of prosurvival 
pathways PI3K and STAT5, and possible redox potentiation of this mode of RTK 
signalling by inhibition of a transmembrane PTP.343 Although in a cancer cell model, this 
study is particularly interesting as it implicates a pro-survival role for Nox4D-derived 
H2O2, and also suggests Nox4D as a source of ROS in response to constitutive RTK 
activation. Whether such ROS-dependent prosurvival signalling pathways are relevant 
in the partial reparative response of the Ind-csNox4D transgenic model to MI remains 
unclear, but poses an intriguing avenue to investigate.  
Based on the current literature on the regulation of cardiac remodelling by redox 
signalling pathways, it would seem plausible to hypothesise that Nox4D-dependent 
nuclear ROS release may impact on various signalling or transcriptional processes 
associated with cardioprotection. In addition to proliferation, the PI3K-Akt pathway is a 
known regulator of cardiomyocyte survival.119 PTEN is also known for its regulatory 
involvement in apoptosis in addition to cell growth.323 Although not activated at baseline, 
it is possible that injurious stimulation of the Ind-csNox4D model may yield greater 
activation of Akt, which may preferentially favour transduction of downstream survival 
effectors as opposed to proliferation, but in light of incomplete restoration of function, this 
may more likely reflect an insufficient level of activation. Given its distinct localisation, it 
would be interesting to establish whether the pathways modulated by Nox4D are 
independent of, or complementary to those exerted by Nox4. Overall, it is clear that in 
depth mechanistic studies are needed to unravel the precise pathways that may be 
involved.    
6.3 Translational implications 
Although it is evident that further work is needed to fully realise whether Nox4D may hold 
therapeutic potential in the adult heart, considerations must be made with respect to the 
broader clinical picture in the advancement of regenerative interventions towards 
translation. The existence of intrinsic regenerative capacity in the adult mammalian heart 
has engendered significant interest, however the augmentation of endogenous pathways 
to replace the ~1 billion cardiomyocytes lost during MI is a big ambition.18,41 The 
replacement of pathological cardiac tissue by induction of proliferation in surviving 
cardiomyocytes is a strategy that should therefore address multiple underlying repair 
pathways in addition to formation of new cardiomyocytes for enhancement of contractility 
and survival.15 A holistic approach to reconstituting human heart function has recently 
been proposed, defined by a set of 5 hallmarks of cardiac regeneration that are 
consistently seen in organisms with innate regenerative capacity.184 These hallmarks 
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include remuscularisation of the cardiac wall, electromechanical stabilisation, 
vascularisation by angiogenesis and arteriogenesis, resolution of fibrosis, and balanced 
immunological activation.184 
Stimulation of innate programs to induce cardiomyocyte cell cycle re-entry is particularly 
advantageous as it enables the generation of autologous cardiomyocytes and thus 
facilitates their mechanical, electrical, and vascular integration within the myocardium. A 
significant challenge surrounds the ability of the proposed manipulation to induce 
genuine cardiomyocyte renewal at the required magnitude to enhance long-term 
myocardial outcomes and be considered therapeutically meaningful.41 However, the 
large-scale dedifferentiation and electric uncoupling that would be necessary for 
cardiomyocyte proliferation would pose further compromise to myocardial function if 
prolonged.11 A major concern that could limit pro-proliferative therapies is their oncogenic 
potential. Interventions should be developed to selectively target cardiomyocyte 
pathways, and should be intensely evaluated for assessment of their safety.41 Genetic 
manipulations would require efficient gene therapy approaches, although 
pharmacological targeting with small molecules may be preferable, which may be locally 
delivered using viral vectors that are biologically targeted to the heart.21,41  
Furthermore, in the development of therapies that may target redox pathways associated 
with proliferation, it is evident that a much more targeted approach than non-specific 
antioxidant therapy is required for the modulation of oxidant species in the heart. Given 
the diversity of the signalling effects of ROS, it is necessary to selectively modulate either 
specific ROS sources in a cell-specific or even cell compartment-specific manner, or 
downstream molecular pathways. The targeting of Nox enzymes would require careful 
development to ensure isoform selectivity and avoidance of suppression of beneficial 
effects that mediate protection. Likewise, an approach designed to enhance Nox function 
should not be associated with deleterious effects as a result of excessive ROS 
production. As such, it is vital that the optimum level within the therapeutic index is 
established to maintain the specificity and confinement of the desired redox 
modifications.138,150   
6.4 Limitations and future work 
It should first be mentioned that the use of the αMHC-MCM-negative genotype as WT 
control throughout this study may represent a confounding factor. This is in light of a 
previous study that found cardiac fibrosis and reduced LV function in αMHC-MCM-
positive adult animals at 6 – 7 weeks following a tamoxifen injection protocol of 20 mg/kg 
per day for 5 days, irrespective of the presence of the floxed target gene.344 This 
phenotype was attributed to the nuclear levels of the MerCreMer protein or its duration 
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in the nucleus, or a combination of both.344 This is in keeping with a previously described 
study that also reported cardiac fibrosis and dysfunction in tamoxifen-induced αMHC-
MCM mice, but at doses in excess of 30 mg/kg per day for 3 days.274 Although we did 
not detect any obvious signs of αMHC-MCM-mediated toxicity in our experiments, these 
studies highlight the importance of including tamoxifen-treated αMHC-MCM single-
genotype animals as controls, which should be implemented in future relevant studies.   
The physiological relevance of the level of Nox4D protein expression induced by the 
tamoxifen protocol employed in this study remains to be established. Further 
manipulation of cardiac-targeted Nox4D expression in the Ind-csNox4D model by 
modulation of the tamoxifen induction dose is likely undesirable due to poor translatability 
and likely poor ability to control even distribution of cellular expression levels. It is 
possible that reducing the dose of tamoxifen may only serve to achieve reduced Nox4D 
expression at whole heart level, but may actually reflect a ‘mosaic’ pattern of expression 
depending on the response of individual cardiomyocytes to tamoxifen exposure, and the 
distribution of tamoxifen across the cardiomyocyte population.  
A more translatable method would be a viral-based delivery system using an AAV9 
vector for the in vivo gene transfer of Nox4D. The use of AAV9 vectors as investigational 
tools for transduction of the heart has become increasingly popular in recent years due 
to their favourable safety profile, high efficiency, and cardiotropism.301 The expression of 
the transferred gene may be further confined by the use of tissue-specific promoters, 
which provide an added layer of control over transgene expression.301,345 The promoters 
recognised so far for their ability to achieve restricted transgene expression in 
cardiomyocytes include the αMHC, Mlc2v, and cardiac troponin genes.301 In comparison 
to αMHC, it has been demonstrated that the Mlc2v and cardiac troponin promoters yield 
lower transgene expression levels,345 and so it would be preferable to design a Nox4D 
expression construct under the control of either of these alternative promoters. This 
would permit the investigation of the Nox4D overexpression phenotype in the adult heart 
at comparatively reduced expression, but would need to include validation of the 
distribution of expression. Due to the limitations associated with use of the Nox4 antibody 
for immunohistochemical applications, it would be necessary to use additional methods 
for further confirmation of Nox4D expression. This could be performed by cell 
fractionation, as shown previously,154 of whole cardiac tissues or isolated 
cardiomyocytes. Fluorescence in situ hybridisation (FISH) could also be used to 
establish the spatial-temporal pattern of Nox4D expression.346   
In order to more optimally establish whether the proliferative and reparative potential of 
Nox4D may be enhanced in the adult heart in vivo, it would be necessary to subject WT 
C57BL/6J mice to MI in conjunction with AAV9-mediated gene transfer of Nox4D. This 
197 
 
would permit greater elucidation of the limited response to MI seen in the Ind-csNox4D 
model, as AAV9-mediated delivery would be able to address currently unanswered 
questions regarding the effects of Nox4D expression titration. Conversely, parallel 
experiments using the developed AAV9 vector for in vivo silencing of Nox4D would be 
important for the study of the relevance of endogenous Nox4D. As discussed in 4.5.1, a 
widely recognised limitation of experimental MI models is the intrinsic variability of MI 
infarct size. An added complication is that a given infarct size measurement can translate 
to a range of plasma biomarker release.226 Cardiac magnetic resonance imaging is a 
non-invasive technology that can reliably and serially measure infarct size,210 and can be 
performed in addition to biomarker measurement for correlative measurements. 
Furthermore, permanent LAD ligation is a severe model of MI and so it may be more 
clinically relevant to measure the response to ischaemic injury using the 
ischaemia/reperfusion model.210    
Investigation of the mechanistic pathways that may be regulated by cardiomyocyte 
Nox4D in normal and stressed hearts is a priority. This could be addressed by screening 
technologies such as multicellular transcriptional analysis by RNA sequencing gene 
expression profiling and proteomic analysis for the identification of potential 
transcriptional and protein targets, respectively. Initial probing for signal transduction 
pathways that may be activated should include Akt, ERK1/2 and downstream targets. 
The measurement of proliferation in adult cardiomyocytes in vivo is renowned for its 
challenges associated with cellular identification and overestimation of division due to 
non-proliferative cell cycling.81 Therefore, further assessment of the proliferative capacity 
of Nox4D in the adult heart should include more direct methods such as advanced 
reporter models that permit lineage tracing and measurement of cytokinesis.95 The 
investigation of ROS release and potential non-specific effects in Nox4D-overexpressing 
hearts, particularly after MI, should also be continued.  
To complement the delineation of the mechanistic pathways involved in vivo, and to fully 
understand the proliferative potential of Nox4D in adult cardiomyocytes, further 
experiments to expand sample sizes should be carried out on the dedifferentiation of 
cardiomyocytes ex vivo. It would be interesting to repeat the same experiment with 
isolated WT cardiomyocytes and overexpress Nox4D in vitro. Equally, this should also 
be done with our developed AV for Nox4D knockdown. As performed previously,286 high-
throughout western blotting could be used as a screening technique against a large panel 
of phospho-specific antibodies to establish the signalling pathways that may be 
upregulated in Nox4D-overexpressing myocytes in response to FGF2 stimulation. The 
differential cellular morphologies detected in cultured myocytes may be associated with 
events of mitosis, but without conclusive evidence of cytokinesis, may be representative 
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of polyploidisation or karyokinesis. Therefore, future analyses should include direct 
measurement of cytokinesis with immunofluorescent markers and time-lapse 
microscopy, and assessment of the ploidy and nucleation states of cardiomyocytes. For 
greater translatability, the ability of dedifferentiated cardiomyocytes to redifferentiate 
back to a functional phenotype should also be assessed. Furthermore, cardiomyocyte 
identity could be further verified by isolation from a cardiomyocyte-specific, fate-mapping 
reporter model such as GFP.202    
Lastly, a key limitation inherent to animal studies is the use of young, otherwise healthy, 
homogeneous populations that lack the comorbidities and confounding drug therapies 
typically representative of the patient population. Increasing age is known to correlate 
with worsening capacity for myocardial repair, and so studies in relatively young animals 
can lead to false-positive results in large-animal or human studies, but can be minimised 




The current work presents a novel transgenic model of inducible, cardiomyocyte-specific 
Nox4D overexpression. Induction of Nox4D overexpression in the adult mouse heart is 
well tolerated, but in contrast to overexpression in cultured neonatal cardiomyocytes, is 
not associated with increased activity of pathways that promote proliferation under 
normal physiological conditions. In the setting of pathological stress induced by 
myocardial ischaemic injury, inducible Nox4D is again not associated with regenerative 
recovery, but may confer a partial reparative response characterised by regionally 
enhanced contractile function and increased cardiomyocyte survival. This response 
remains insufficient to globally restore LV function, but poses an interesting avenue to 
pursue in future study. Additional work in isolated cardiomyocytes importantly provides 
evidence that Nox4D may enhance proliferation in adult myocytes when dedifferentiated, 
and so the realisation of this in vivo may depend on certain priming stimuli in combination 
with optimal levels of Nox4D expression. However, it remains a possibility that the 
maturity level at which Nox4D is overexpressed may represent an ultimate limiting factor 
due to the underlying cell cycle regulatory networks that are differentially expressed.  
The studies presented here add to accumulating evidence that NADPH oxidases play 
complex roles in cellular proliferation, the understanding of which requires cell-specific 
analysis of the temporal and spatial characteristics of their expression and function. 
Therefore, the further development of Nox4D as a protective Nox isoform is highly 
dependent on the capacity for modulation of Nox4D expression to optimise 
cardiomyocyte redox balance and more effectively enhance pathways that govern 
proliferation and survival for the promotion of regeneration and repair in the adult 
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